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1. Summary 
1.1 Summary 
Many studies demonstrated that transcription factors are critical for eye development, such as Pax6, 
Pax2, Sox2 and Foxe3. However, the roles of other proteins rather than transcription factors in eye 
development are largely unknown. Here, I focus on the role of two fascinating and conserved 
proteins rather than transcription factors in eye development, one is peroxidasin and the other one 
is Bmpr1b.  
 
Peroxidasin is an extracellular peroxidase combining with multiple domains found in extracellular 
matrix molecules. The manifestations of patients with peroxidasin (PXDN) mutations seem to be 
confined to the eyes including corneal opacity, congenital cataract and developing glaucoma. 
However, the function of peroxidasin in higher organisms is still largely unknown. Here, I explored 
the role of peroxidasin in eye development using an ENU-induced peroxidasin (Pxdn) mutant 
mouse line (with the point mutation in the peroxidase domain). Peroxidasin is expressed in the 
lens vesicle, developing lens and vitreous nucleated cells and the inner part of the retina. In 
peroxidasin-mutant mice, the anterior segment and eye size are severely affected which starts from 
embryonic stages, especially at E15.5. Moreover, the proliferation and differentiation of the lens 
is disrupted in association with aberrant expression of transcription factor genes (Pax6 and Foxe3) 
and Tgfβ1 during eye development. In addition, it is also involved in the consolidation of basement 
membrane in the mammalian eyes. Lens matrix including γ-crystallin in the anterior chamber due 
to local lens ruptures is a secondary damage to the anterior segment development. Further, the 
mutant eyes are associated with up-regulated expression of inflammation markers (TNF-α and IL-
1β) during eye development. Early-onset glaucoma was detected in the Pxdn mutants in the 
postnatal periods and it develops progressively. Thus, this study has shown that peroxidasin has 
multiple roles in eye development, including cell proliferation and differentiation, basement 
membrane consolidation and regulation of the inflammation.  
 
The other protein, Bmpr1b (Bmp receptor type 1b), is a receptor for Bmp signaling. In previous 
studies, Bmpr1b was found to be involved in retinal axon guidance, and ablation of Bmpr1a and 
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Bmpr1b causes defects in retinal neurogenesis and dorso-ventral patterning in mice. Here, I further 
investigated the role of Bmpr1b in eye development using a mutant mouse line caused by a splice 
donor site mutation in intron 10 of Bmpr1b. This point mutation results in RNA mis-splicing 
(skipping of exon 10), which is predicted to affect the cytoplasmic domain including the conserved 
serine/threonine kinase activity. Then this event further has caused delayed closure of ventral optic 
fissure and dysregulated the expression of Pax2 during embryonic retinal development, leading to 
optic nerve hypoplasia and congenital ventral retinal gliosis in association with retinal dysplasia 
in mice. The ventral retinal gliosis is proliferative and dominated by activated astrocytes but not 
retinal Müller cells. Interestingly, some of activated glial cells seem to be from retinal neurons 
(retinal ganglion cells and bipolar cells). These activated glial cells express some progenitor cell 
markers such as Sox2, Pax2 and Nestin, but not Pax6. Consistent with this result, similar activated 
glial cells were also found in epiretinal membranes (ERMs) and inner limiting membranes (ILMs) 
from patients with retinal gliosis. Moreover, the axons in the optic nerve are disorganized in 
association with decreased number of Sox2-positive precursor cells in mutants, indicating a 
maldevelopment of the optic nerve. In addition, axon guidance is disrupted in the ventral retina in 
mutants. This study demonstrated that Bmpr1b is essential for ventral retinal and optic nerve 
development, and the activated glial cells expressing progenitor cell markers may play a general 
role in the pathogenesis of retinal gliosis in mice and humans.  
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1.2 Zusammenfassung 
Viele Studien zeigen, dass Transkriptionsfaktoren (Pax6, Pax2, Sox2 und Foxe3) entscheidend für 
die Entwicklung des Auges sind. Die Funktion anderer Proteingruppen ist dagegen weitgehend 
unbekannt. Zu diesen Gruppen zählen unter anderem Peroxidasin und BMPR1B, deren Rolle in 
der Augenetwicklung im Rahmen dieser Arbeit untersucht wurde. 
 
Peroxidasin ist eine extrazelluläre Peroxidase, die mit mehreren Domänen von extrazellulären 
Matrix-Molekülen interagiert. Patienten mit Peroxidasin - Mutationen scheinen ausschließlich im 
Auge betroffen zu sein, wobei Hornhauttrübungen, kongenitale Katarakte und Glaukome auftreten. 
Allerdings ist die Funktion von Peroxidasin in höheren Organismen noch weitgehend unbekannt. 
Im Rahmen dieser Arbeit wird die Rolle von Peroxidasin in der Entwicklung des Auges mit Hilfe 
einer ENU - induzierten Peroxidasin (Pxdn) - Mausmutante untersucht, die eine Punktmutation in 
der Peroxidase-Domäne trägt. Peroxidasin wird in frühen Entwicklungsstadien in der 
Linsenplakode exprimiert. Zu späteren Zeitpunkten findet sich eine Expression vor allem im 
Bereich der vorderen Linse, in mesenchymalen Zellen und in der inneren Retina. In den 
Peroxidasin-Mutanten sind die vorderen Augensegmente und die Augengröße stark betroffen. 
Diese Auswirkungen treten bereits in embryonalen Stadien auf, vor allem ab dem Zeitpunkt E15.5. 
Darüber hinaus sind während der Augenentwicklung Proliferation und Differenzierung der Linse 
betroffen in Verbindung mit irregulärer Expression von Transkriptionsfaktoren (Pax6 und Foxe3) 
und TGF1. Weiterhin ist Peroxidasin auch an der Entwicklung der Basalmembran im 
Säugetierauge beteiligt. Linsenaufbrüche und der damit verbundene Eintritt von Linsenmaterial in 
die vordere Augenkammer (einschließlich γ-Kristallin) stellen sekundäre pathologische Effekte 
während der vorderen Augenentwicklung dar. Darüber hinaus ist in den betroffen Augen die 
Expression von Entzündungsmarkern (TNF-α und IL-1β) während der Entwicklung hochreguliert. 
In den Pxdn - Mutanten traten Glaukome schon in frühen postnatalen Stadien auf und zeigten einen 
progressiven Verlauf. Im Rahmen dieser Studie wurde gezeigt, dass Peroxidasin verschiedene 
Funktionen während der Augenentwicklung übernimmt. Dies schließt eine Beteiligung an der 
Zellproliferation und Differenzierung, an der Entwicklung der Basalmembran sowie an der 
Regulation von Entzündungsreaktionen mit ein. 
 
BMPR1B (BMP-Rezeptor Typ 1 b) ist ein Rezeptorprotein des BMP-Signalwegs. In früheren 
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Studien wurde gezeigt, dass BMPR1B an der Orientierung der retinalen Nervenfasern beteiligt ist. 
Die Deletion von BMPR1A und BMPR1B führt zu einer fehlerhaften retinalen Neurogenese sowie 
zu einer inkorrekten Ausbildung des dorso-ventralen Musters in Mäusen. Im Rahmen dieser Arbeit 
wurde die Rolle von BMPR1B in der Entwicklung des Auges mit Hilfe einer mutierten Mauslinie 
untersucht, die durch eine Mutation in der Spleißdonorstelle des Introns 10 von Bmpr1b 
charakterisiert ist. Diese Punktmutation führt zu einem irregulären Spleißen der mRNA mit einem 
Ausschluss von Exon 10, das voraussichtlich für die Zytoplasma-Domäne einschließlich der 
konservierten Serin/Threonin-Kinase-Aktivität kodiert. Dies führt zu einer verzögerten 
Schließung der ventralen optischen Naht sowie zu einer irregulären Pax2 Expression während der 
embryonalen Retinaentwicklung. Letztendlich kommt es zu einer Hypoplasie des Sehnervs sowie 
zu einer ventralen retinalen Gliose in Verbindung mit einer Retinadysplasie in den betroffenen 
Mäusen. Die ventrale retinale Gliose ist sehr ausgeprägt und scheint durch aktivierte Astrozyten, 
aber nicht durch retinale Müller Zellen dominiert zu werden. Interessanterweise scheinen einige 
der aktivierten Gliazellen von Netzhautneuronen (retinale Ganglienzellen und bipolar Zellen) zu 
stammen. Diese aktivierten Gliazellen exprimieren einige Marker für Vorläuferzellen wie Sox2, 
Pax2 und Nestin, nicht jedoch Pax6. In Übereinstimmung mit diesem Ergebnis wurden ähnliche 
aktivierte Gliazellen auch in epiretinalen Membranen (ERM) und in inneren Grenzmembranen 
(ILM) von Patienten mit retinaler Gliose gefunden. Darüber hinaus sind in Mutanten die 
Sehnervaxone fehlerhaft organisiert in Verbindung mit einer verringerten Anzahl von Sox2-
positiven Vorläuferzellen. Dies deutet auf eine fehlerhafte Entwicklung des Sehnervs hin. Darüber 
hinaus ist in Mutanten die Axonausrichtung innerhalb der ventralen Retina gestört. In dieser Arbeit 
wurde gezeigt, dass BMPR1B für die Entwicklung der ventralen Retina und des Sehnervs 
essentiell ist. Ferner könnten die aktivierten Gliazellen, die Marker für Vorläuferzellen exprimieren, 
eine allgemeine Rolle während der Pathogenese der retinalen Gliose in Mäusen und Menschen 
spielen. 
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2. Introduction 
2.1 Eye development 
2.1.1 General introduction to eye development 
Eye development is a complex developmental process involving different molecular signaling 
interactions within and from different tissues (mainly cornea, lens, vitreous and retina (Figure 1.1, 
A)). The eye development originates from three different tissues during early development, 
neuroectoderm, surface ectoderm and periocular mesenchyme. The neuroectoderm gives rise to 
the retina, the epithelium of the iris and ciliary body, the smooth muscle of the iris and optic nerve. 
The surface ectoderm gives rise to the corneal epithelium, lens, eyelids and lacrimal apparatus. 
The periocular mesenchyme migrates into the eye during the optic cup formation and gives rise to 
the stroma and endothelium of the cornea, iris and ciliary body, trabecular meshwork, choroid and 
the vessel of the eyes.  
 
 
Figure 1.1 The anatomy of the eye. (A) Anterior segment of the eye comprises the structure before the front 
face of the vitreous and mainly include cornea, anterior chamber, iris, ciliary body, anterior chamber angle, 
trabecular meshwork and lens. Posterior segment of the eye contains vitreous, retina, retinal pigment epithelium 
and optic nerve. (B) A section of retina. The retina is composed of different layers of neurons and glial cells, 
including retinal pigment epithelium, photoreceptor, outer nuclear layer, outer plexiform layer, inner nuclear 
layer, inner plexiform layer, retinal ganglion cell layer outside to inside. The outside of the retina is covered with 
internal limiting membrane. (The picture from webvision.med.utah.edu.cn) 
 
 
2.1.2 Anterior segment development (except lens) 
Anterior segment contains the front part of the eye, including cornea, anterior chamber, iris, ciliary 
body, anterior chamber angle, trabecular meshwork and lens (Figure 1.1, A). The anterior segment 
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development is coordinated by interactions between lens vesicle, surface ectoderm and ocular 
mesenchymal cells. Ocular mesenchymal cells play a key role in the anterior segment development. 
In general, corneal development starts from the stage that lens vesicle makes contact with the 
overlying surface ectoderm. Then the single cell layer of surface ectoderm proliferate and form 3-
4 cell layers of corneal epithelium. Shortly after the lens vesicle is separated from lens surface 
ectoderm, the mesenchymal cells of neural crest origin in the space between corneal epithelium 
and lens differentiate into corneal stromal keratocytes and endothelium (Figure 1.2, A-B). The 
mesenchymal cells in the anterior chamber angle also contribute to the formation of the iris and 
ciliary body and trabecular meshwork (Figure 1.2, C-D).  
 
 
Figure 1.2 The development of ocular mesenchymal cells during anterior segment development. (A) In the 
early eye development, mesenchymal cells (yellow, round) migrate into the front part of the eye between surface 
ectoderm (blue) and lens vesicle (LV) at E11.5. (B-D) The mesenchymal cells aggregate in organized layers at 
E13.5 and differentiate into corneal stromal cells and endothelial cells around E13.5-E15.5 and further 
differentiate into the iris and form proper corneal-iris angle after E17.5. C, cornea; EF, eyelid folds; E, eyelid; P, 
periderm (The picture from Gage and Zacharias, 2009) 
 
 
2.1.3 Lens development 
The first step of lens morphogenesis is that surface ectoderm thickens to form the lens placode 
(Figure 1.3, A-B). Then the surface ectoderm invaginates and further forms the optic vesicle, 
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followed by the separation of the optic vesicle from surface ectoderm, and thus lens vesicle is 
formed (Figure 1.3, C-D). The epithelial cells in the posterior part of the lens vesicle begin to 
proliferate and further differentiate into primary lens fiber cells; these lens fiber cells elongate and 
fill up the lens vesicle (Figure 1.3, E). The epithelial cells around the lens equator still proliferate 
and have the capacity to differentiate into the fiber cells throughout life of the organisms. These 
newly-formed fiber cells elongate in the anterior-posterior direction and form secondary fiber cells, 
which are laid down around the primary lens fiber cells. Both, the primary and secondary lens fiber 
cells lose their cytoplasmic organelles including nucleus, mitochondria and endoplasmic reticulum, 
and become transparent forming an organelle-free zone in the lens center. The innermost part of 
the lens is made up of primary lens fibers surrounded by secondary fiber cells and newly-formed 
secondary fiber cells. The lens development is a complex process involving cell proliferation, cell 
differentiation, cell migration and organelle degradation. The anterior epithelial cells of the lens 
remain active. The lens capsule is detected at E11.5 after the lens vesicle is separated from surface 
ectoderm. Then the lens capsule thickens and has also the permeability to make some molecules 
selectively diffuse into the lens, such as growth factors and nutrients. The lens epithelium and fiber 
cells secrete some basement membrane molecules which are involved in the formation and 
consolidation of the lens capsule. The capsule is also necessary for lens epithelium survival 
(Danysh and Duncan, 2009). 
 
Figure 1.3 Lens development. (A-B) 
At the earliest stage of eye 
development, the surface ectoderm 
thicken to form lens placode once it 
contact with optic vesicle (OV). (C-
D) Then the placode invaginates and 
form the lens vesicle followed by its 
separation from the lens placode. (E) 
The posterior lens epithelial cells 
proliferate and differentiate into the 
lens fiber cells, which elongate to fill 
the lens vesicle, which are called 
primary fibers. (F-G) The lens 
epithelium in the equator of the lens 
proliferate and differentiate into the 
secondary lens fibers. PLE: 
presumptive lens ectoderm; OV: 
optic vesicle. (The picture from 
Robinson, 2006) 
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2.1.4 Molecular pathway during anterior segment development  
Transcription factors 
Pax6 (Paired box gene 6) 
Pax6 is a “master control” and highly-conserved gene for eye development. The canonical Pax6 
consists of an N-terminal paired domain, a linker region to a paired-type homeodomain, and a 
proline/serine/threonine (P/S/T)-rich C-terminal domain. The paired domain and paired-type 
homeodomain have DNA-binding capacity and the P/S/T-rich domain contains the transactivation 
activity. Pax6 has three isoforms, the canonical Pax6, Pax6 (5a), and Pax6 (ΔPD). Pax6 (5a) 
contains a 14 amino acid insertion in the paired domain due to alternative splicing of exon 5a, 
resulting in a low capacity of DNA binding. Pax6 (ΔPD) or paired-less isoform encodes from an 
alternative translate start codon of the paired domain. Thus, Pax6 (ΔPD) has no DNA binding 
capacity.  
 
Patients with heterozygous PAX6 mutations manifest variable phenotypes, including aniridia, 
coloboma of the iris and choroid, or anterior segment malformations (Lin et al., 2011) and aniridia 
and cataract (Cai et al., 2010). Some patients with PAX6 mutations also showed Peters anomaly 
(Jia et al., 2010; Nanjo et al., 2004), Rieger syndrome (Riise et al., 2001) and autosomal dominant 
keratitis (Mirzayans et al., 1995). Some mutations lead to congenital nystagmus, foveal hypoplasia, 
iris hypoplasia or atypical coloboma (Vincent et al., 2004) and ocular anterior segment anomalies 
including uveal ectropion of the iris, invasion of the conjunctival epithelia into the cornea, and 
posterior embryotoxon caused by a missense mutation of the PAX6 gene (Azuma and Yamada, 
1998). But another study showed that PAX6 is not affected in most patients with Peters anomaly 
(Churchill et al., 1998). In mice, homozygous mutations in Pax6 lead to anophthalmia (no eyes) 
and embryo lethality (Hill et al., 1991; Puk et al., 2013). Heterozygous mutations in Pax6 causes 
a wide spectrum of anterior segment abnormalities including Peters anomaly in mice (Baulmann 
et al., 2002; Hanson et al., 1994) and corneal opacity including thinner corneal epithelium and 
thicker corneal stroma and microphthalmia (smaller eyes) (Ramaesh et al., 2003), which are 
similar to the symptoms observed in the patients. Interestingly, overexpression of Pax6 also causes 
microphthalmia and anterior segment dysgenesis (Schedl et al., 1996; Manuel et al., 2008).  
 
Foxc1 (Forkhead box C1) 
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Interestingly, mutations in FOXC1 cause a similar phenotype, including Axenfeld-Rieger 
syndrome (Panicker et al., 2002), Peters anomaly and iris hypoplasia. Global or neural crest-
specific Foxc1 null mutant mice exhibit corneal neovascularization and excessive growth of 
lymphatic vessels which is associated with aberrant extracellular matrix and up-regulation of 
matrix metalloproteinase (MMP) (Seo et al., 2012). A zebrafish study showed that vascular 
basement membrane is disrupted caused by loss of FoxC1 (Skarie and Link, 2009), suggesting a 
possible role of FoxC1 in glaucoma development. Haploinsufficiency of Foxc1 also results in 
anterior segment dysgenesis in mice, which is similar to human patients (Smith et al., 2000). 
Further work demonstrated that FGF19 is a direct target of FOXC1 in corneal and mesenchymal 
cells (Tamimi et al., 2006) which provide a mechanism for the role of FOXC1 in the anterior 
segment development.   
 
Foxe3 (Forkhead box protein E3)  
The manifestations of patients with FOXE3 mutations are variable. Some patients showed a 
variable phenotype of anterior segment dysgenesis including Peters anomaly (Doucette et al., 
2011), while others showed sclerocornea, aphakia, microphthalmia and optic nerve coloboma (Ali 
et al., 2010), congenital aphakia (Anjum et al., 2010), microphthalmia associated with aphakia 
and/or corneal defects without systemic diseases (Reis et al., 2010) and anterior segment 
dysgenesis and microphthalmia (Semina et al., 2001).  
 
Foxe3 is a key transcription factor for lens development and Foxe3 is mapped to the short arm of 
chromosome 4 in mice. It can be detected in the developing eye at E9.5, the earliest stage for eye 
development in mice, and later it is only expressed in the lens epithelial cells in the eyes during 
the embryonic and postnatal periods. The first study on Foxe3 and lens development in the mouse 
is that mutants dysgenetic lens (dyl) with the mutation in Foxe3 exhibit reduced proliferation of 
the lens epithelium and persistent lens-corneal adhesion, suggesting that it is necessary for lens 
proliferation and closure of the lens vesicle (Blixt et al., 2000). Foxe3-null mice exhibit the anterior 
segments including iris, cornea, ciliary body and trabecular meshwork are malformed (Blixt et al., 
2007), and the Foxe3-null mice are regarded as a model of Peters anomaly (Ormestad et al., 2002), 
and in these mutant mice, the proliferation and differentiation of the lens epithelial cells are also 
affected (Medina-Martinez et al., 2005). In addition, persistent activation of Foxe3 causes a partial 
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epithelialization of lens fiber cells (Landgren et al., 2008). A few studies investigated the upstream 
regulator of Foxe3 in vivo and in vitro. Recent data from our lab strongly supports that Pitx3 is a 
direct upstream regulator of Foxe3 in mice, which explains the eye phenotype of aphakia and 
dysgenetic lens in Pitx3 mutants (Naffees Ahmed, PhD dissertation, Technical University of 
Munich, 2011). In addition, Msx-2 (Msh homeobox 2) is regarded as another upstream molecule 
regulating Foxe3, since the expression of Foxe3 is greatly reduced in the lens epithelium of the 
Msx-2 knockout mice (Zhao et al., 2012).   
 
Pitx2 and Pitx3 
Pitx2 (Paired-like homeodomain transcription factor 2) 
Mutations in PITX2 also can cause anterior segment dysgenesis in humans including Axenfeld-
Rieger syndrome (Idrees et al., 2006; Vieira et al., 2006; Li et al., 2008; Footz et al., 2009). The 
neural crest-specific Pitx2 knockout mice exhibit anophthalmia and severe optic nerve defects 
(Evans and Gage, 2005). The upstream and downstream regulators of Pitx2 are largely unknown. 
Gpr48 (G protein-coupled receptor 48) was found to be an upstream regulator of Pitx2 (Weng et 
al., 2008). Pitx2 is found to be a responsive gene for retinoic acid during eye development (Matt 
et al., 2008). Recently, retinoic acid was found to be a key upstream molecule regulator of Pitx2 
during eye and craniofacial development in a zebrafish model of Axenfeld-Rieger syndrome 
(Bohnsack et al., 2012). In addition, Pitx2 also regulates the morphogenesis of extraocular muscles 
(Kitamura et al., 1999; Diehl et al., 2006). 
 
Pitx3 (Paired-like homeodomain transcription factor 3)  
Pitx3 is expressed in the lens epithelium and midbrain dopaminergic neurons (Dutta et al., 2005; 
Korotkova et al., 2005). Mutations in PITX3 causes microphthalmia and aphakia in mice and 
congenital cataract with anterior segment dysgenesis (ASD) in humans (Semina et al., 1998). 
Similar to humans, two deletions in Pitx3 also causes severe abnormal lens development in 
aphakia mice (Semina et al., 2000; Rieger et al., 2001). A point mutation in Pitx3 also causes 
microphthalmia in mice (Rosemann et al., 2010). The development and differentiation of the lens 
in Pitx3-mutants is severely disrupted (Medina-Martinez et al., 2009). In addition, Pitx3 also plays 
a role in Parkinson’s disease (Li et al., 2009; Rosemann et al., 2010). The direct target of Pitx3 is 
still unclear, but recently it was shown that Pax6, Crybb1 (βB1-Crystallin), Hes 7.1 (Hes, Hairy 
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and enhancer of split), and Hes4 are likely to be direct targets of Pitx3 based on microarray 
identification (Hooker et al., 2012). The data from our lab strongly supports that Pitx3 is a direct 
upstream regulator of Foxe3 in mice (Naffees Ahmed, PhD dissertation, Technical University of 
Munich, 2011).   
 
 
BMP (Bone morphogenetic protein) signaling 
Overexpression of Tgfβ1 (Transforming growth factor beta 1) with βB-crystallin promoter causes 
severe anterior segment dysgenesis without microphthalmia in the transgenic mice (Flügel-Koch 
et al., 2002). Another Tgfβ1 transgenic mouse line with αA-crystallin promoter showed 
subcapsular cataract formation (Banh et al., 2006), but corneal-lens adhesion and disorganized lens 
matrix can be found from the histology picture although the authors did not mention it in the text. 
In consistency with this study, overexpression of Beta ig-h3 (Transforming growth factor-beta-
induced protein ig-h3) also causes anterior segment dysgenesis in mice (Kim et al., 2007). In 
addition, Bmp4, another member of the Bmp family, is also important for anterior segment 
development. Lens induction is defective and the lens cannot be formed in Bmp4 homozygous null 
mutant mice (Furuta and Hogan, 1998), and haploinsufficiency of Bmp4 results in anterior segment 
dysgenesis and elevated ocular pressure (Chang et al., 2001). These data showed that Bmp 
signaling is important for eye development. The role of Bmp receptors in eye development will be 
discussed later (2.3.2). 
 
Extracellular matrix (ECM) 
ECM is a complex network of extracellular macromolecules surrounding most of the cells in the 
multicellular organisms. ECM interactions play essential roles during organ development and 
many pathological processes. Several studies showed that extracellular matrix molecules are 
essential for anterior segment development (Hopfer et al., 2005; Van Agtmael et al., 2005; Rødahl 
et al., 2013). Collagen IV is a main component of the basement membrane. Patients with a COL4A1 
(Collagen 4A1) mutation manifest variable anterior segment phenotypes with corneal clouding, 
anterior synechiae, iris hypoplasia, posterior embryotoxon, corectopia (displacement of the pupil) 
and early cataract (Rødahl et al., 2013). In mice, mutations in Col4a1 causes anterior segment 
dysgenesis including buphthalmos (enlarged eye increased by intraocular pressure), corneal 
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opacity, iris-corneal adhesion and vacuolar cataracts which are associated with the defects of the 
basement membrane (Van Agtmael et al., 2005). A point mutation in Col8a2 (Collagen 8a2) 
showed increased anterior chamber depth, extended axial length and reduced thickness of corneal 
layers but without reduced visual acuity in mice (Puk et al., 2009). Further studies showed that this 
mutant line seems to be resistant to the retinal ganglion cells damage induced by ocular pressure 
(Steinhart et al., 2012). Also, targeted inactivation of Col8a1 (Collagen 8a1) and Col8a2 causes 
thinner corneal stroma and Descemet’s membrane, and decreased proliferation of corneal 
endothelial cells (Hopfer et al., 2005). Compared with Col8a1 and Col8a2, Col4a1 showed more 
important roles in the development of anterior segment. These findings suggest that ECM plays a 
novel and specific role during anterior segment development.  
 
Other genes 
G protein-coupled receptor 48 (Gpr48) 
Gpr48, also known as LGR4, is a member of G protein-coupled receptors (GPCRs). It consists of 
leucine-rich repeats in the N-terminal and several transmembrane domains. The ligand of Gpr48 
is unknown. Deletion of Gpr48 leads to a broad spectrum of anterior segment dysgenesis in mice, 
including microphthalmia, iris hypoplasia, iris-cornea angle malformation, corneal dysgenesis and 
cataract and early-onset glaucoma and Pitx2 was found to be a direct target of Gpr48 (Weng et al., 
2008). This study suggests that the signaling receptors are also very important for eye development.  
 
2.1.5 Retinal development 
In general, there are seven layers in the mammalian retina including retina pigmental epithelium 
(RPE), outer segment of the photoreceptors (OS), outer nuclear layer (ONL), outer plexiform layer 
(OPL), inner nuclear layer (INL), inner plexiform layer (IPL), retinal ganglion cell layer (GCL) 
from outside to inner part (Figure 1.1). There is a nerve fiber layer on the surface of the retinal 
ganglion cell (RGC) layer which consists of axons from RGCs. The first six layers are usually 
called neuroretina, which is separated from RPE by a tiny space called subretinal space. The 
neuroretina contains six types of retinal neurons including rod and cone photoreceptors, amacrine 
cells, horizontal cells, bipolar cells, retinal ganglion cells and one type of glial cells (retinal Müller 
cells). There are also retinal astrocytes whose origin is from a distinct progenitor in the optic stalk 
and optic nerve during eye development (Stone and Dreher, 1987; Ling and Stone, 1988; Watanabe 
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and Raff, 1988). The photoreceptor layer consists of the outer segment (OS) of rod and cone 
photoreceptors. The outer nuclear layer contains the cell bodies from rod and cone photoreceptors. 
The inner nuclear layer consists of the cell bodies of bipolar cells, horizontal cells and amacrine 
cells. The axons from retinal ganglion cells comprise the retinal nerve fiber layer. The outer 
plexiform layer is composed of the axons and synapses between photoreceptor cells, horizontal 
cells and bipolar cells, and the inner plexiform layer contains the axons and synapses between 
amacrine cells, bipolar cells and retinal ganglion cells.  
 
In the early retinal development, progenitor cells are multi-potent with the ability to differentiate 
into all the types of retinal cells. As they divide symmetrically, one begins to differentiate into a 
specific type of retina cell, and the other one still keep its multi-potent competence, but they receive 
different signals, such as signaling through lateral inhibition, to restrict them to produce the same 
type of retinal cells (Agathocleous and Harris, 2009; Reese, 2011). Thus, the retinal cells are 
generated in a defined sequence: retinal ganglion cells generate firstly followed by cone 
photoreceptors, horizontal cells and amacrine cells during embryonic stages, and rod 
photoreceptors, bipolar cells and Müller glia are generated after birth in mice (Agathocleous and 
Harris, 2009; Reese, 2011). However, retinal astrocytes are regarded to come from a distinct 
progenitor in the optic stalk and optic nerve during eye development (Stone and Dreher, 1987; 
Ling and Stone, 1988; Watanabe and Raff, 1988). 
 
There are a number of genes encoding transcription factors which regulate retinal development. 
Multiple basic helix-loop-helix (bHLH) genes are well studied and they play a key role in 
regulating differentiation of the retinal progenitor cells (Ohsawa and Kageyama, 2008), and these 
different types of bHLH genes cross-regulate each other to specify the retinal neuronal subtypes 
(Akagi et al., 2004). Math 5 (Helix-loop-helix protein mATH-5) is critical for retinal ganglion cell 
development and deletions of Math5 or Ath5 (Ath5 in zebrafish equals Math5 in mouse) causes 
dramatic loss of retinal ganglion cells (Brown et al., 2001; Kay et al., 2001). But the following 
study traced the fate of Math5-expressing progenitor cells during retinal development and found 
they can differentiate into multiple types of retinal neurons, indicating that Math5 defines the 
competence of the retinal ganglion cell progenitors but it is not a final determinator of retinal 
ganglion cells (Yang et al., 2003). The member of Brn3 (POU-domain transcription factors) family 
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also plays a key role for retinal ganglion cell development. Deletions of Brn3 also greatly reduced 
the number of retinal ganglion cells (Erkman et al., 1996; Gan et al., 1996). Ath5 was found to 
function upstream of Brn3 to regulate retinal ganglion cell development (Liu et al., 2001). It 
appears that amacrine cells and horizontal cells have common regulators (Graw, 2010). Foxn4 
(Forkhead box N4) controls the genesis of retinal amacrine cells and horizontal cells. Disruption 
of Foxn4 causes greatly decreased number of retinal amacrine cells and completely loss of 
horizontal cells, whereas overexpression of Foxn4 promotes the fate of amacrine cells (Li et al., 
2004). Barhl2 (BarH-like homeobox 2) is another key factor for amacrine cells development. In 
Barhl2-deficient mice, the number of glycinergic and GABAergic amacrine cells is decreased, 
whereas the number of cholinergic amacrine cells is increased (Ding et al., 2009). Mash1 
(Mammalian achaete-scute complex homolog-1) and Math3 (Helix-loop-helix protein mATH-3) 
are required for the fate determination of retinal bipolar cells. Either Mash1 or Math3 mutants 
showed very weak defects, whereas Mash1 and Math3 double mutants exhibit a lack of retinal 
bipolar cells, and these bipolar cells become retinal Müller cells (Tomita et al., 2000). The 
photoreceptor cells fate is controlled by Otx2 (Orthodenticle homeobox 2) and Crx (Cone-rod 
homeobox transcription factor), and deletion of either gene causes loss of photoreceptors but 
generates more amacrine cells instead (Graw, 2010). p27Xic1, a Xenopus cyclin dependent kinase 
inhibitor, is key for retinal Müller cell differentiation. Overexpression of p27Xic1 promotes early 
differentiation of retinal Müller cells in Xenopus (Ohnuma et al., 1999). Sox2 (SRY(Sex 
determining region Y)-box 2 transcription factor) was found to be essential for postnatal Müller 
glial cells differentiation, and conditional knockout of Sox2 in mice causes disrupted morphology 
and cell cycle quiescence of retinal Müller cells, leading to depletion of retinal Müller glia and 
retinal degeneration (Surzenko et al., 2013). In addition, Notch signalling is important for retinal 
Müller cells development. Inactivation of Notch-Delta signalling leads to the defect of retinal 
Müller cell differentiation, whereas the differentiation of retinal neurons is not affected in zebrafish 
(Bernardos et al., 2005).  
 
 
2.2 Eye diseases in this study 
2.2.1 Anterior segment dysgenesis (ASD) 
Anterior segment dysgenesis is a broad manifestation of failures during anterior segment 
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development, including cornea, lens, iris, corneal-iris angle and trabecular meshwork. Clinically, 
it is usually characterized by corneal opacity, cataract, glaucoma, aniridia and microphthalmia. In 
patients with corneal opacity, the most common manifestation of ASD is Peters anomaly and 
Axenfeld-Rieger syndrome representing 80% of those patients (Shigeyasu et al., 2012).  
 
Peters anomaly: it is characterized by persistent corneal-lens adhesion and central/peripheral 
corneal opacity. It is often associated with glaucoma, cataract and microphthalmia. There are 
several mutations in these genes found in patients with Peters anomaly, such as PAX6 (Azuma et 
al., 1998), FOXC1 (Honkanen et al., 2003; Weisschuh et al., 2008) and FOXE3 (Docette et al., 
2010).  
 
Axenfeld-Rieger syndrome: The most common manifestations of the disease are the iris 
correctopia/atrophy and posterior embryotoxon (A congenital eye malformation characterized by 
a prominent displaced Schwalbe's line). But the cornea is clear and there is no corneal-lens 
adhesion in this disease compared with Peters anomaly. It is also often associated with glaucoma. 
PITX2 (Idrees et al., 2006; Vieira et al., 2006; Li et al., 2008; Footz et al., 2009) and FOXC1 
(Honkanen et al., 2003; Weisschuh et al., 2008) are found to be mutant genes for the disease. 
 
We still know less about the mechanisms of ASD although there are a number of mutant genes 
found in the patients. The majority of the mutant genes associated with ASD are transcription 
factors, such as PAX6, FOXC1, PITX2, PITX3, FOXE3, AP2α (Reis and Semina, 2011). These 
transcription factors were found to regulate the mesenchymal cells to differentiate into distinct 
anterior segment tissues, and these developmental processes are also sensitive to the dose of these 
transcription factors (Sowden, 2007). The complex interactions between transcription factors may 
be one reason for phenotype variability of anterior segment dysgenesis (Sowden, 2007). Recently, 
there are several extracellular matrix molecules which are found to be related to anterior segment 
dysgenesis, such as Collagen4 A1 (Rødahl et al., 2013; Van Agtmael et al., 2005) and heparan 
sulfate (Iwao et al., 2009). Collagen4 A1 has been discussed in 2.1.4. Heparan sulfate is a 
glycosaminoglycan component of the extracellular matrix. Ablation of Exostosin 1 (an enzyme 
indispensable for heparan sulfate synthesis) in neural crest cells causes the disruption of Tgfβ2 
signaling and further down-regulates the expression of Foxc1 and Pitx2, leading to anterior 
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segment dysgenesis (Peters anomaly) in mice (Iwao et al., 2009). These studies suggest that ECM 
molecules play a critical role in anterior segment development as well as transcription factors. 
 
2.2.2 Retinal gliosis 
Gliosis is a process of glial scar formation caused by activated glial cells in the neural system 
which usually occur after injury. It is characterized by activated and/or proliferating glial cells and 
up-regulation of intermediate filament expression (Glial fibrillary acidic protein, GFAP) in the 
gliosis region. We often called gliosis induced by injury as reactive gliosis which is due to the 
properties of reactive cell process. In the retina, retinal Müller cells are the main glial cells, but the 
other cell types of glial cells including astrocytes and microglia cells were found to come from a 
distinct progenitor in the optic stalk and optic nerve during eye development (Stone and Dreher, 
1987; Ling and Stone, 1988; Watanabe and Raff, 1988). Retinal reactive gliosis is characterized 
by the activation of retinal Müller cells and astrocytes. There are a number of studies showing that 
retinal Müller cells are involved in reactive gliosis induced by injury or other retinal diseases 
(Bringmann et al., 2009; 2012). Deficiency of transcription factors also leads to retinal reactive 
gliosis, suggesting that gliosis can also be controlled by genetic factors. Mice lacking p27Kip1, a 
tumor suppressor gene, showed retinal reactive gliosis which results in the retinal dysplasia and 
abnormal vessels (Dyer and Cepko, 2000). In consistency with this study, retinal reactive gliosis 
occurs in P27 knock-out mice, but retinal function and visual acuity are not affected in the mutants 
(Vázquez-Chona et al., 2011). Conditional knock-out mice of Lhx2, a LIM homeodomain 
transcription factor, showed hypertrophic reactive gliosis in retina under the conditional ablation 
of Lhx2 in mature Müller glia (de Melo et al., 2012). These studies showed that retinal gliosis is 
not only induced by injury or degeneration but also caused by intrinsic factors such as gene 
regulation.  
 
In the human retina, gliosis is usually found in the pre-retina area. For example, the epiretinal 
membrane (ERM), a thin sheet of glial scar, can be found on the surface of the retina in patients 
with diabetic retinopathy, retinal detachment, ocular inflammation such as uveitis, etc. It also 
occurs on the front surface of the macula which is the small center region of the retina responsible 
for central vision. Sometimes it is associated with vitreous traction but without obvious other 
diseases and called idiopathic retinal gliosis. The exact cause, initial events, the progression and 
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the recurrent reasons of retinal epiretinal membrane remains largely unknown. But we still get 
some insights about the ERMs based on the morphological observations by different histology 
methods. The main cells of ERMs are glial cells, which are initially found based on the observation 
of 8 enucleated eyes with ERMs and it seems that the glial cells migrate out of the retina through 
the ruptured inner limiting membrane (ILM) and contribute to ERMs (Foos, 1974). The subsequent 
work found that the cell components of the epiretinal membranes are not only the glial cells, but 
also fibroblasts, myofibroblasts and macrophages based on morphology by electron microscopy 
(Kampik et al., 1981; Gandorfer et al., 2002; 2005). Then glial cells as well as hyalocytes may be 
predominant cells in the ILMs from patients with idiopathic macular hole, which were analyzed 
by immunostaining of cell markers and electron microscopy (Schumann et al., 2011). Growth 
factors may contribute to the pathogenesis of ERMs, because the expression level of some growth 
factors such as TGFβ2 and NGF (Nerve growth factor) is elevated in the vitreous from patients 
with idiopathic epiretinal membranes (Iannetti et al., 2011). In addition, in patients with macular 
holes, ERMs can be found on the surface of the macula with or without vitreous traction. But 
whether the vitreous detachment is a cause or effect of the ERMs remains unclear.  
 
Interestingly, Nestin, a marker for neural stem cells, is also expressed in the epiretinal membranes 
(Mayer et al., 2003). Recently, glial cells were found in the vitreous from patients with diabetic 
retinopathy, and these cells can co-express neural stem/progenitor cell markers, such as Nestin 
(Johnsen et al., 2012), but whether these cells are involved in the ERM formation is still unknown. 
As the main glial cell type in retina, retinal Müller cells may have the properties of neural stem 
cells. One evidence is that, MIO-M1 (Moorfields/Institute of Ophthalmology-Müller 1), a retinal 
Müller cell line derived from postmortem adult human neural retina, exhibited the characteristics 
of neural stem cells. The cell lines can express the markers for neural stem cells, such as Sox2, 
Pax6, Chx10 and Notch1, in the presence of growth factors such as FGF-2 or retinoic acid 
(Lawrence et al., 2007). Moreover, adult retinal Müller cells have the ability to differentiate into 
rod photoreceptors (Giannelli et al., 2011). And a further study demonstrated that Wnt and Notch 
pathways are involved in activating the neural stem cell properties of retinal Müller cells (Das et 
al., 2006). Sonic hedgehog (Shh) signaling also can induce retinal Müller cells to dedifferentiate 
and promote their neurogenic potential to photoreceptor cells (Wan et al., 2007). These studies 
suggest that the retinal Müller cells as the main glial cells in retina showed characteristics of neural 
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stem cells. We can imagine that retinal Müller cells may play a unique role in the pathogenesis of 
the retinal gliosis because of their stem cell properties.  
 
2.2.3 Optic nerve coloboma/hypoplasia 
Optic nerve coloboma is a developmental disorder which is characterized by a demarcated bowl-
shaped excavation in the optic disc (Dutton, 2004). It usually causes poor vision from moderate to 
severe blindness. It is often associated with other eye diseases, such as microphthalmos, cyst, 
microcornea, retinal detachment and abnormal retinal vessels. The cause and pathogenesis of the 
disease are not completely known. There are also some mutant genes found in patients with optic 
nerve coloboma, such as PAX2 (Sanyanusin et al., 1995; Schimmenti et al., 2003), PAX6 (Shukla 
and Mishra, 2011), FOXE3 (Ali et al., 2010), TMEM126A (Transmembrane protein 126A) (Meyer 
et al., 2010) and TUBA8 (alpha-tubulin 8) (Abdollahi et al., 2009).  
Because the relationship of Pax2 and optic nerve coloboma is well studied, here I focus on the role 
of Pax2 during optic nerve development and coloboma. Pax2 (Paired box gene 2) is a transcription 
factor which is critical for embryonic morphogenesis. Pax2 also plays an important role in kidney 
development (Harshmann et al., 2012) and a variety of cancers (Ordóñez, 2012). In mouse eyes, 
Pax2 is expressed in the ventral optic cup and stalk in early eye development and then restricted 
to the optic nerve-retina junction and optic nerve (Otteson et al., 1998). Pax2 is a regulator for 
neuron-glial cell fate determination in the optic nerve, and if Pax2 is down-regulated, the cells in 
the optic nerve turn to generate neurons. If Pax2 is overexpressed, it will trigger glial cells 
differentiation of the optic nerve precursors (Soukkarieh et al., 2007). A frameshift mutation in 
Pax2 causes misguidance of the optic nerve during eye development and a coloboma in the optic 
nerve head in mice (Favor et al., 1996). In consistency with this study, a missense mutation in 
Pax2 also causes the congenital excavation of the optic nerve head but with retinal rosette 
formation and this mutation results in the changes in protein localization, transactivation and DNA 
binding (Alur et al., 2010). Like loss of function of Pax2, overexpression or ectopical expression 
of Pax2 appears to cause similar coloboma (failure of choroid fissure closure) during chicken eye 
development (Sehgal et al., 2008). There are a few studies demonstrating the pathway regulating 
the expression of Pax2. The earlier study showed that c-Jun NH2-terminal kinase (JNK) initiates 
Bmp4 and Shh signaling which induces Pax2 expression (Weston et al., 2003). Another study 
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showed that BMP7 and SHH (Sonic hedgehog) can regulate Pax2 in the retinal astrocytes through 
relieving TLX (an orphan nuclear receptor) repression (Sehgal et al., 2009). In addition, Grg4 (a 
Groucho/TLE family protein) can specifically interact with Pax2 to suppress transactivation 
(phosphorylation of the Pax2 active domain) (Cai et al., 2003). Nevertheless, the upstream 
regulation pathway of Pax2 is not completely understood.   
2.2.4 Microphthalmia 
Microphthalmia is a congenital manifestation of reduced eye size. It is usually associated with 
other congenital eye diseases, such as anterior segment dysgenesis (Peters anomaly and Axenfeld-
Rieger syndrome) and eye coloboma. As well as anterior segment dysgenesis, there are a number 
of genes found to be associated with microphthalmia. Besides transcription factor genes such as 
MITF (Microphthalmia-associated transcription factor), PAX6, SOX2, OTX2 and FOXE3 
(Bardakjian and Schneider, 2011), there are several other mutated genes found recently which 
cause microphthalmia, such as ALDH1A3 (Aldehyde dehydrogenase family 1, subfamily A3) 
(Yahyavi et al., 2013), c12orf57 (chromosome 12 open reading frame 57) (Zahrani et al., 2013), 
ODZ3 (odd Oz/ten-m homolog 3, a transmembrane protein) (Aldahmesh et al., 2012). In addition, 
mutations in ALDH1A3 (Yahyavi et al., 2013) or ODZ3 (Aldahmesh et al., 2012) can also cause 
anophthalmia (the absence of the eye). These studies suggest that there is a more complex 
molecular network regulating eye size and growth including transcription factors. The other genes 
such as given above are as important as the transcription factors. 
 
 
2.3  Two novel protein molecules in eye development and diseases 
2.3.1 Peroxidasin (Pxdn) 
Peroxidasin is also known as P53-responsive gene 2, Melanoma-associated gene 50 (MG50) or 
Vascular peroxidase 1 (VPO1). Peroxidasin is a conserved molecule combining multiple domains 
(leucine rich repeats, immunoglobulin domains and a von Willebrand factor domain) found in 
other extracellular matrix proteins and a peroxidase domain. It is also regarded as extracellular 
peroxidase. The coding sequence of Pxdn mRNA is around 4.5 kb and the protein size is around 
165 kDa.  
 
20 
 
Although the function of peroxidasin is still largely unknown, several studies showed that 
peroxidasin may play multiple roles in extracellular matrix formation, development, homeostasis 
and host defense. Peroxidasin was firstly identified in Drosophila; it is expressed by hemocytes 
and involved in the formation of the extracellular matrix (Nelson et al., 1994). Furthermore, an in 
vitro study demonstrates that peroxidasin can be secreted from myofibroblasts and incorporated 
into the extracellular matrix and this process can be stimulated by TGF-β1 but seems not mediated 
by the peroxidase enzyme activity (Péterfi et al., 2009). Further, disrupted extracellular matrix was 
also found in C. elegans with peroxidasin (PXN) mutations by electron microscopy (Gotenstein et 
al., 2010). Recently, it was known that peroxidasin crosslinks with collagen IV, and the expression 
of collagen IV is aberrant in Drosophila with a peroxidasin mutation (Bhave et al., 2012). On the 
other hand, peroxidasin is not only involved in the extracellular matrix, but also essential for 
embryonic development in lower organisms. In C. elegans, mutations in peroxidasin can cause 
embryonic and larval lethality, and variable epidermal morphology phenotypes, suggesting that it 
is essential for embryonic development and further experiments showed that these phenotypes are 
dependent on the peroxidase activity (Gotenstein et al., 2010).  
 
Moreover, peroxidasin is highly expressed in the heart and vascular wall (Cheng, et al, 2008). It 
plays a role in promoting oxidative stress, and its function as an extracellular matrix molecule 
seems independent of its peroxidase activity in cardiovascular systems (Ma et al., 2013). 
Peroxidasin also can form sulfilimine chemical bonds using hypohalous acids (Bhave et al., 2012; 
Li et al., 2012) and also can generate hypochlorous acid, a reagent with microbicidal activity, and 
may further play a role in host defense in human plasma (Li et al., 2012). In addition, it is up-
regulated in the P53-dependent apoptotic cells (Horikoshi et al., 1999). It may be involved in ox-
LDL-induced (ox-LDL, oxidized low-density lipoprotein) endothelial cell apoptosis (Bai et al., 
2011) and also in tumor pathogenesis since peroxidasin is highly expressed in melanoma cell lines 
(Mitchell et al., 2000).  
 
Interestingly, mutations in PXDN gene (one affects the leucine-rich repeats domain and the other 
two affect the peroxidase domain) cause severe anterior segment dysgenesis in humans including 
corneal opacity, developmental glaucoma and congenital cataract, and the phenotypes of these 
patients are mainly present in the eyes (Khan et al., 2011) (Figure 1.4), suggesting that peroxidasin 
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plays an important role during eye development. Other work about peroxidasin and eye research 
is only confined to the expression pattern analysis in lower animals. In Xenopus tropicalis, 
peroxidasin can be detected in the eye-forming region, especially in the developing lens by in-situ 
hybridization (Tindall et al., 2005). Another in-situ hybridization study showed that peroxidasin is 
expressed in the lens vesicle and in the retina, especially in the lens at E10 in mice (Homma et al., 
2009). However, the role of peroxidasin during eye development is still unknown. 
 
 
Figure 1.4 The clinical manifestations of patients with PXDN mutations. The point mutation of CA2 family 
is located at the leucine-rich repeats domain (p.Arg341X). The point mutations of MEP60 and MEP59 families 
are located at the peroxidasin domains, one is Cys857AlafsX5 (MEP60) and the other is p.Arg880Cys (MEP59). 
The manifestations of patients in CA2 families is more severe and whole cornea opacity, whereas the patients in 
MEP60 and MEP59 families showed similar phenotype, including partial central/peripheral corneal opacity. 
Congenital cataract and developmental glaucoma are also found in these patients (The picture from Khan et al., 
2011) 
 
2.3.2 Bmpr1b 
BMP receptors are a family of transmembrane serine/threonine kinases, which consist of an N-
terminal signal sequence, a transmembrane domain and a serine/threonine kinase in the cytoplasm. 
There are three types of BMP receptors, Bmpr1a (Bmp receptor type 1a), Bmpr1b (Bmp receptor 
type 1b) and Bmpr2 (Bmp receptor 2). These three receptors may dynamically form different 
receptor complexes. In the absence of a Bmp ligand, the heteromeric and homomeric complexes 
of Bmp receptors (BR) are formed in living cells including BR-II/BR-Ia, BR-II/BR-Ib, BR-II/BR-
II, BR-Ia/BR-Ia, BR-Ib/BR-Ib and BR-Ia/BR-Ib, whereas in the presence of Bmp2, the hetero- and 
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homo-oligomerization is increased (Gilboa et al., 2000). Here I focus on the expression and 
function of Bmpr1b.  
 
Bmpr1b is highly conserved between human and mice. It is widely expressed in different types of 
cells and involved in multiple processes including proliferation, apoptosis and differentiation. It is 
expressed in neurons, astrocytes, oligodendrocytes, ependymal cells and microglia in the spinal 
cord (Miyagi et al., 2012). It also can be detected in embryonic stem cells during early development 
(Roelen et al., 1997), in the neural precursor cells in the dorsal region of the neural tube (Panchision 
et al., 2001) and in the proximal mesenchymal cells at the onset of mouse limb bud development 
(Barna et al., 2005). In addition, it is highly expressed in different malignant tumors, such as 
malignant glioma (Yamada et al., 1996), prostate cancer tissue (Ide et al., 1997; Kim et al., 2000) 
and epithelial ovarian cancer tissue (Ma et al., 2010), indicating that it may play a role in the 
pathogenesis of malignant tumors. In the eyes, Bmpr1b is expressed in the corneal epithelial and 
stromal cells (You et al., 1999). During early eye development, Bmpr1b mRNA is expressed in the 
optic vesicle at E9.0-E9.5 (Danesh et al., 2009; Faber et al., 2002), and it is mainly expressed in 
the ventral retina during E10.5-E11.5 by in-situ hybridization (Faber et al., 2002; Figure 1.5). 
Moreover, it is highly expressed in the embryonic retina at E13.5 and then its expression is 
decreased after E13.5 revealed by western blot, and its mRNA is detected in retinal progenitor 
cells at E14.5 by RT-PCR (Du et al., 2010). In adult mouse retina, Bmpr1b is expressed in the 
retinal ganglion cell layer (Du et al., 2010). In the chick retina, Bmpr1b is much less expressed in 
the retina and choroid compared to Bmpr1a and Bmpr2, and it is not detected in RPE by real-time 
PCR (Zhang et al., 2012).        
                              
Most studies about the role of Bmpr1b in development are from bone and ovarian research. 
Bmpr1b is required for distal limb development in the mouse (Baur et al., 2000; Kobayashi et al., 
2005). In the truncated-Bmpr1b (lacking of Bmpr1b kinase domain) transgenic mouse, Bmp 
signaling is blocked and bone formation is reduced during postnatal periods (Zhao et al., 2002). In 
humans, mutations in BMPR1B lead to Brachydactyly type A2 and whether the serine/threonine 
kinase activity is affected according to different mutations (Lehmann et al., 2003) and 
acromesomelic chondrodysplasia with genital anomalies (Demirhan et al., 2005). Mutations in 
GDF-5 (Growth differentiation factor 5, a ligand of Bmpr1b (Nishitoh et al., 1996; Nickel et al., 
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2005)) also cause Brachydactyly type A2 which is similar to the phenotype caused by Bmpr1b 
mutations (Seemann et al., 2005; Kjaer et al., 2006). At the cellular level, it plays a role in cell 
apoptosis and terminal differentiation (Panchision et al., 2001). For example, Bmpr1b can induce 
apoptosis in osteoblastic cells (Haÿ et al., 2004). Overexpression of mutant Bmpr1b (truncated 
Bmpr1b) leads to the block of Bmp2-induced osteoblast differentiation in vitro (Chen et al., 1998). 
In addition, Bmpr1b is important for ovarian development (Souza et al., 2002; Shimasaki et al., 
2003; Reader et al., 2012; Pulkki et al., 2012).  
 
Bmpr1b plays a role in the pathogenesis of gliosis. Bmpr1a conditional knockout mice (ablation 
of Bmpr1a in GFAP-expressing cells) exhibit defects in hyperactive glial cells, reduced gliosis and 
inflammatory cell infiltration in the spinal cords after injury, whereas Bmpr1b knockout mice 
showed that glial cells appear to be more active and attenuated glial is formed after injury. The 
gliosis phenotypes can be relieved by Bmpr1a/Bmpr1b double knock-out mice (Sahni et al., 2010). 
These also indicate that both the receptors function coordinately in a different way. Moreover, 
Bmpr1b is a major mediator of glial cell differentiation in the cultured hippocampus progenitor 
cells (Brederlau et al., 2004). 
 
Figure 1.5 The expression of Bmpr1b mRNA during 
early eye development by in-situ hybridization. The 
expression of Bmpr1b mRNA starts from E9.5, the earliest 
stage of eye development in mice and it is expressed in the 
optic vesicle. From E10.5 to E11.5, Bmpr1b is mainly 
expressed in the ventral retina. OV: optic vesicle. (The 
picture from Faber et al., 2002) 
 
 
A few studies demonstrate functional redundancy of Bmpr1 receptors. This means that either 
deletion of Bmpr1a or Bmpr1b does not cause any defects but deletion of Bmpr1a and Bmpr1b 
lead to severe phenotypes. For examples, deletions of Bmpr1a or Bmpr1b in cartilage are able to 
form intact cartilaginous elements in mice, whereas double mutants develop a severe generalized 
chondrodysplasia (Yoon et al., 2005). Similar to this condition, either Bmpr1a or Bmpr1b knock-
out mice does not exhibit any cerebellar defects, but Bmpr1a/Bmpr1b knock-out mice exhibit 
severe defects in cerebellar patterning and reduced size of cerebella (Qin et al., 2006). In addition, 
Bmpr1a/Bmpr1b knock-out mice showed that the development of two different types of 
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interneuron cell (D1 and D2) is defective in the dorsal spinal cord: D1 interneurons are absent and 
D2 interneurons are significantly reduced (Wine-Lee et al., 2004). 
 
However, there are very few studies focusing on the role of Bmpr1b in eye development. From 
previous very limited studies, Bmpr1b also seems important for eye development. In Bmpr1b 
knockout mice, some retinal axons are misguided in the optic nerve head at E15.5 - E16.5, and 
apoptosis may be increased in the retina (Liu et al., 2003). Interestingly, Bmpr1a knockout mice 
have normal eye development, whereas Bmpr1a/Bmpr1b double knockout mice showed severe 
retinal defects including retinal growth and neurogenesis (Murali et al., 2005), suggesting that 
mpr1b may interact with Bmpr1a and function coordinately. In addition, primary lens fiber cell 
differentiation is defect in the lenses of Bmpr1b transgenic mice (Faber et al., 2002).  
 
 
2.4 Two new ENU-induced mouse mutants with different eye phenotypes  
2.4.1 KTA48: ENU-induced peroxidasin-mutant mice 
In the past, the in vivo functions of peroxidasin were investigated in lower organisms such as 
Drosophila and C. elegans. Mammalian animal models with peroxidasin defects are lacking. 
KTA48, to the best of my knowledge, is the first peroxidasin-mutant mouse line and also the first 
mammalian model with a peroxidasin mutation. ENU (N-ethyl-N-nitrosourea) is an alkylating 
agent by which the ethyl group can be transferred to the oxygen and nitrogen atoms of the 
nucleotide base in the genomic DNA and it causes point mutations in the spermatogonial stem 
cells with a high frequency in mice (Justice et al., 1999). ENU is widely used for generating mouse 
mutants, followed by a phenotype-driven screening and the identification and confirmation of gene 
mutations. The ENU-induced peroxidasin mutant mice have an appearance of microphthalmia, 
white spots on the coat and kinky tail (Figure 1.6). The KTA48 mutation was identified and found 
to be located at T3816A (cDNA) in exon 19 of Pxdn mRNA (coding sequence, from start codon 
to the stop codon) by linkage analysis, positional candidate approach, haplotype analysis and 
sequencing (unpublished work by Dr. Sibylle Sabrautzki, Dr. Helmut Fuchs and Dr. Jochen Graw, 
HMGU (Helmholtz Center Munich or German Research Center for Environmental Health)). It is 
predicted to cause a premature stop codon (Figure 1.7) and thereby leads to a partial loss of 
function of peroxidasin in the mutant mice.   
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Figure 1.6 The procedure for identification of the point mutation in KTA48. KTA48 homozygous mice 
exhibited microphthalmia, white spots on coat and kinky tail due to a point mutation induced by ENU. Linkage 
analysis, haplotype analysis and sequence analysis have been used to identify the point mutation (The picture 
taken by Ms. Erika Bürkle and Ms. Monika Stadler, HMGU).  
 
 
Figure 1.7 The point mutation of KTA48 mutant mice. The point mutation in KTA48 mutants is located at 
T3816A (Exon 19 of Pxdn mRNA, coding sequence from start codon to the stop codon) and it produces a new 
restriction site for Alw26I and a new stop codon (TGA, underlined). (Performed by Dr. Sibylle Sabrautzki, Dr. 
Helmut Fuchs and Dr. Jochen Graw, HGMU) (The figure of peroxidasin structure from Cheng et al., 2008, 
modified). 
 
 
2.4.2 Ali030: ENU-induced Bmpr1b-mutant mice 
Ali030 is another ENU-induced mutant mouse line characterized by a point mutation in the 
Bmpr1b gene (Figure 1.8, A). Ali030 mutant mice have an appearance of severe brachydactyly 
(Figure 1.8, B). The mutation was identified by similar genetic methods used for KTA48 mutants, 
including linkage analysis, positional candidate approach, haplotype analysis and sequencing. This 
point mutation in Ali030 mutants is located at the second base pair in intron 10 of Bmpr1b gene 
(Figure 1.8, A) and it is predicted that it may influence the alternative pre-mRNA splicing. The 
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identification of the point mutation in Ali030 mutant mice was performed by Dr. Sibylle Sabrautzki 
(unpublished work). The mutant mice were sent to GMC (German mouse clinic) for initial eye 
screening by AC master (a special equipment used to measure anterior chamber depth, lens 
thickness and eye size (Puk et al., 2006)), funduscopy and optokinetic drum. There is a big hole in 
the optic nerve head (Figure 1.8, C) and the vision acuity was reduced (Figure 1.8, D) in Ali030 
homozygous mice, and larger axial eye length was found in mutants which may be due to the 
enlarged optic nerve head, but the lens size and transparency are not changed in these mutants 
(Ali030 GMC report, unpublished). In addition, the global retinal function is not changed in Ali030 
mutant mice at 10 weeks, because they exhibit regular electrical activity of the retina response to 
flash light (12,500 cd/m2) by ERG (Electroretinogram), and there are no obvious differences 
between wild types and mutants (Figure 1.8, E, performed by Susanne Weber, unpublished).  
 
 
     A 
         
       
     B                                                                               C 
                           
                        Brachydactyly                                            A coloboma in the 
                                                                                                    optic nerve head 
                                                                                                     
      D                                                                               E 
 
                 Visual acuity in Ali030 mice                                            ERG in Ali030 mice 
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Figure 1.8 A point gene mutation, brachydactyly, the hole in the optic nerve head and reduced visual 
acuity in Ali030 mutants. (A) A point mutation was found in the second base pair of intron 10 of Bmpr1b in 
Ali030 mutants (From Dr. Sibylle Sabrautzki, HMGU). (B-C) The distal limb showed a phenotype of 
Brachydactyly (B) and the optic nerve head coloboma (C) by fundoscopy (performed by Dr. Claudia Dalke, 
HMGU). (D) The visual acuity was measured by optokinetic drum and it is significantly reduced in Ali030 
homozygous mutants compared to wild types and heterozygous, but no difference in visual acuity was found 
between wild types and heterozygous (performed by Susanne Weber, HMGU). (E) Ali030 mutant mice exhibit 
regular electrical activity of the retina response to flash light (12,500 cd/m2) at 10 weeks (performed by Susanne 
Weber, HMGU). 
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3 Aims of the study 
3.1 KTA48 project 
The role of peroxidasin in eye development is largely unknown. Here, I investigated the role of 
peroxidasin in eye development using the ENU-induced KTA48 mutant mice, in which the eye 
phenotype is highly similar to the manifestations in patients with PXDN mutations. The first 
question is the expression pattern of peroxidasin and morphological phenotypes of peroxidasin-
mutant eyes during embryonic eye development and postnatal periods. The second question is to 
identify possible cellular and molecular mechanism of peroxidasin in eye development based on 
in-situ hybridization, BrdU assay, immunostaining and real-time PCR.  
 
 
3.2 Ali030 project 
Very limited studies showed that Bmpr1b may play roles in retinal growth, neurogenesis and axon 
guidance. The roles of Bmpr1b in retinal development are still not clear. In this study, ENU-
induced Ali030 mutant mice were used to investigate the role of Bmpr1b during retinal and optic 
nerve development. Specifically, the first question is to analyze how this point mutation affects 
RNA splicing process. The second question is to find and analyze the detailed ocular phenotypes 
in mutants and to investigate the role of Bmpr1b in retinal development in vivo and in vitro. Finally, 
clinical samples (epiretinal and inner limiting membranes) from patients with different types of 
retinal gliosis were analyzed.  
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4 Materials and Methods 
4.1 Materials 
 
4.1.1 Equipment 
 
Equipment Manufacturer 
Balance (TE 1502S) Sartorius AG, Germany 
Cell culture incubator (CO2 -Teco 20) Selutec GmbH, Germany 
Light microscope camera (Axiocam) Zeiss, Germany 
Cell counting chamber Paul Marienfeld GmbH, Germany  
Centrifuge (Eppendorf 5415D) Eppendorf, Germany 
Centrifuge (Sigma 3K18) Sigma, Germany 
Centrifuge (Eppendorf 5415R) Eppendorf, Germany 
Centrifuge (Biofuge) Heraeus, Germany 
Centrifuge (SD2 20) Car Roth GmbH, Germany 
Fume hood Waldner Laboreinrichtungen GmbH, Germany 
Gel electrophoresis apparatus Biorad, Germany 
Gel documentation system (Argus X1) Biostep GmbH, Germany 
Incubator Memmert, Germany 
Laminar flow Gelaire Pty Ltd, Australia 
Microwave Samsung, Germany 
Fluorescence microscopy (DMI 6000B) Leica, Germany 
Confocal microscopy (Olympus 8934 ) Olympus, Japan 
Microtome (RM 2050) Leica, Germany 
Microtome (Cryotome) Leica, Germany 
pH meter (761 calimetic) Knick, Germany 
Pipettte Eppendorf, Germany 
Refrigerators Liebherr, Germany 
Shaker (Polymax 1040) Heidolph Instruments GmbH, Germany 
Shaker (Rotamax 120) Heidolph Instruments GmbH, Germany 
Shaker (Centromat S) Braun Melsungen AG, Germany 
Spectrophotometer (Nanodrop: ND1000) PeQlab Bioehcnology GmbH, Germany 
Thermal cycle (PTC-225) MJ Research, Germany 
Stereomicroscope Zeiss, Germany 
Vortex (G-560E) Scientific Industries, USA 
Water bath LTF labortechnique GmbH, Germany 
Water purification sytem (MilliQ biocel) Millipore, Germany 
Heating plate (Ikamag) Ludwig Empgenzeder, Germany 
Thermomixer (7410) Bachofer, Germany 
 
4.1.2 Consumables 
 
Consumables Manufacturer 
96-well optical well adhesive film ABI, Germany 
48-well optical well adhesive film ABI, Germany 
Petri dishes   Greiner Bio-One GmbH, Germany 
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Cell culture plates (96-well) Becton Dickinson, France 
Cover glass  Roth, Germany 
Coverslips Roth, Germany 
Disposable cuvettes Eppendorf, Germany 
Glass slides Gerhard Menzel Gmbh, Germany 
Parafilm Carl Roth GmbH, Germany 
Pipette tips Biozym, Germany  
Reaction tubes (1.5 ml, 2 ml) Eppendorf, Germany 
Gloves Meditrade GmbH, Germany 
Syringes  Braun, Germany 
Needles (27G) Henke sass, wolf GmbH, Germany 
Reaction tubes (15 ml, 50 ml) BD Falcon, Germany 
SuperFrost® Plus microscope slides Menzel, Germany 
Pipetman (2µl  10µl    20µl  200µl  1ml) Gilson, France 
96-well plates for luminometer Thermo Fisher Scientific, Denmark 
 
 
4.1.3 Chemicals 
 
Chemical Catalogue 
number 
Manufacturer 
Acetic acid  1.00063 Merk, Germany 
Agarose 840004 Biozyme, Germany 
Aqua Poly Mount 
 
18606 Polysciences, Germany 
Ampicillin K029.1 Carl Roth GmbH, Germany 
5-Bromo-2’-Deoxyuridine B5002 Sigma-Aldrich, Germany 
BMP-2 A gift from Prof. Sebald Walter, Würzburg, Germany 
Citric acid X863.2 Carl Roth GmbH, Germany 
4',6-diamidino-2-phenylindole (DAPI) D9564 Sigma-Aldrich, Germany 
Diethyl pyrocarbonate (DEPC) 18835 Serva Electrophoresis GmbH, Germany 
DMEM with low glucose E15-806 PAA Laboratories GmbH, Austria 
DMEM with high glucose and sodium 
pyruvate 
E15-843 PAA Laboratories GmbH, Austria 
DiI D-282 Invitrogen, Germany 
DiO D-275 Invitrogen, Germany 
dNTPs R0241 Fermentas GmbH, Germany 
Eosin A gift from Mr. Shen Chi from Institute of Experimental 
Genetics, HGMU 
Ethylenediaminetetraacetic acid (EDTA) 8043.2 Carl Roth GmbH, Germany 
Ethanol 2246.2500 Th. Geyer GmbH and Co. KG Renningen, 
Germany 
Ethidiumbromid A1152 Applichem GmbH, Germany 
Eukitt quick hardening mounting medium 03989 Fluka, Germany 
Fetal bovine serum A15-104 PAA GmbH, Austria 
Formamide P040.1 Carl Roth GmbH, Austria 
Formamide (37%) 4979.1 Carl Roth GmbH, Germany 
GDF-5 (recombinant murine) 315-24 Peprotech, Germany 
25% Glutaraldehyde G5882 Sigma-Aldrich, Germany 
Glycerol  1.04093 Merk KgaA, Germany 
Glycine G7126 Sigma-Aldrich, Germany 
31 
 
Hydochloric acid (HCl) 1.00319 Merk KgaA, Germany 
Isopropylthio-β-galactoside (IPTG) 2316.3 Carl Roth GmbH and Co. KG, Germany 
Levamisole 31742 Sigma-Aldrich, Germany 
Mayer’s hematoxylin MHS16 Sigma-Aldrich, Germany 
2-Mercaptoethanol M7522 Sigma-Aldrich, Germany 
Methnol  1.06009 Merk KGaA, Germany 
MgCl2 2189.1 Carl Roth, Germany 
NaAc 1.06268 Merk KGaA, Germany 
OCT Compound Tissue Tek 4583; 
1200600006 
Sakura Finetek, USA 
Osmium tetroxide solution (2%) 23310-10 Polysciences, Germany 
100× Penicillin/streptomycin P11.010 PAA GmbH, Austria 
Paraformaldehyde (PFA) 0335.3 Carl Roth, Germany 
2-Propanol 9866.1 Carl Roth, Germany 
Phenethyl acetate 290580 Sigma-Aldrich, Germany 
Precision Plus Protein™ Dual Color 
Standards 
161-0374 BIO-RAD, Germany 
Potassium chloride (KCl) 4936 Merk, Germany 
RNase Zap R2020 Sigma-Aldrich, Germany 
Roti-Histol  6640 Carl Roth GmbH and Co. KG, Germany 
Roti-Mount HP-19 Carl Roth GmbH and Co. KG, Germany 
Sodium chloride (NaCl) 1.06404 Merk KGaA, Germany 
Sodium citrate 3580.1 Carl Roth GmbH, Germany 
Sodium deoxycholate D6750 Sigma-Aldrich, Germany 
Sodium dodecyl sulfate  (SDS) 20760 Serva Feinbiochemica GmbH and KG, 
Germany 
Sodium hydroxide (NaOH) 1.06482 Merk KGaA, Germany 
Sodium phosphate dibasic 1.06580 Merk KGaA, Germany 
Sodium phosphate monobasic 1.06346 Merk KGaA, Germany 
Sucrose 4621.1 Carl Roth GmbH and Co. KG, Germany 
Toluidine blue A gift from Institute of Pathology, HGMU 
0.05% Trypsin-EDTA L11-004 PAA, Germany 
Trypan blue L6323 Biochrom, Germany 
Tween-20 9127.1 Carl Roth GmbH and Co. KG, Germany 
X-gal  R0404 Fermentas GmbH, Germany 
Xylene 1.08685 Merk KGaA, Germany 
   DiI: 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate 
   DiO: 3,3'-Dioctadecyloxacarbocyanine perchlorate     
 
4.1.4 Enzymes 
Enzymes Catalogue number Company 
Alw36I ER0031 Fermentas GmbH, Germany 
Dream Taq Green PCR 
Master Mix 
K1082 Fermentas GmbH, Germany 
HindIII ER0501 Fermentas GmbH, Germany 
Phusion® High-Fidelity 
DNA Polymerase 
M0530S New England Biolabs, Germany 
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SP6 polymerase EP0131 Fermentas GmbH, Germany 
T7 polymerase EP0111 Fermentas GmbH, Germany 
Taq DNA Polymerase 18038 Invitrogen, Germany 
XhoI 742929 Boehringer Manheim, Germany 
 
4.1.5 Commercial kits 
 
Kits Catalogue number Manufacturer 
Anti-Digoxigenin-Ap Fab 
fragments 
11093274910 Roche Dignostics GmbH, 
Germany 
BM purple Ap substrat 11442074001 Roche Dignostics GmbH, 
Germany 
DH5α competent cells 18258012 Invitrogen, Germany 
DIG RNA labeling mixture  11277073N5P12 Roche Dignostics GmbH, 
Germany 
DNA Midi preparation Kit 12143 Qiagen, Germany 
DNA Mini preparation Kit 
(NucleoSpin® Plasmid) 
740588.50 Macherey-Nagel, Germany 
DreamTaq Green PCR Master 
Mix 
K1082 
 
Fermentas, Germany 
 
Embed-It™ Low Viscosity 
Epoxy Kit 
24300-1 Polysciences, Germany 
5x HOT FIREPol® EvaGreen® 
qPCR Mix Plus (ROX) 
08-24-00001 Solis BioDyne, Estonia 
JB-4® Embedding Kit 00226-1 Polysciences, Germany 
Lipofectamine®2000 
Transfection Reagent 
11668-027 Invitrogen, Germany 
NucleoSpin® Gel and PCR 
Clean-up 
740609.50 Macherey-Nagel, Germany 
pcDNA™3.1 Directional 
TOPO® Expression Kit 
K4900-01 Invitrogen, Germany 
Phusion® High-Fidelity DNA 
Polymerase 
M0530S New England Biolabs, Germany 
Ready-To-Go T-primed First-
stand Kit 
GEHE27-9263-01 
 
Amsterdam Biosciences,   
Germany 
RNeasy Mini Kit 74104   Qiagen, Germany 
1kb DNA ladder marker SM0311 Fermentas GmbH, Germany 
 
4.1.6 Softwares and tools 
 
Softwares and tools Website 
BioEdit software 9.0 http://www.mbio.ncsu.edu/bioedit/bioedit.html 
DNA sequence and gene analysis http://www.ensembl.org 
ImageJ http://rsb.info.nih.gov/ij/ 
Microsoft office 2010 http://www.microsoft.com 
NCBI http://www.ncbi.nlm.nih.gov/ 
Olympus FluoView 1.7a http://www.olympusconfocal.com/ 
Primer premier 5.0 http://primer-premier.softpedia.com/ 
StepOne™ Real-Time PCR Systems http://www.appliedbiosystems.com/ 
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4.1.7    Primers 
Table 4.1 Primers for genotyping 
Primer Sequence Anealing 
temperature (°C) 
Product 
size (bp) 
Pxdn-Ex19-L1  5’-CCTTGTGGCTGACATTCTCCC-3’ 55 356 
Pxdn-Ex19-R1            5’-CACTTTCCCCGTTCTCAGGC-3’         
AliCR       5’-CAGGAGGTTGTGAGCTAGGAAA-3’  
62 
 
see below AliCF       5’-GGAATGTAACCAGGAGATGAGG -3’ 
AliWtF 5’-CGATGGAGCAGTGATGAGGT-3’ 
AliMtF           5’-CGATGGAGCAGTGATGATGG-3’ 
 
Product size (Ali030 genotyping):    
  
     WT                     AliCR and AliWtF  291 bp    AliCF and AliWtF  376 bp 
                                AliCR and AliMtF  291 bp    AliCF and AliMtF      0  bp 
 
   Homozygous        AliCR and AliWtF  291 bp    AliCF and AliWtF   0   bp 
                                AliCR and AliMtF  291 bp    AliCF and AliMtF  373 bp 
 
   Heterozygous       AliCR and AliWtF  291 bp    AliCF and AliWtF  376 bp 
                                AliCR and AliMtF  291 bp    AliCF and AliMtF   373 bp 
 
 
Table 4.2 Primers for cloning of Bmpr1b cDNA 
Primer Sequence Anealing 
temperature (°C) 
Product 
size (bp) 
Bmpr1b-cDNA-CACCL1    5’-CACCATGCTCTTACGAAGCT-3’ 55 
 
1509 
Bmpr1b-cDNA-R1 SC    5’-TCAGAGTTTAATGTCCTGGG-3’ 
 
 
 
Table 4.3 Primers for cloning of riboprobes for in-situ hybridization 
Primer Sequence Anealing 
temperature (°C) 
Product 
size (bp) 
Pax6-forward     5’-GGGAGTGCCCTTCCATCT-3’  62 885 
Pax6-reverse     5’-CCCATGGGCTGACTGTTC-3’  
 
 
Table 4.4 Primers for real-time RT-PCR 
Gene Primer Sequence 
Pax6 Pax6-qF   
Pax6-qR                   
             5’-GTTCTTCGCAACCTGGCTA-3’ 
     5’-TGAGCTTCATCCGAGTCTTCT-3’ 
TGFβ1 TGFβ1_FW 
TGFβ1_RV 
             5’-TGACGTCACTGGAGTTGTACG-3’ 
             5’-GGTTCATGTCATGGATGGTGC-3’ 
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TNF-α TNFα_2F 
TNFα_2R 
             5’-CACCACGCTCTTCTGTCT-3’ 
             5’-GGCTACAGGCTTGTCACTC-3’ 
IL-1β IL-1β_FW 
IL-1β_RV 
             5’-CAACCAACAAGTATTCTCCATG -3’ 
             5’-GATCCACACTCTCCAGCTGCA-3’ 
Tubea TubeaF 
TubeaR 
             5’-CCAGATGCCAAGTGACAAGA-3’ 
             5’-GTGGGTTCCAGGTCTACGAA-3’ 
 
 
4.1.8    Buffers and solutions 
DNA preparation and PCR 
Lysis buffer 
 
Tris pH 8.0  
5M NaCl 
0.5M EDTA pH8.0  
10% SDS 
Add H2O to 50 ml  
 
                 500 μl 
                    1 ml 
                  1 ml 
                 2.5 ml 
dNTP mix 
 
dATP  
dTTP 
dGTP  
dCTP 
in dd H2O 
 
               2.5 mM 
               2.5 mM 
               2.5 mM 
               2.5 mM 
 
Tissue preparation 
0.2 M Phosphate buffer 
 
Sodium phosphate monobasic  
Sodium phosphate dibasic 
Disolve in H2O 
 
              16.56 g/l  
              65.70 g/l 
4% Paraformaldehyde 
 
Paraformaldehyd(PFA)  
Dissolve in 1xPBS  
 
                   40 g/l 
30% Sucrose solution 
 
Sucrose  
dd H2O                         
 
                      15 g 
                    50 ml 
In-situ hybrydization 
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1M Tris-Cl  
 
Tris-base 
Disolve in H2O adust PH 7.4 with 
HCl  
 
                121.4 g/l 
Hybe buffer  
 
Deionized formamide  
20X SSC 
Heparin solution  
Tween-20 
dd H2O 
Adjust  pH  to  6.0 with 1M Citric 
acid  
 
                     10 g/l 
                     10 g/l 
                      5 μl  
                      10 μl 
                  2.05 ml 
 
Hybridization solution 
 
 
50x Denhardt’s 
100mg/ml baker yeast tRNA 
20x SCC 
form amide 
Fill up to 50 ml with dd H2O  
 
                       5 ml 
                    125 ul 
                  12.5 ml  
                     25 ml 
 
20X SSC 
 
 
NaCl 
Sodium citrate 
Add dd H2O and adjust pH to 7.0 and 
autoclave   
 
        175.3 g 
          88.2 g 
 
 
MAB  
 
Maleic acid  
NaCl 
Add 800 ml dd H2O 
Adjust pH to 7.5 with NaOH 
Add to 1L with dd H2O 
 
11.6 g 
  8.8 g 
 
 
MABT 
 
MAB + 0.1% Tween-20 
 
 
NTE  
 
5M NaCl 
1M Tris/HCl pH 7.0 
0.5M EDTA 
 
100ml 
10 ml 
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Add to 1L with dd H2O 10 ml 
 
 
NTMT  
 
 
 
5M NaCl 
1M Tris/HCl pH 9.5 
1M Mg2Cl 
0.1% Tween-20 
Add to 1L with dd H2O 
 
 
 
       20 ml 
     100 ml 
       50 ml 
 
PBS: 
 
5M NaCl 
1M Na-phosphate buffer pH7.3 
Add to 1L with dd H2O 
 
       30 ml 
       15 ml 
 
 
Immunofluorescence staining   
0.2 M Phosphate buffer: 
 
Sodium phosphate monobasic  
Sodium phosphate dibasic 
Disolve in H2O 
 
  16.56 g/l  
  65.70 g/l 
Blocking solution: 
(for sections) 
 
Fetal bovine serum  
TritonX-100 
In 1Х PBS 
 
           3%  
      0.25% 
Blocking solution: 
(for whole-mount) 
 
Fetal bovium serum  
TritonX-100 
In 1Х PBS 
 
           3%  
      0.25% 
2M HCl: 
(for BrdU sections) 
 
 
100% HCl  
Add d H2O to 100 ml 
 
 
   16.95 ml 
 
2M HCl in PBST: 
(for BrdU sections) 
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37% HCl  
Add d PBS/0.1%TritonX-100 to 12 ml 
          2 ml 
 
 
4M HCl: 
(for BrdU sections) 
 
   37% HCl  
   Add d H2O to 12 ml 
 
          4 ml 
 
 
Borate buffer: 
 
 
Sodium citrate (1M): 
 
Boric acid 
Dissolved in 1L H2O and adjust pH to 
8.5 
 
Sodium citrate * 2H2O    
Add d H2O to 500 ml      
Total volume   1L                      
 
                6.183 g   
 
 
 
                129.1 g        
            
 
Histology 
Methylene blue and  
Basic fuchsin solution 
 
 
 
 
Methylene Blue Stock  
     Methylene blue      
     Distilled water    
 
Basic Fuchsin Stock 
     Basic fuchsin             
     Distilled water 
Working solution 
         
 
 
 
             
                     0.5 g 
                  400 ml 
 
 
                      0.5 g 
                   400 ml 
 
 
 
 
Working solution 
     Methylene Blue stock    
     Basic Fuchsin stock      
     0.2M PBS pH 7.2 
     95% Ethnol 
 
                     12 ml 
                     12 ml 
                     21 ml 
                     15 ml 
 
Sorensen’s buffer (0.133 
M, pH 7.2) 
 
 0.133 M Na2HPO4                                              
 0.133 M KH2PO4      
 
35.76g Na2HPO4 / 1L dH2O                                         
9.08g KH2PO4/ 0.5L dH2O 
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 71.5 mL 0.133 M Na2HPO4 and 
28.5 mL 0.133 M KH2PO4 
                      
pH 7.2 
 
Davidson’ solution  
 
 
 
 
    95% Ethanol      
    37% Formadehyde    
    Acetic acid  
    Distilled water              
 
          
  28.5. ml 
      20 ml 
      10 ml 
   31.5 ml                                     
 
1% Toluidine blue solution 
 
 
 
    Toluidine blue 
    Distilled water              
 
          
       1.0 g 
    100 ml 
Western blot 
RIPA  
 
 
5M NaCl  
NP40 
10% SDS 
0.5M EDTA 
1M Tris-HCl pH 8.0 
10% Deoxycholate 
Add dd H2O to 500 ml 
 
 15 ml  
 5 ml 
2.5 ml 
 1 ml 
 25 ml 
 25 ml 
4Х loading dye 
 
2-Mercaptoethanol 
Glycerin 
20% SDS 
1M Tris HCl pH 8.5 
Bromphenol blue 
dd H2O  
 
1.6 ml 
5 ml  
8 ml 
2 ml 
50 mg 
3.4 ml 
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4.2 Methods 
4.2.1 Animal experiments 
4.2.1.1 Mouse strains 
All animal care and experimental procedures were conducted in accordance with the German Law 
for Animal Protection and the corresponding rules in Helmholtz Center Munich. The mouse lines 
in the studies were as follows: 
 
KTA48 mouse line: a point mutation (Exon 19, T3816A, coding sequence) within the peroxidase 
domain of peroxidasin with the background of C3H or C57BL/6J. The control mice used were 
littermates or C3H or C57BL/6J wild-type mice at the same age. 
 
Ali030 mouse line: a point mutation (a T->G transversion in the second base pair of intron 10) in 
Bmpr1b with the background of C57BL/6J. The control mice used were littermates or C57BL/6J 
mice with the same age. 
 
4.2.1.2 BrdU labelling 
The thymidine analog, 5-bromo-2-deoxyuridine (BrdU), can incorporate itself into newly 
synthesized DNA during the S-phase of the cells. It is used to label proliferating cells in mice and 
it is widely used in the study of neurogenesis (Abrous et al., 2005). Timed pregnant mice were 
intraperitoneally injected with BrdU (0.1mg/g, dissolved in 0.09% NaCl solution) and sacrificed 
after 2 hours. The embryos were collected and tails were used for genotyping.  
 
In order to investigate the proliferation of ventral glial cells in postnatal Ali030 mice (P21), BrdU 
was intraperitoneally injected (0.05mg/g, dissolved in 0.09% NaCl solution) and the mice were 
sacrificed at 24 hours after injection.   
 
4.2.1.3 Embryo and tissue preparation 
Embryo preparation 
The noon of the day on which the presence of the vaginal plug is regarded as day 0.5 of pregnancy 
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(E0.5). At noon next day the embryo is regarded as E1.5, and so on. For embryonic eyes, timed 
pregnant females were sacrificed by CO2 asphyxiation and embryos were dissected and collected 
from uterus.  
 
For cryosections or paraffin sections, the embryo heads were fixed in 4% PFA/0.1M PBS for at 
least two hours at room temperature, followed by washing in PBS and transferring in 30% sucrose 
until they sink to the bottom of the tubes. For cryosections, they were embedded in Tissue-Tek 
O.C.T (Sakura Finetek, USA) and stored at -80 °C. For paraffin sections, they were dehydrated in 
graded ethanol series (25%, 50% and 75% ethanol) for 10 minutes each and embedded in paraffin 
and stored at -20 °C.  
 
For plastic sections, the embryos were fixed in Davidson’s solution overnight, and then dehydrated 
in 100% ethanol for 3 times, with each for 15 minutes, followed by fixation in JB-4 solution 
(Polysciences, Germany), and then embedded in JB-4 plastic medium and stored at room 
temperature in dark.  
 
Postnatal tissue preparation 
For cryosections of whole postnatal eyes, mice were sacrificed by CO2 asphyxiation or cervical 
dislocation and fresh eyes were immediately embedded in Tissue-Tek O.C.T and stored at -80 °C.  
 
For the cryosections from postnatal retinal tissues, the mice were sacrificed by CO2 asphyxiation 
or cervical dislocation, followed by dissection of the eyes. Further preparation was done in ice-
cold PBS under the microscope. Briefly, the cornea was excised and the lens was removed. Then 
the retina and optic nerve were fixed in 4% PFA/PBS for 30 minutes at 4°C, followed by wash in 
PBS and then cryoprotection in 30% sucrose overnight at 4°C. The samples were embedded in 
Tissue-Tek O.C.T. Compound and stored at -80 °C before further processing.  
 
For plastic sections, the procedure is the same as the method used in embryo preparation. The JB-
4 plastic block holders were stored at room temperature in dark. 
 
For the semithin section of the optic nerve, the procedure is the same as the method used in electron 
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microscopy sample preparation. Briefly, the samples were immersed in 2% PFA/2.5% 
glutaraldehyde in 0.133 M Sorensen’s buffer, pH=7.2 for 24-48 hours at 4 °C. Then the samples 
were washed in 0.133 M Sorensen’s buffer, pH=7.2 for three times. After that, the samples were 
stained with 2% OsO4 in 0.133 M Sorensen’s buffer for 1 – 1.5 h, followed by washing the samples 
in 0.1 M 0.133 M Sorensen’s buffer, pH 7.2 for three times. Then the tissues were dehydrated in 
50% ethanol, 50% ethanol, 70% ethanol, 90% ethanol and 95% ethanol for 10 minutes, 
respectively. The samples were infiltrated and embedded in Embed-It Low Viscosity Epoxy Resin 
using Embed-It™ Low Viscosity Epoxy Kit (Polysciences, Germany). Finally place the samples 
in the mold and let them polymerise in 60°C oven for 24-48 hours. 
 
Eye tissue preparation for gene expression analysis 
For real time PCR experiments, two eyes from each embryo or one eye from each postnatal mouse 
as one group were or was collected and stored at -80 °C for further experiments. The tail tissues 
were collected and stored at -20 °C for genotyping.  
 
Eye tissue preparation for protein analysis 
For Western blot experiments for embryonic eyes, twelve eyes from six E15.5 embryos as one 
group (wild types and mutants, respectively) were collected and stored at -80 °C for further 
experiments.  
 
For Western blot experiments for 1 month eyes, four eyes from two mice were collected as one 
group (wild types and mutants, respectively). The eyes were stored at -80 °C for further 
experiments. 
 
Sectioning of eyes 
For the cryosections, the eyes were cut at 10 μm (embryonic eyes) or 12 μm (postnatal eyes or 
retina) using a Cryostat (Leica Microsystems, Germany) at -20 °C, and a series of sagittal or 
coronal sections were collected using SuperFrost® Plus slides (Menzel, Germany). The slides were 
stored in -80 °C.  
 
For the paraffin sections, the embryonic eyes were cut at a thickness of 8 μm using Microtome 
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(Leica Microsystems, Germany), floated out on a warm water bath (37-40 °C) and then picked up 
by SuperFrost® Plus slides. The slides were dried on the warm plate at 37 °C for 1 hour and then 
stored at -20 °C. 
 
For the plastic sections, the eyes were cut along a sagittal plane with a glass knife on a Microtome 
(Leica Microsystems, Germany) and the thickness of each section was at 2-3 μm. Then the sections 
were put into a drop of distilled water on the SuperFrost® Plus slides to remove any folding, 
followed by drying them on the hot plate (100 °C). The slides were stored at room temperature.  
 
4.2.2 Clinical samples 
This study was conducted in cooperation with Dr. Goran Petrovski from Department of 
Ophthalmology, University of Debrecen, Hungary and Dr. Xhevat Lumi from University Medical 
Centre Ljubljana, Slovenia. The study was approved by the Medical Ethics Committee of 
University Medical Centre Ljubljana, Slovenia, and informed consent was obtained from each 
patient according to the tenets of the Declaration of Helsinki. All the epiretinal membranes (ERM) 
and inner limiting membranes (ILM) were kindly provided by Dr. Goran Petrovski and Dr. Xhevat 
Lumi in the University Medical Centre Ljubljana. The ERMs and ILMs samples were collected 
from 15 patients with retinal gliosis, which were used for studying the expression of four different 
markers (GFAP, Sox2, Pax2 and Nestin) by whole-mount immunofluorescence. There are 6 
patients with secondary retinal gliosis (retinal detachment, PVR, diabetic retinopathy, and uveitis) 
and 9 patients with idiopathic retinal gliosis. Totally 14 epiretinal membranes and 15 inner limiting 
membranes were used in the study. All the samples were fixed in 4% PFA for 24 hour to 1 week 
until further whole-mount immunofluorescence. The protocol details were described in 4.2.3.5. 
The clinical characteristics is summarized in Table 4.5.  
 
Table 4.5 Clinical characteristics of epiretinal and inner limiting membranes 
No Diagnosis Types of Membrane 
1 
Epimacular membrane (fibrotic), Lattice degeneration, 
retinal detachment 
    Secondary (Retinal detachment) 
2 Epimacular membrane    Idiopathic 
3 Epimacular membrane     Idiopathic 
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4 Rhegmatogenous retinal detachment     Secondary (Retinal detachment) 
5 Proliferative diabetic retinopathy     Secondary (Diabetic retinopathy) 
6 Epimacular membrane      Idiopathic 
7 Epimacular membrane     Idiopathic 
8 Epimacular membrane, uveitis     Secondary (uveitis) 
9 Retinal detachment after PPV     Secondary (PVR) 
10 Epimacular membrane     Idiopathic 
11 Epimacular membrane     Idiopathic 
12 Proliferative diabetic retinopathy     Secondary (Diabetic retinopathy) 
13 Vitreomacular traction (VMT)     Idiopathic/VMT 
14 Epimacular membrane     Idiopathic 
15 Epimacular membrane     Idiopathic 
 
PPV: Pars Plana Vitrectomy; PVR: Proliferative vitreoretinopathy. 
 
4.2.3 Histology 
4.2.3.1 Methylene blue and Basic fuchsin staining 
The plastic sections were directly immersed in Methylene blue-Basic fuchsin solution for 25 
seconds, followed by washing 4 times in MilliQ water, with each for 2-3 minutes. The slides were 
dried in the fume hood and mounted using EUKITT quick-hardening mounting medium.  
 
4.2.3.2 Hematoxylin and Eosin staining 
The paraffin sections were deparaffinized in xylene, with first change for 15 minutes and second 
change for 10 minutes. Then the slides were rehydrated in graded ethanol series (100%, 100%, 
95%, 80%, 70%, 50%, 30%) with each for 2 minutes. After rinsing in MilliQ water, the slides were 
stained with Mayer’s Hematoxilin for 3-5 minutes and then washed in tape water. The slides were 
immersed in 0.1% sodium bicarbonate solution for 1 minute. After rinsing in 95% ethanol, the 
slides were counterstained in Eosin Y solution for 30 seconds. Then the slides were dehydrated 
through 95% ethanol and 100% ethanol, with each for 5 minutes. The slides were dried in the fume 
hood and mounted with EUKITT quick-hardening mounting medium. 
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4.2.3.3 Toluidine blue staining  
The cross sections (2-3 μm) of the optic nerve were immersed in Toluidine blue solution and dried 
on a hot plate for 1 minute, followed by washing them with tape water. The slides were mounted 
with EUKITT quick-hardening mounting medium after completely dried.  
 
4.2.3.4 In-situ hybridization  
Paraffin sections were deparaffinized through two changes of xylene with each for 15 minutes and 
then rehydrated in a graded series of ethanol (100%, 100%, 95%, 90%, 80%, 70%, 50%, 30%) 
with 2 minutes per change. Then the slides were fixed in 4% PFA for 30 minutes, incubated with 
proteinase K (2 mg/ml) and re-fixed in 4% PFA. After washing in PBS with two changes for 5 
minutes each and in SSC for two times with each 2 minutes, the slides were incubated with 
hybridization solution for 30 minutes. Then the slides were incubated at 65°C overnight in 
hybridization solution with the DIG labelled probes. 
 
Unbound probes were removed by washing three times with 20 minutes each, with 5 X SSC at 
room temperature and 0.5 X SSC with 20% formamide at 65 °C. After that, it cooled down to 
37 °C in the same solution for 30 minutes. Then the slides were treated with RNase A (10 𝑢g/ml) 
for 30 minutes at 37 °C. After washing, the slides were incubated with NTE buffer for 15 minutes 
at 37 °C. 
 
After washing with 0.5X SSC for three times with each for 30 minutes at 65 °C and 2X SSC for 
30 minutes, the slides were incubated in 1% blocking solution for 45 minutes and then overnight 
with antibody (1: 5000) at 4 °C. 
 
After washing with TBST to remove unbound antibodies for 2 hours and with NTMT for 3 times 
with each for 15 minutes, and developed in staining solution at 4 °C. The slides were washed with 
NTMT for two times with each for 15 minutes, fixed in 4% PFA for 5 minutes, dried and mounted 
with Roti-mount and stored at 4 °C. 
 
The results for in-situ hybridization were repeated in a series sections (5 sections per slide, two 
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slides) from two independent samples in each group at the same stage. 
  
4.2.3.5 Immunofluorescence 
Immunofluorescence for cryosections  
The cryosections were washed in PBS, and then incubated with primary antibody in 
PBS/0.25%TritonX-100/3%FBS overnight at 4°C. After washing the slides for 3 times, with each 
for 5 minutes, the slides were incubated with secondary antibody in PBS/0.25%TritonX-
100/3%FBS for 1-1.5 hours at room temperature. Then the slides were stained with DAPI (1:10000) 
for 10 minutes. After washing in PBS for three times, the slides were dried at room temperature in 
dark, mounted with Aqua-PolyMount medium and then stored at 4°C. 
 
Immunofluorescence for paraffin sections  
For the paraffin sections, the slides were deparaffinized in xylene for two times (15 minutes and 
10 minutes, respectively). Then the slides were serially hydrated with 100% ethanol, 100% ethanol, 
95% ethanol, 80% ethanol, 60% ethanol and 30% ethanol, with each for 5 minutes. After rinsing 
in distilled water, the slides were heated with antigen unmask solution (0.1 M sodium citrate buffer, 
pH 6.0) for antigen retrieval using microwave oven at 600W for 15 minutes, and then cooled down 
for 15 minutes at room temperature. The following procedure is the same to the 
immunofluorescence for cryosections.  
 
Whole-mount or Flat-mount immunofluorescence  
For the whole-mount immunostaining, E9.5 embryos were fixed in 4%PFA for 20 minutes, and 
then washed in PBS/0.1%TritonX-100 for two times, and penetrated in 0.1M Glycin/PBS. The 
embryos were incubated in primary antibodies or blocking solution (Control) for two days. After 
washing in PBST, the embryos were incubated with secondary antibodies for 24 hours, followed 
by staining in DAPI (1:10000) for 20 minutes. The embryos were preserved and imaged in 80% 
glycerol and the Poly-Mount mounting medium (Polysciences, USA). All the procedures were 
conducted under a microscope. 
 
For the flat-mount immunofluorescence, the whole mouse retina and clinical gliosis samples 
(epiretinal membrane and inner limiting membrane) were used. The general procedure is the same 
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as whole-mount immunofluorescence, for the staining of clinical samples, the first antibody was 
incubated overnight and second antibodies were incubated for 1 hour at room temperature. 
 
Immunofluorescence for staining cells  
The cultured cells were washed with PBS for three times, with each for 5 minutes, followed by 
fixation with 4% PFA for 20 minutes. Then after washing in PBS for three times, the cells were 
rinsed in PBS/0.25%TritionX-100 for 10 minutes, followed by incubation with first antibody at 
4°C overnight. After washing in PBS for three times, the samples were incubated with second 
antibody for 1 hour at room temperature. Finally, the samples were stained with DAPI for 10 
minutes. Then the samples were mounted with Aqua-PolyMount medium. 
 
In all the immunofluorescence methods above, negative control (without primary antibody but the 
same dilution of secondary antibody) were used to test whether the binding of the primary antibody 
with the given sample tissue is specific. All these immunohistochemistry mouse experiments were 
performed using a series of sections (4-10 sections per slide) from at least two independent samples 
at the same stage. For the whole-mount or flat-mount immunofluorescence mouse experiments, 
two samples from wild types and two samples from mutants or two samples from wild types and 
one sample as negative controls were used at one stage. Representative pictures were selected.  
 
 Table 4.6 Primary antibodies used in the study 
Target protein Species Dilution Catalog number Company 
β-actin-peroxidase 
(WB) 
Mouse 1:2000 A3854 Sigma-Aldrich, Germany 
BrdU Rat 1:500 OBT0030CX AbD Serotec, Germany 
Brn3 Goat 1:100 Sc-6026 Santa Cruz, Germany  
Calretinin Rabbit 1:1000 7699/3H Swant, Switzerland 
Caspase 3 Rabbit 1:200 557035 BD Pharmingen, Germany 
Col4A2 Rabbit 1:200 sc-70246 Santa Crutz, Germany 
E-cadherin Rat 1:200 U3254 Sigma-Aldrich, Germany 
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Foxe3 Rabbit 1:200 sc-134536 Santa Crutz, Germany 
GFAP Rabbit 1:500 G9269 Sigma-Aldrich, Germany 
Glutamine 
Synthetase 
Mouse 1:200 BD 610517 
 
BD Biosciences, Germany 
N-Cadherin(H-63) Rabbit 1:250 sc-7939 Santa Cruz, Germany 
Neurofilament 
2H3 
Mouse 1:100 None 
 
Developmental Studies Hybridoma 
Bank, U.S 
Neurofilament 
200 
Rabbit 1:500 N4142 
Santa Cruz, Germany 
Nestin Mouse 1:500 561230 BD Pharmingen, Germany 
Otx2 Rabbit 1:200 -------- From Dr. A. Simeone 
Pax2 Rabbit 1:200 2549-1 Epitomics, Germany 
Pax6 Rabbit 1:400 PRB-278P Chemicon, Germany 
PDE6b Rabbit 1:500 PA1-722 Thermo Scientific, Germany 
PKC-α Mouse 1:500 Ab1723 Abcam, Germany 
Prox1 Rabbit 1:1000 AB 5475 Millipore, Germany 
PXDN (MG50) Goat 1:80 sc-168598 Santa Cruz, Germany 
PXDN (Immuno) Rabbit 1:500 -------- From Dr. G. Bhave 
PXDN (WB) Rabbit 1:1000 -------- From Dr. G. Bhave 
Sox2 Goat 1:500 sc-17320 Santa Cruz, Germany 
γ-crystallin Rabbit 1:200 sc-22746 Santa Cruz, Germany 
TGFβ1 Rabbit 1:200 NB100-91995 Novus Biologicals, Germany 
 
(BrdU Ab: a gift from Dr. Chichung Lie, IDG, HGMU; GS and CRALBP Ab: gifts from Mrs. Nicole Senninger 
and Prof. Marius Ueffing, Protein Science Department, HGMU; Neurofilament 200 Ab: a gift from Dr. Andrea 
Huber-Brösamle, IDG, HGMU; OTX2 Ab: a gift from Dr. Antonio Simeone, Institute of Genetics and 
Biophysics, CNR, Napoli, Italy; PXDN Ab (one for immunofluorescence and the other one for Western blot): 
gifts from Dr. Gautam Bhave, Vanderbilt University Medical Center, USA; WB: Western blot) 
 
 
48 
 
 
 
Table 4.7 Second antibodies used in the study 
Name Species Dilution Catalog No. Company 
Alexa Fluor ® 488 Anti-Rabbit 1:250 A21206 Invitrogen, Germany 
Alexa Fluor ® 488 Ant-Rat 1:250 A21208 Invitrogen, Germany 
  Cy3 Anti-Goat 1:250 705-165-147 Dianova, Germany 
Cy3 Anti-Rat 1:250 712-165-153 Dianova, Germany 
Cy5 Anti-Mouse 1:250 715-175-150 Jackson immuno, Germany 
Goat Anti-Rabbit     
IgG (HRP) (WB) 
Anti-rabbit 1:1000 Ab6721 Abcam, Germany 
     (WB: Western blot) 
 
Confocal microscopy 
All the immunofluorescence pictures (single plane images and Z-stacks) were taken by Olympus 
confocal microscopy (Olympus, Hamburg, Germany). 20X, 40X, and 60X confocal objectives 
were used. The DAPI, Alex488, Cy3 and Cy5 fluorescence were detected by DAPI, 488, Cy3 and 
Cy5 (647) channel, respectively. The tissue sections (10-12 µm) were scanned from top to the 
bottom with 0.5-1 µm thickness of each scan. The colocalisation of two different fluorescence was 
observed by the scanning of the same thin sections (0.5-1 µm). For the control and mutant samples, 
the same laser power and the same HDR (High Dynamic Range Imaging) were used to take the 
pictures. The images were analyzed by a FluoView 1.7 software (Olympus, Japan).  
 
4.2.3.6 Anterograde tracing 
E15.5 embryos were fixed in 4% PFA in PBS overnight, and the cornea was incised by a forcep, 
the lens was removed and the optic cup was packed with DiI or DiO. The lens was sent back into 
the eyes and the cornea was covered. The embryos were refixed in 4% PFA in PBS for about 5 
weeks at room temperature or 3 weeks at 37°C to allow the tracers to diffuse along axons 
completely. The optic nerve, optic chiasm and optic tract were exposed after removing the heads, 
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and analyzed under the stereo-fluorescence microscopy. 
 
4.2.3.7 Morphometric analysis 
For KTA48 project, the middle sections of the eyes stained by methylene blue and Basic fuchsin 
were used to measure eye size, lens size and the depth of anterior chamber at E15.5, E17.5 and 
P21. The length between the central corneal epithelium and the central point of the optic nerve 
head was measured as eye size, the length between the anterior central point of anterior lens 
capsule and posterior lens capsule was measured as lens size. The depth of anterior chamber was 
measured between the central point of corneal endothelium and the central point of the anterior 
lens capsule. To measure the number of the secondary fiber cells of the lens in KTA48 project 
(E15.5 and P21), the number of these cells with nuclei was calculated at the bilateral lens equator 
regions using Image J (http://rsb.info.nih.gov/ij/) and the average number was calculated and used 
for statistics. For Ali030 project, the pictures from the anterograde tracing experiments were used 
to measure the thickness of the optic nerve at E15.5. The thickness was measured at three points 
of the optic nerve (proximal, distal and central) where are perpendicular to the optic nerve. The 
average thickness was calculated for statistical analysis.   
 
4.2.4 Molecular biology technology 
4.2.4.1 DNA isolation  
The tails were collected and digested in 500 μl lysis buffer containing protein kinase K and 
incubated at 55°C overnight (350 rpm shaking speed). Then proteins were precipitated with 5M 
NaCl and incubated on ice for 10 minutes. The samples were centrifuged at 6500 rpm for 15 
minutes, followed by transferring the supernatant to new 1.5 ml tubes. DNA was precipitated with 
absolute methanol and centrifuged at 13000 rpm for 15 minutes at 4°C. Then the DNA pellet was 
washed with 70% ethanol to wash out the salts. After drying for 10 minutes, DNA was dissolved 
in dH2O and stored at 4°C. 
 
4.2.4.2 PCR reaction 
PCR for genotyping 
The primers Pxdn-Ex19-L1 and Pxdn-Ex19-R1 were used for KTA48 genotyping and the primers 
AliCR, AliCF, AliWtF and AliMtF were used for Ali030 genotyping. The sequence of the primers 
50 
 
were given in Table 4.1. The PCR reaction mix is given in Table 4.8 and 4.9. For KTA48 genotyping, 
PCR initial activation step was at 94 °C for 2 min, followed by 40 three-step cycles (denaturation 
at 95 °C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72 °C for 30 seconds). 
Then PCR product was enzymatically digested with Alw36I at 37 °C for 2 hours. The DNA bands 
size were checked by agarose gel electrophoresis. For Ali030 genotyping, PCR initial 
denaturation/enzyme activation step is carried out at 94 °C for 30 seconds, and the PCR cycles (32 
cycles) consist of three-step cycling (denaturation at 95 °C for 30 seconds, annealing at 62°C for 
30 seconds, and extension at 72 °C for 80 seconds). The PCR products were run on the 1.5% 
agarose gel to check the band size.  
 
         Table 4.8 The components of reaction mix for KTA48 genotyping 
Reagent Volume per reaction (μl) 
DreamTaq Green PCR Master Mix (2X) 5 
Pxdn-Ex19-L1    (10 μM) 1 
Pxdn-Ex19-R1    (10 μM) 1 
Genomic DNA     (100ng/µl) 
MilliQ-H2O 
1 
2 
Total volume 10 
 
 
         Table 4.9 The components of reaction mix for Ali030 genotyping 
Reagent Volume per reaction (μl) 
DreamTaq Green PCR Master Mix (2X) 5 
AliCR         (10 μM) 1 
AliCF          (10 μM)                                                                   
AliWtF/AliMtF   (10 μM)          
0.5
                0.5 
Genomic DNA   (100ng/µl) 
MilliQ-H2O  
1 
2 
Total volume 10 
 
 
PCR for cloning Bmpr1b cDNA 
The primers Bmpr1b-cDNA-CACCL1 and Bmpr1b-cDNA-R1SC were used for amplifying the 
whole-length Bmpr1b cDNA. The sequence of the primers were given in Table 4.2. The PCR 
reaction mix is given in Table 4.10. PCR initial denature step was at 98 °C for 30 seconds, followed 
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by 40 three-step cycles (denaturation at 95 °C for 10 seconds, annealing at 55°C for 30 seconds, 
and extension at 72 °C for 1 minutes). The target band was checked by running agarose gel 
electrophoresis. 
         Table 4.10 The components of reaction mix for amplifying Bmpr1b cDNA 
Reagent Volume per reaction (μl) 
Phusion HF buffer       (5X) 10 
10 mM dNTPs         (10 μM)  1 
Forward primer        (10 μM)                                                                   
Reverse primer            (10 μM)   
Phusion DNA polymerase       
                 2.5  
                 2.5 
                 0.5 
cDNA                     (100ng/µl) 
Nuclease-free H2O  
                   2 
                31.5 
Total volume 50 
 
 
4.2.4.3 Real time PCR 
RNA isolation 
RNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufacture’s instruction. 
Briefly, the samples were homogenized in 350 μl RLT containing 1% β-mercaptoethnol and then 
loaded in Qia-shredder column. After centrifugation, 100 μl DPEC-H2O and 200 μl absolute 
ethanol were added into the lysate. After incubation at the RNeasy mini spin columns and 
centrifugation, the RNA was combined on the column. The column was washed with 350 μl RW1 
buffer for 1 minute and centrifuged at maximum speed for 15 seconds. 70 μl RDD buffer 
containing 10 μl DNase 1 was added on the column to degrade DNA in the samples and incubated 
for 15 minutes. Then the columns were washed for two times using RW1 buffer. Then the columns 
were washed for two times with RPE buffer. Then transfer the column into new tubes and 
centrifuge for 2 minutes and further 5 minutes with open lid. The columns were left with open lids 
for 10 minutes and the RNA was dissolved in 30-50 μl DEPC-H2O. RNA yield and purity were 
measured using NanoDrop ND-1000. The samples with A260/A280 above 2.0 and A260/A230 
above 2.0 were used in the study. 
 
cDNA synthesis 
cDNA was synthesized using Ready-To-Go T-primed first strand kit (Invitrogen). 1-5 μg total RNA 
was used in 33 μl DEPC-H2O and then was heated at 65°C for 5 minutes. Then it was incubated 
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at 37°C for 5 minutes and meanwhile the first-strand reaction mix was also incubated at 37°C for 
5 minutes, followed by transferring the RNA solution to the first-strand reaction mix and 
incubating at 37°C for 5 minutes. After that, the reaction mix containing RNA was gently vortexed 
and briefly centrifuged. The mixture solution was incubated 37°C for 1 hour and then the cDNA 
was diluted 1:10 for PCR experiments. The samples were stored at -20°C. 
 
Standardization of real-time PCR primers 
The primers were standardized and the efficiency was tested before performing real-time PCR. 
Five different concentrations were used with each concentration repeating three times. The 
components of PCR reaction were described in Table 4.11. PCR reaction was performed with 
StepOneTM Real-Time PCR System (Applied Biosystem) and the standard curve was generated 
and analyzed by StepOne software 2.0. The primers with the efficiency above 90 were used in this 
study. 
 
         Table 4.11 The components of reaction mix for standardizing the primers 
Reagent Volume per reaction (μl) 
5X HOT FIREPol® Eva Green qPCR mix    4 
Primer Forward (10 μM) 0.5 
Primer Reverse (10 μM) 0.5 
cDNA (1:10) 
DEPC-H2O 
  4 
 11 
Total volume  20 
 
 
Quantitative real-time PCR 
Quantitative real-time PCR was performed with StepOneTM Real-Time PCR System (Applied 
Biosystem). The components of the reaction mix was described in Table 4.12. In each reaction, 1 
μl cDNA, 1 μl reverse and forward primers (1:1), 4 μl EvaGreen mix and 14 μl DEPC-H2O were 
mixed in one well in a 96-well plate and centrifuged briefly. After the initial denaturation step at 
95°C for 15 minutes, PCR reaction was cycled for 40 times with denature at 95°C for 30 seconds 
and annealing-extension temperature at 65 for 30 seconds. Relative expression was calculated 
following 2(-Delta Delta C(T)) method (Livak and Schmittgen, 2001).  
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        Table 4.12 The components of reaction mix for qRT-PCR 
Reagent Volume per reaction (μl) 
5X HOT FIREPol® Eva Green qPCR mix   4 
Primer Forward (10 μM) 0.5 
Primer Reverse (10 μM) 0.5 
cDNA (1:10) 
DEPC-H2O 
 1 
14 
Total volume 20 
 
 
4.2.4.4 Molecular cloning 
DNA extraction from agarose gel 
PCR product was amplified by Phusion DNA polymerase (New England Biolabs, Germany) and 
then run on 1.5% agarose gel. The target PCR band was extracted from the gel under UV 
illumination and purified using the NucleoSpin Gel kit (Macherey-Nagel, Germany). Briefly, the 
agarose gel with target band was dissolved in NT buffer (binding buffer) at 55°C for 10 minutes. 
Then the sample was transferred to a column and centrifuged at 12000 rpm for 1 minute to make 
DNA bind to the silica membrane, followed by wash with NT3 buffer (wash buffer) and 
centrifugation. The column was re-centrifuged to dry the silica membrane at 13,000 rpm for 2 
minutes. DNA was eluted in 30 μl of elution buffer and stored at -20°C. DNA yield and purity 
were measured by NanoDrop ND-1000.  
 
Adding 3’ A overhang to a PCR product 
Taq DNA polymerase (Invitrogen) was used to add 3’ A overhang to the purified PCR (amplified 
by Phusion DNA polymerase). The reaction mix was described in Table 4.13. In each reaction, 
purified PCR product, dATP, PCR buffer, Taq DNA polymerase and DEPC-H2O were mixed. Then 
the reaction mix was incubated at 72°C for 20 minutes to add 3’ polyA tail.  
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         Table 4.13 The mix components for A-addition reaction 
Reagent Volume per reaction (μl) 
Purified PCR product (10 ng/μl)   20 
dATP (10 mM) 10 
PCR buffer with Mg (10X)  5 
Taq DNA polymerase (5U/μl) 
DEPC-H2O 
0.2 
                14.8 
Total volume 50 
 
TA cloning 
The PCR fragments were cloned into pcDNA3.1 vector according to the instruction 
(pcDNATM3.1/V5-His TOPO TA Expression Kit, Invitrogen). The components of TOPO Cloning 
reaction was described in Table 4.14. The reagents were mixed gently and incubated for 5 minutes 
at room temperature.  
 
         Table 4.14 The mix components of TOPO Cloning reaction 
Reagent Volume per reaction (μl) 
Fresh PCR product  3 
Salt solution 1 
TOPO vector 
DEPC-H2O 
1 
1 
Total volume 6 
 
Then 3 μl of the TOPO Cloning reaction was added to a thawed vial of One Shot Chemically 
Competent E.coli and incubated on ice for 20 minutes, followed by incubation at 42°C for 1 
minutes to heat-shock the cells. Then transfer the tube on ice. After mixing with 250 μl S.O.C 
medium, the cells were incubated at 37°C for 1 hour with a shaking speed of 400 rpm. Then 80 μl 
cells were put on the agarose gel with ampicillin and incubated at 37°C overnight. 5 single positive 
colonies were selected and then incubated in 5 ml LB medium at 37°C overnight, respectively. 4 
ml of culture medium was used to isolate plasmid using mini-preparation by Nucleospin plasmid 
kit (Macherey-Nagel, Germany). HindIII and Xhol enzymes were used to digest the plasmid to see 
whether there is a target band. Then the plasmids were confirmed by sequencing in GATC Biotech. 
For the transfection experiments, the plasmid will be further amplified in 200 ml LB medium and 
purified by midi preparation.  
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Mini-preparation 
The NucleoSpin Plasmid kit (Macherey-Nagel) was used for mini-preparation. 4 ml of culture 
medium was spinned down at 13,000 rpm for 30 seconds. After discarding the supernatant, 250 μl 
Buffer A1 (resuspension buffer) was added to resuspend the cell pellet by vortex. Then 250 μl 
Buffer A2 (lysis buffer) was added and mixed gently by inverting the tube and incubated for 5 
minutes at room temperature. 300 μl Buffer A3 (neutralization buffer) was added and mixed by 
inverting the tube, followed by centrifugation at 13,000 rpm for 5 minutes. The supernatant was 
transferred on the column and spinned down to make the plasmids bind to the silica membrane. 
The column was washed by 600 μl Buffer A4 (wash buffer) and centrifuged at 13,000 rpm for 1 
minute, followed by re-centrifugation for 2 minutes to dry the silica membrane. Then 50 μl Buffer 
AE (Elution buffer) was used to elute the plasmid DNA. The DNA yield and purity were measured 
by NanoDrop ND-1000.  
 
Midi-preparation  
The Qiagen Midi Prep Kit was used for isolate large amounts of plasmids. Briefly, a single colony 
was cultured in 25 ml LB medium with selective antibiotic and then incubated at 37°C with 
vigorous shaking for 12-16 hours. The cells were centrifuged at 6000 x g for 15 min in a 15 ml 
falcon tube. Resuspend the bacterial pellet in 4 ml Buffer P1 thoroughly. 4 ml Buffer P2 (lysis 
buffer) was added and mixed by inverting the sealed tube for 5 times, and then incubate at room 
temperature for 5 min. 10 ml of Buffer P3 (neutralization buffer) was added and mixed by 
vigorously inverting for 5 times, and then incubated on ice for 15 min. Then the solution was 
centrifuged at 20,000 x g for 30 min at 4°C. The supernatant was transferred to a new falcon tube 
and centrifuged again at 20,000 x g for 15 min at 4°C. Transfer the supernatant to a new falcon 
tube gently. A QIAGEN-tip 100 was equilibrated by 4 ml Buffer QBT and allow the liquid to pass 
through the column by gravity flow. Then the QIAGEN-tip was washed by 10 ml Buffer QBT for 
two times. DNA was eluted with 5 ml Buffer QF (elution buffer). Then 3.5 ml isopropanol was 
added and mixed gently and centrifuged at 15,000 x g for 30 min at 4°C. The supernatant was 
discarded carefully. 
 
DNA pellet was washed with 2 ml 70% ethanol and then centrifuged at 15,000 x g for 10 min. 
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After carefully discarding the supernatant, the pellet was air-dried for 5–10 min and dissolved in 
100 µl TE buffer. Then DNA yield and purity were measured by NanoDrop ND-1000. The samples 
were used in this study with A260/A280 above 2.0 and A260/A230 above 2.0. All the samples 
were stored at -20°C. 
 
4.2.4.5 Sequencing 
PCR product and plasmids were sent to GATC Biotech (Konstanz, Germany) for sequencing using 
the Sanger method. 
  
4.2.5 Cell culture techniques 
4.2.5.1 Cell culture 
MIO-MI (Moorfields/Institute of Ophthalmology-Müller 1) cell line, a retinal Müller cell line 
derived from postmortem adult human neural retina, was kindly provided by Dr. Stefanie Hauck 
(Research Unit Protein Science, HGMU) which originates from Dr. Astrid Limb (Moorfields Eye 
Hospital, London) (Limb et al., 2002; Lawrence et al., 2007). The cells were cultured in DMEM 
(Dulbecco’s Modified Eagle’s Medium) supplemented with L-glutamine, sodium pyruvate, 10% 
FBS (Fetal bovine serum) and 100× penicillin/streptomycin. The cells were kept in a humidified 
5% CO2 incubator at 37ºC. When the adherent cells reach 80% confluence, they were detached 
with 1 × Trypsin-EDTA and split 1:6. 
 
4.2.5.2 Cell number counting    
The cultured cells were diluted in trypan blue at 1:1 - 1:3, and the cell number was counted in 2-3 
big squares of a Neubauer chamber under the microscopy. The cells on the lower and right limits, 
and the dead cells stained with trypan blue were excluded. The cell number was calculated by the 
following formula. 
 
Cell concentration (number/ml) = average cell number/large square × dilution factor × 104 
 
4.2.5.2 Transient transfection of DNA plasmids into the cells 
The day before transfection, 1 × 105 cells were grown in 500 µl of culture medium in 24-well cell 
culture plate without antibiotics. The next day when the cells grew to 80-90% confluent, 
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transfection reagents were prepared. Briefly, 2 µg plasmid (pcDNA3.1 Bmpr1b wt cDNA or 
pcDNA Bmpr1b mt cDNA or GFP-plasmid) was firstly diluted in 50 µl Opti-MEM medium and 
mixed gently. Then 1 µl lipofectamine 2000 was diluted in 50 µl Opti-MEM medium for 5 minutes 
at room temperature. The two solutions were mixed gently and incubated for 20 minutes at room 
temperature. 100 µl transfection complex were added to the culture medium from each well. The 
cells were incubated for 48 hours. TOPO2.1-GFP plasmid was used to test the transfection 
efficiency. Then the culture well was changed by new medium with antibiotics and for some wells, 
they were treated by BMP-2 (500 ng/ml) or GDF-5 (100 ng/ml; 500 ng/ml). The cells were 
incubated for 4 days before further processing. 
 
4.2.6 Protein techniques 
4.2.6.1 Total protein isolation from tissues 
Add 20 µl RIPA buffer with protease inhibitors (Protease inhibitor cocktail, Roche, Germany) per 
100 mg tissue to the tube and the sample was homogenized in a 1.5 ml tube, followed by sonication 
for three times on ice and then centrifugation at 13,000 rpm for 10 minutes at 4ºC. The supernatant 
was removed and saved in a new tube. 
 
4.2.6.2 Protein concentration measurement 
Protein concentrations were measured using Roti®-Nanoquant protein quantitation assay (Roth, 
Germany) which is the modified Bradford method (Bradford, 1976). A series of the dilutions of 
BSA (Bovine serum albumin) was prepared (0; 2.5; 5; 10; 25; 50; 100; 200; 300; 400; 500 mg/l). 
200 μl diluted Roti®-Nanoquant (5x) (1:5) was added into standard BSA and the diluted samples 
on 96-well plate. Incubate the culture plate for 5 mins at room temperature. OD590 and OD450 
were measured and OD590/OD450 was plotted to yield the calibration curve. 
 
4.2.6.3 Western blot analysis 
Briefly, protein samples were adjusted to the same amount (20 µg). The loading buffer (4x) was 
added into the samples and incubated at 95ºC for 10 minutes. The samples were loaded on the gel 
and the proteins were firstly transferred to a PVDF (Polyvinylidene fluoride) membrane in a 
transfer chamber by electrophoresis. The blotting is performed with plate electrodes in a horizontal 
direction with sandwiching gel and membrane between sheets of transfer buffer. The 
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electrophoretic transfer was carried out at a constant flow of 400 mA for 60 minutes at room 
temperature. The PVDF membranes were blocked in 5% milk power in TBST for 30 minutes at 
room temperature. The membranes were washed with PBST on the shaker for two times, with each 
for 5 minutes. Then the membranes were incubated with primary antibody at 4ºC overnight. After 
washing the membrane for 3 times in PBST, the horseradish peroxidase (HRP)-conjugated 
secondary antibodies were incubated for 45 minutes at room temperature on the PVDF membrane. 
After washing the membranes in PBST, the HRP from secondary antibody was detected by adding 
chemiluminescence detection reagent (ECL Prime Western Blotting Detection Reagent, Cat. No. 
RPN2232, GE Healthcare, UK) on the membrane. The membrane was visualized and the images 
were produced using ChemiDoc XRS system (Bio-Rad, Germany). Each Western blot result was 
repeated for three times.  
 
4.2.7 In vivo retinal imaging and electrophysiology 
4.2.7.1 Spectral domain optical coherence tomography (SD-OCT) imaging 
This experiment was approved by the ethics committee of the upper Bavarian government (No. 
TVA#55.2-1-54-2531-78-06). SD-OCT was used to acquire retinal images. The mice were 
anesthetized with intraperitoneal injection of ketamine and xylazine and the pupils were dilated 
with 1% atropine. Then the mouse eyes were covered with lens glass to neutralize the refractive 
power of the cornea and make the OCT beam focus on the retina. OCT images were recorded with 
the equipment set to 30° field of view. Horizontal or vertical consecutive images were made in the 
center of the optic nerve head. To improve the ratio of the signal-to-noise, the images were 
averaged using the built-in functions in the system.  
 
4.2.7.2 Electroretinography (ERG)   
This experiment was approved by the ethics committee of the upper Bavarian government (No. 
TVA#55.2-1-54-2531-78-06). Ganzfeld ERG was performed in both eyes of the mice to examine 
the retinal function as described earlier (Dalke et al., 2004). The mice were kept in dark for at least 
12 hours and then anesthetized with intraperitoneal injection of ketamine and xylazine. After the 
pupils were dilated with 1% atropine, the mice were placed on the sled. The ground electrode was 
inserted subcutaneously around the tail, the active electrodes were placed on both corneas and the 
reference electrode was inserted subcutaneously between the two eyes. The mice were introduced 
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into a handheld Ganzfeld LED stimulator (Espion ColorBurst; Diagnosys LLC, Littleton, MA) on 
a rail to guide the sled (High-Throughput Mouse ERG setup, Steinbeis-Transfer Centre for 
Biomedical Optics and Function Testing, Tübingen, Germany). The impedance of electrodes was 
tested before each measurement using the built-in algorithm (less than 10 kΩ at 50 Hz). ERGs 
were recorded from both eyes respectively under Ganzfeld stimulation at a frequency of 0.48 Hz 
in 10 steps at 0.0125, 0.025, 0.125, 0.5, 12.5, 5, 12.5, 50, 125, 500 and 12500 cd-s/m2 and analyzed 
by built-in softwares.  
 
4.2.8 Statistics 
The two sample t-test was used to compare the means of two groups. If the variance was not equal 
and confirmed by F-test, a nonparametric Mann–Whitney test was used for further statistical 
analysis. If p < 0.05, it is reported as statistically difference. 
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5 Results 
5.1  PartⅠ: Peroxidasin is essential for eye development 
5.1.1 The expression of peroxidasin in the developing and postnatal eye 
To investigate the expression of peroxidasin in eyes, immunofluorescence staining for Peroxidasin 
(PXDN) was performed at different stages. The embryonic eyes were analyzed at E9.5, E11.5, 
E13.5 and E17.5. Postnatally, the peroxidasin expression was analysed at 3 months. At E9.5, the 
earliest stage of eye development, the expression of peroxidasin is mainly detected in the eyes by 
whole-mount immunostaining (Figure 5.1, I, A), and further immunostaining for sections 
demonstrated that peroxidasin is specifically expressed in the lens placode and optical vesicle at 
E9.5 (Figure 5.1, I, B-C). At E11.5, peroxidasin is mainly expressed in the developing cornea and 
lens (Figure 5.1, I, D-E). At E13.5, peroxidasin is strongly expressed in the developing cornea and 
nucleated cells in the vitreous and weakly expressed in the anterior lens (Figure 5.1, I, F-I). 
Interestingly, these nucleated cells appear to secrete peroxidasin into the vitreous cavity (Figure 
5.1, I, I). At E17.5, the expression of peroxidasin is dramatically decreased compared to the 
previous stages and it is still highly expressed in the corneal epithelium and eye lids, but weakly 
expressed in the lens and inner limiting membrane (Figure 5.1, I, J-O). Peroxidasin staining is not 
found in the vitreous at E17.5, because the vitreous cells are almost missing at this stage. 
Interestingly, similar to the nucleated cells in the vitreous at earlier stage, these cells in the anterior 
chamber also express peroxidasin but the expression is weaker (Figure 5.1, I, L). In adult mice (3 
months), the expression of peroxidasin is only maintained in the corneal epithelium, the lens 
epithelium and in the outer layer of lens capsule (Figure 5.1, I, P-S). All the negative controls 
(without primary antibody) showed absent fluorescence or very weak fluorescence compared to 
wild types (Figure 5.1, I, negative controls).  
 
Moreover, I would like to confirm the expression pattern of Pxdn in the eyes using a different 
PXDN antibody. Therefore, I did the expression pattern of peroxidasin during eye development 
using another PXDN antibody from Dr. Gautam Bhave (Vanderbilt University Medical Center, 
USA). At E11.5, Pxdn is weakly expressed in the lens vesicle especially the lens epithelium cells 
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(Figure 5.1, II, A-B). At E13.5, Pxdn is highly expressed in the lens especially the lens epithelium 
cells and also expressed in the nuclear cells in the vitreous (Figure 5.1, II, C-D). At E17.5, Pxdn is 
mainly expressed in the lens including the epithelium cells as well as the inner nuclear blast layer 
(Figure 5.1, II, E-F). All the negative controls (without primary antibody) showed absent 
fluorescence or very weak fluorescence compared to wild types (Figure 5.1, II, negative controls).  
 
From the results performed by MG50 antibody, peroxidasin is strongly expressed in developing 
cornea especially corneal epithelium, and vitreous nucleated cells, but weakly expressed in the 
lens and inner limiting membrane during eye development. Later the expression is reduced during 
postnatal period and in adult it is only expressed in the corneal epithelium and the lens epithelium. 
These peroxidasin-positive nucleated cells in the vitreous could be some of the component cells of 
vitreous hyaloid vascular system during eye development. From the results performed by another 
PXDN antibody (Dr. G. Bhave), peroxidasin is mainly expressed in the lens especially lens 
epithelium cells, vitreous nucleated cells and inner part of the retina, but weakly expressed in the 
developing cornea during eye development. The differences between both antibodies may be due 
to a different sensitivity of the antibodies and different antigen epitopes. For MG50 antibody, an 
internal region of MG50 of human origin was used to raise the antibody. However, the exact amino 
acid sequence of this internal region is lacking due to the Santa Crutz company proprietary 
information. For PXDN antibody from Dr. G. Bhave, the peptide (sequence: 
IREKLKRLYGSTLNI) from human PXDN was used to raise the antibody and antigen affinity 
purification was used to purify the antibody. The mouse sequence differs only by the sixth amino 
acid of this peptide (K in humans and Q in mouse).  
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Figure 5.1 The expression pattern of peroxidasin from eye development to adult.  
I.The expression pattern of peroxidasin in the eyes using MG50 antibody. (A-E) Whole-mount 
immunostaining showed that peroxidasin is expressed in the eye at E9.5 (A, arrow) and there is no staining in 
the eyes of the negative control. Further sectional immunostaining showed that it is expressed in the lens placode 
and optic vesicle at E9.5 (C) and it is still expressed in the developing cornea and lens vesicle at E11.5 (E). (F-
I) By E13.5, it is still highly expressed in the developing cornea but weakly expressed in the anterior lens (G). 
In addition, it is highly expressed in the vitreous nucleated cells and it appears to be secreted by these cells (I, 
arrow). (J-O) At E17.5, the expression level of peroxidasin is reduced and it is mainly expressed in the 
developing corneal epithelium and eye lid (K) and the lens (M). It appears that it is weakly expressed in the 
inner limiting membrane at this stage (O, arrow). (P-S) At adult (3 months), it is only expressed in the cornea 
epithelium (Q), lens epithelium and outer layer of the lens capsule (S). C: cornea; CE: corneal epithelium; DC: 
developing cornea; EL: eye lid; ILM: inner limiting membrane; L: lens; R: retina; LC: lens capsule; LE: lens 
epithelium; LP: lens placode; LV: lens vesicle; OV: optic vesicle. Red: peroxidasin; Blue: DAPI. Scale bar: 100 
µm. 
II. The expression pattern of peroxidasin in the eyes using PXDN antibody (from Dr. G. Bhave). (A-
B) At E11.5, Pxdn is weakly expressed in the lens vesicle. (C-F) At E13.5, Pxdn is expressed in the lens 
especially in the lens epithelial cells, the nuclear cells in the vitreous (arrow) and inner part of the retina. (E-H) 
At E17.5, Pxdn is mainly expressed in the lens (E-F) and inner nuclear blast layer (G-H). There is very weak or 
absent staining in the eyes of the negative control on the most right side of each column. DC: developing cornea; 
L: lens; R: retina; LE: lens epithelium; LV: lens vesicle; INBL: inner neuroblast layer; ONBL: outer neuroblast 
layer. VC: vitreous cavity. Green: peroxidasin; Blue: DAPI. Scale bar: 50 µm.  
 
5.1.2 The point mutation in peroxidasin causes loss of function of peroxidasin 
In the ENU-induced peroxidasin mutant mice (KTA48 mutants), a point mutation (T3816A in the 
peroxidasin mRNA coding sequence) was found in in the peroxidase domain. It is predicted that 
it causes a premature stop codon, resulting in a partial loss of function of peroxidasin. Whether 
this mutation affects the expression level of peroxidasin is unclear. Peroxidasin is predicted to have 
two isoforms, one is full-length protein (X1 isoform, 1475 aa) and the molecular weight is 167 
kDa (NCBI Reference Sequence: XP_006515268.1), and the other one is X2 isoform (784 aa) and 
the molecular weight is 88 kDa (NCBI Reference Sequence: XP_006515269.1). The total amino 
acid sequence of the X2 isoform is the sequence from 720 aa to 1503 aa of the X1 isoform. This 
PXDN antibody was made against the peptide (sequence: IREKLKRLYGSTLNI) from human 
PXDN. The mouse sequence differs only by the sixth amino acid (K in humans and Q in mouse). 
Western blot showed that peroxidasin is expressed in E15.5 eyes (target band 167 kDa, the first 
band, Figure 5.2, A), whereas it is absent in the mutant eyes at E15.5 (Figure 5.2, A). This result 
showed that peroxidasin is expressed in a relatively low level compared to β-actin in wild types 
(Figure 5.2, A) and loss of function of peroxidasin occurs in the eyes of KTA48 mutants during 
embryonic eye development. This may be due to instability of N-terminal structure of the protein 
(a stop codon is formed in the peroxidase domain at the N-terminal of this protein) which could 
further lead to protein degradation. Interestingly, there is a 150 kDa band in E15.5 wild-type eyes. 
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This band could be a proteolytic processing product or alternative splicing of Pxdn. However, 
nonspecific band cannot be ruled out completely. At 1 month, the target band (167 kDa) was not 
found in wild-type eyes at 1 month (Figure 5.2, B). However, there is only one band (around 100 
kDa) found in wild-type and mutant eyes, and there are no obvious differences in the level of 
protein expression between wild-type and mutant eyes (Figure 5.2, B). Thus, whole-length 
peroxidasin could not be expressed or very weakly expressed in the mouse eyes at 1 month. 
Moreover, this 100 kDa band was also found in both wild types and mutants at E15.5. The 100 
kDa band could be an alternative splicing product of Pxdn (Figure 5.2, B). However, nonspecific 
band cannot completely be ruled out. Mass spectrometry could be helpful to identify them in the 
future. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Figure 5.2 The expression of peroxidasin is reduced in KTA48 mutants. (A) The comparison of peroxidasin 
expression from whole eyes protein between wild types and mutants at E15.5 by western blot. There are three 
bands (target band 164 kDa, 150 kDa and 100 kDa) detected in wild-type eyes at E15.5 by Western blot. However, 
in mutants, there are one band (100 kDa) detected, whereas two bands (164 kDa and 150 kDa) are absent. β-
actin was used as positive controls and there are no obvious differences in the protein expression between wild 
types and mutants at E15.5. Compared to the expression of β-actin, peroxidasin expresses in very low level. (B) 
The comparison of peroxidasin expression from whole eyes protein between wild types and mutants at 1 month 
by western blot. There is one band (around 100 kDa) in both wild-type eyes and mutant eyes at 1 month. β-actin 
was used as positive controls and there are no obvious differences in the protein expression level between wild 
types and mutants at 1 month. The band marker (Precision Plus Protein™ Dual Colour Standards (BIO-RAD, 
Germany)) was used. 
 
 
5.1.3 Anterior segment and eye size are severely affected in KTA48 mutant embryos during 
eye development  
Based on the expression pattern of peroxidasin in the embryonic eyes, the role of peroxidasin in 
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eye development was investigated using peroxidasin-mutant mice (also called KTA48 mutants). 
Here I compared wild types and KTA48 homozygous mutants. Firstly, I performed and analysed 
eye histology in different embryonic stages. At E9.5 and E11.5, there is no obvious difference 
between wild types and mutants (Figure 5.3, A-D). At E13.5, there are no obvious differences in 
the lens and eye size between wild types and mutants, but retrolental cell mass is found in the 
vitreous in mutants (Figure 5.3, E-F). At E15.5, the ocular phenotype is the most obvious in KTA48 
mutants compared to previous periods (Figure 5.3 G-H and 5.5 A-H). Specifically, the lens size is 
significantly reduced in mutants compared to wild types (p＜0.05) but there is no statistical 
difference in eye size between wild types and mutants at this stage (Figure 5.4). Moreover, the 
anterior segment is severely impaired in mutants compared to the wild types. All the mutants 
showed that the lens epithelia and capsule are ruptured which causes abnormal migration of the 
lens fiber cells into the anterior and posterior chamber and vitreous (Figure 5.3, H; Figure 5.5, D, 
F; Table 5.1). The anterior and posterior chamber including iridocorneal angle are filled by lens 
fiber cells. In some cases (12/28, 42.9%), the lens vesicle remains attached to the cornea by a 
persistent connecting lens stalk (Figure 5.5, B; Table 5.1). In 75% mutant mice (21/28), retrolental 
tissue in the vitreous (Figure 5.3, H, J; Table 5.1). The corneal stroma thickens, the number of 
keratocytes is increased, their parallel arrangement is distorted and the keratocytes are more 
densely distributed (Figure 5.5, B). This corneal phenotype was found in those mutants with lens 
stalk, which could be due to the differentiation of mesenchymal cells into corneal stromal cells 
affected by the lens stalk. At E17.5, the mutant eyes present more severe ocular phenotypes (Figure 
5.3, J; Figure 5.5, J, K-M), both the eye and lens size were significantly smaller than those in wild 
types (p＜0.05) (Figure 5.4) and the anterior segment was further developmentally delayed in 
mutants and the anterior chamber angle is filled by lens fibers depending on the range which lens 
fibers invade (Figure 5.3, J; Figure 5.5, J). At E15.5, a part of the anterior chamber (Fig. 5.3, H) 
was filled by the lens fibers, whereas at later stage the anterior chamber is further filled by more 
lens fibers (Fig. 5.3, J). The lens epithelium was severely disorganized with some cells missing 
and the lens capsule was more severely ruptured, and the anterior and posterior chamber were 
filled with more lens fibers (Figure 5.3, J). The retina in a few mutants (9/28, 32.1%) showed 
ruptures of the inner limiting membrane which were accompanied by the inner retinal cells 
migrating out of the inner limiting membrane, and retinal folds are also found (Figure 5.5, L-M; 
Table 5.1). All the mutant eyes and lens analysed were smaller than wild types from E17.5 to adult 
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(p＜0.05, Figure 5.4) and the depth of anterior chamber is progressively reduced from E17.5 to 
adult (p＜0.05, Figure 5.4), suggesting that the development of normal eye growth is affected in 
these mutant mice and the anterior segment development is progressively affected. 
 
 
Figure 5.3 Anterior segment is severely 
affected during eye development in 
KTA48 mutants. (A-D) At E9.5 and E11.5, 
there is no obvious difference between wild 
types and mutants. (E-F) At E13.5, there 
are not dramatic difference in the lens 
between wild types and mutants, but there 
is abundant retrolental cells in the vitreous 
in mutants. (G-H, O-P) At E15.5, when the 
eye phenotype is the most obvious, the lens 
size is smaller in mutants compared to wild 
types. The lens epithelium and capsule are 
ruptured and lens fibers migrate into the 
anterior chamber and posterior chamber. 
The lens matrix is disorganized and in some 
cases the lens is attached to the cornea by a 
persistent lens stalk and the retrolental 
tissue in the vitreous. (I-J) At E17.5, the 
eye phenotype is more severe in mutants. 
The anterior chamber is further filled by the 
lens fibers and the lens matrix is obviously 
disorganized. There are still retrolental 
tissues in the vitreous in mutants. (K-L). 
The ocular phenotypes in mutants are 
variable. In most cases, the cornea is 
detached from the lens, but in some cases 
the corneal-lens adhesion are persistent. All 
the cases have a rupture in the lens 
epithelium and capsule. C: cornea; L: lens; 
R: retina; LP: lens placode; OV: optic 
vesicle; ON: optic nerve. Scale bar: A-D, 50 
µm; E-J, 100 µm.  
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Figure 5.4 Reduced eye and lens size, and the depth of anterior chamber in KTA48 mutants during eye 
development. (A) At E15.5, there is no differences in ocular length between wild types (blue line) and mutants 
(red line) (p>0.05), but the ocular length is significantly reduced at E17.5 and further decreased at P21 (red line) 
compared to wild types (blue line) (p<0.05). (B) Then lens size is slightly reduced at E15.5 and E17.5 and 
obviously decreased in mutants (red line) compared to wild types (blue line) at P21 (p<0.05). (C) There is no 
significant difference in the depth of anterior chamber between wild types (blue line) and mutants (red line) at 
E15.5 (p>0.05). But from E17.5, the depth of the anterior chamber is obviously reduced in mutants (red line) 
compared to wild types (blue line) (p<0.05) due to the lens fibers moving outside, especially at P21, the anterior 
chamber is almost missing because the anterior chamber is filled by the lens fibers and the lens is attached to the 
cornea. Blue line: wildtype; Red line: homozygous mutants; asterisk ( ): p<0.05. The number of the sample 
eyes was used: E15.5 (Wt 4, Mt 4); E17.5 (Wt 6, Mt 7); P21 (Wt 6, Mt 6). 
 
 
 
Table 5.1 Summary of eye phenotypes in KTA48 homozygous mutants at E15.5-E17.5 
 
Phenotype 
 
Smaller 
lens 
 
Disorganized 
lens matrix 
 
Lens 
rupture 
 
Lens 
tissue in 
AC 
 
Lens tissue 
out of the 
eye 
 
Lens 
stalk 
 
Retrolental 
tissue in the 
vitreous 
 
Retinal   
folds and 
rosset 
 
Number  
(28 eyes) 
   
 25/28 
 
27/28 
 
28/28 
 
26/28 
 
2/28 
 
12/28 
 
21/28 
 
9/28 
 
Percentage 
 
89.3% 
 
96.4% 
 
100% 
 
92.9% 
 
7.1% 
 
42.9% 
 
75% 
 
32.1% 
 This data is based on the histological observation of 28 eyes. AC: anterior chamber 
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Figure 5.5 The most obvious ocular phenotype in KTA48 mutants at E15.5 and E17.5. (A-H) At E15.5, there 
are persistent corneal-lens adhesion (B, black arrow), disorganized corneal stroma (B, red arrow), rupture in lens 
capsule and lens epithelia (B, arrowhead), lens matrix in the anterior chamber (B), thinner lens epithelium (D, 
arrowheads), disorganized lens matrix (F), abnormal fiber cell migration (F, arrow) and more vitreous 
mesenchymal tissues (H, arrow) in KTA48 mutants. (I-M) At later stage E17.5, the anterior chamber angle is 
developmentally delayed (J) in mutants and there are more mesenchymal cells in the anterior chamber angle (J) 
compared to wild types (I). In very few cases, the rupture in retinal limiting membrane was found (L) and retinal 
rosette structure is formed (M). C: cornea; L: lens; R: retina; V: vitreous cavity; LE: lens epithelium; ON: optic 
nerve; ICA: corneal-iris angle; ILM: inner limiting membrane. Scale bar: A-B, E-F, I-M, 20 µm; C-D, H, 50 µm; 
G, 200 µm. 
 
 
5.1.4 Reduced proliferation and aberrant differentiation of the lens during eye development 
in KTA48 mutants 
E14.5, E15.5 and E17.5 pregnant mice were injected with BrdU and sacrificed two hours after 
injection. At E14.5, BrdU labelling showed an intense cell proliferation of lens epithelium and 
cornea in wild types (N=2), but a sparse distribution of BrdU positive cells in the anterior lens 
epithelium of the mutants (N=2) (Figure 5.6, A-B). At E15.5, At E15.5, there are a number of lens 
epithelial cells which were incorporated with BrdU in wild types (N=5), whereas in mutants BrdU 
incorporated cells were obviously reduced in the lens epithelial cells (N=5) (Figure 5.6, C-D). At 
E17.5, there is a number of BrdU positive cells in the anterior lens epithelium of wild types (N=2), 
whereas very few positive cells are found in mutants, but the proliferation of the epithelial cells in 
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the transition zone is not affected (N=2) (Figure 5.6, E-G). These results demonstrated that the lens 
proliferation of KTA48 mutant embryonic eyes is reduced but the proliferation of the epithelial 
cells in the transition zone is not severely affected.  
 
 
Figure 5.6 Reduced proliferation in KTA48 mutant embryos. (A-B) At E14.5, the lens epithelial cells were 
incorporated with a number of BrdU in wild types (N=2) (A), while the mutant lens showed that there are a 
reduced number of BrdU incorporated cells in the central part of lens epithelium (N=2) (B). (C-D) At E15.5, 
there are a number of lens epithelial cells which were incorporated with BrdU in wild types (N=5), whereas in 
mutants BrdU incorporated cells were obvious reduced in the lens epithelial cells (N=5). (E-G) At E17.5, in 
wild-type lenses, there are a number of lens epithelial cells labelled with BrdU (N=2) but in mutants (N=2) there 
is greatly decreased numbers of lens epithelial cells in the central part of the mutant lenses (G) compared to 
wild-type lenses (E). However, the proliferation of the epithelial cells (BrdU labelled) in the transition zone of 
the lenses is not severely affected in mutants. L: lens; R: retina; LE: lens epithelium. Scale bar: 50 µm. 
 
 
In addition to proliferation, the lens differentiation is also affected in KTA48 mutant embryonic 
and postnatal eyes. The transition zone is a region necessary for lens differentiation where the lens 
epithelial cells differentiate into the secondary lens fiber cells (Wride, 2011). By E15.5, the nuclei 
of the transition zone are organized well as a bow-like pattern in wild-type lenses, whereas the 
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cells in the transition zone were disorganized and the number of secondary fiber cells is less in 
mutant lens than wild types (Figure 5.7, A-B, E). At P21, the defect of the transition zone is more 
severe: the number of secondary fibers in the transition zone is greatly reduced and they are 
disorganized (Figure 5.7, C-D, E). In consistency with the histology showing that the lens is broken 
(Figure 5.3, H, J, L; Figure 5.5, B, D), γ-crystallin was found in the anterior chamber of the mutants 
by immunostaining at E15.5 (Figure 5.8, E-H) and E17.5 (Figure 5.8, I-L), which could trigger an 
eye inflammation response. In addition, the expression of γ-crystallin appears normal compared to 
the wild types at E13.5 but is reduced in the secondary fibers at E17.5 in mutants compared to the 
wild types (Figure 5.8, A-H), indicating that lens fiber cell differentiation is defect during 
embryonic eye development. These results suggest that the lens epithelial cells in the transition 
zone fail to differentiate into the secondary fiber cells in KTA48 mutants.  
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Figure 5.7 Lens differentiation is affected in KTA48 mutant embryos. (A-B) The transition zone is 
disorganized and the number of secondary fiber cells is significantly reduced in mutants (B) at E15.5 (N=5) 
compared to wild types (A) (N=6) ( p<0.001, E). (C-D) At P21, the epithelial cells in the transition zone is 
thinner and correspondingly the number of secondary fiber cells is also greatly reduced in mutants (N=6) (C) 
compared to wild types (N=6) (D) ( p<0.0001, E). Scale bar: A-B, 20 µm; C-D, 50 µm. 
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Figure 5.8 γ-crystallin in the anterior chamber and disrupted lens differentiation in KTA48 mutant 
embryonic eyes. (A-L) γ-crystallin is a marker for differentiated lens fiber cells. At E13.5, γ-crystallin is 
expressed in the whole lenses but not in the nuclei of the wild types (A and B) and there are no differences in the 
lenses between wild types (A and B) and mutants (C and D). At E15.5, γ-crystallin is still expressed in the whole 
lenses but not in the nuclei of the wild types (E and F) but the mutants exhibited a rupture of the anterior lens 
which causes γ-crystallin extruding in the local anterior chamber (G and H, arrow). At E17.5, the expression of 
γ-crystallin was found more broadly in the anterior chamber of the mutants (K and L, white asterisk) 
accompanied by loss of lens fibers in the lens (K and L, arrowhead) due to a rupture in the lens capsule and 
epithelium. Moreover, the mutants showed reduced expression of γ-crystallin in the transition zone at E17.5 (K 
and L, arrow) compared to wild types (I and J) which suggests that the fiber cells differentiation is affected. 
Scale bar: 150 µm. 
 
Then I analyzed the expression of several genes which control and regulate lens proliferation and 
differentiation by immunostaining. Foxe3 is necessary for lens proliferation and differentiation 
(Blixt et al., 2000, 2007; Medina-Martinez, 2005). Staining for Foxe3 was performed in the eyes 
at E14.5, E17.5 and P11. In the wild-type lenses, Foxe3 is robustly expressed in the lens epithelial 
cells in different stages (Figure 5.9, A, C and E). In the mutant lens, at E14.5 and E17.5, there is 
reduced expression of Foxe3 in the central part of the lens epithelial cells, which are also 
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incorporated with less BrdU (Figure 5.9, B and D). At P11, the expression of Foxe3 is greatly 
reduced and some lens epithelial cells do not express Foxe3, and Foxe3 expression can be 
ectopically found the cells outside of the lens, suggesting the lens epithelial cells may migrate out 
of the lens (Figure 5.9, F). TGFβ signalling is crucial for lens fiber cell differentiation (de Iongh 
et al., 2001; Lovicu et al., 2004). At P11, TGFβ1 is expressed in the lens epithelium and secondary 
fiber cells in the transition zone in the wild-type lens (Figure 5.10, A-F), whereas the mutants 
showed reduced expression of TGFβ1 in the lens epithelium and secondary fiber cells in the lens, 
but it is expressed in the ectopical lens cells in the vitreous (Figure 5.10, G-L). These results 
suggested that the expression of some key genes controlling and regulating lens proliferation and 
differentiation is affected in KTA48 mutants during lens development and in the early postnatal 
periods.  
 
 
 
Figure 5.9 Aberrant expression of Foxe3 in 
mutants. (A-F) At E14.5, there is robust 
expression of Foxe3 in lens epithelia cells in wild 
types (A), while in the anterior lens epithelium in 
mutants the expression of Foxe3 is decreased (B, 
arrow). At E17.5, there is still strong expression 
of Foxe3 in lens epithelia cells in wild types (C), 
but decreased expression of Foxe3 in mutants 
due to persistent cornea-lens adhesion (D, arrow). 
At the later stage, P11, Foxe3 is only expressed 
in lens epithelial cells (E) while in mutants Foxe3 
expression is completely absent in most lens 
epithelial cells (F, white arrow) and decreased 
expression of the other lens epithelial cells (F, red 
arrow) and it is ectopically expressed in some 
lens epithelium cells outside of the lens (F, 
arrowhead). Scale bar: 50 µm. 
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Figure 5.10 Aberrant expression of TGFβ1 in mutant lens at P11. (A-F) TGFβ1 is expressed in the lens 
epithelium (A-B) and lens secondary fibers (C-D) in wild types. (G-L) In mutants, the expression of TGFβ1 is 
reduced in the lens epithelium (G-H; I-J, arrowhead) and lens secondary fiber cells (I-J, arrow) and it is 
ectopically expressed in the lens cells in the vitreous (K-L). There are a number of cells in the posterior lens of 
mutants which express TGFβ1 (K-L, arrowhead), whereas there are only a few cells in the posterior lens of wild 
types which do not express TGFβ1 (E-F). Scale bar: 50 µm. 
 
 
On the other hand, peroxidasin was found to be cross-linked with Collagen IV in the basement 
membrane in vitro and the Collagen IV network is disorganized in peroxidasin-mutant Drosophila 
(Bhave et al., 2012). Then I investigated whether the expression pattern of Collagen IV is changed 
in KTA48 mutants. At E12.5, Col4a2 (Collagen IV a2) is mainly expressed in the lens epithelium 
and inner limiting membrane in the wild-type eyes, and no obvious differences in the expression 
pattern were found between wild types and mutants (Figure 5.11, A-B). At E17.5, Col4a2 is still 
expressed in the lens epithelium (Figure 5.11, C) in wild types, but a disrupted local cell adhesion 
of lens epithelium was found in mutants (Figure 5.11, D-E). E-cadherin is one of the main cell 
adhesion molecules in the epithelial cells (van Roy and Berx, 2008). It is also a marker for 
epithelium-mesenchymal cell transition (EMT) and the expression of E-cadherin is decreased 
during EMT and loss of E-cadherin also promotes EMT (Zeisberg and Neilson et al., 2009). 
Detailed analysis of this disrupted region with staining against E-cadherin showed that the 
expression of E-cadherin is decreased, and some lens epithelial cells are missing and a small hole 
is formed in this region (Figure 5.11, E-G). Interestingly, there are a mass of cells nearby 
expressing E-cadherin in the anterior chamber, which cover the lens epithelial cells (Figure 5.11, 
E-G). These cells are likely to be mesenchymal transmitted from epithelial cells and they express 
E-cadherin. These data suggest that the cell adhesion of the lens epithelium is disrupted in KTA48 
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mutants which may be an early event for lens rupture and the lens fiber cells migrating into the 
anterior chamber.   
 
 
Figure 5.11 The cell adhesion of lens epithelium is locally disrupted in mutants during eye development. 
(A-B) At E12.5, collagen IV (a2) (Col4a2) is highly expressed in the lens epithelium and inner limiting 
membrane in wild types (A). No obvious differences in the expression pattern of Col4a2 were found between 
wild types (A) and mutants (B). (C-D) However, at E17.5, the mutant lens exhibits a local disruption of lens 
epithelium (D, marked). (E-G) The lens epithelium is severely disrupted in this local region of the mutants by 
Col4a2 staining (E, arrow) and E-cadherin staining (F-G, arrow). Interestingly, there is a mass of cells expressing 
epithelial cell adhesion molecule E-cadherin near the lens epithelial cells (F-G, arrowhead). L: lens; R: retina; 
LE: lens epithelium. Scale bar: A-D, 50 µm; E-G, 20 µm. 
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5.1.5 The defects in peroxidasin may affect eye development through regulation of Pax6 and 
Tgfβ1 expression and increased inflammation  
To further investigate the possible signalling pathways of peroxidasin, I firstly compared 
quantitatively and spatiotemporal expression of different genes which are critical for eye 
development in KTA48 mutants and wild-type mice. RNA was isolated from the whole eyes and 
quantitative real-time PCR (qRT-PCR) was performed at E12.5, E15.5 and P10. The genes which 
are critical for eye development and inflammation were selected, including Pax6, Tgf-β1, TNF-a 
and IL-1β. Pax6, a master control gene of eye development, is up-regulated at E15.5 and then 
down-regulated to normal level at P10 in KTA48 mutants (Figure 5.12, A-C). Then in-situ 
hybridization and immunofluorescence were performed to confirm the qRT-PCR results. At E12.5, 
Pax6 is highly expressed in lens epithelium and retina in wild-type eyes (Figure 5.15, A-B), 
whereas Pax6 is not only expressed in the lens epithelium, but also in the lens fiber cells, and the 
expression of Pax6 seems to be decreased in the retinal ciliary margin in mutants (Figure 5.15, C-
D). Pax6 mRNA is also expressed in the lens fiber cells (Figure 5.14, B) compared to wild types 
(Figure 5.14, A), but mRNA expression of Pax6 was not changed in mutants compared to wild 
types by qRT-PCR. At E17.5, KTA48 mutants also showed strong expression of Pax6 in the eye, 
especially in retina (Figure 5.15, E-J), which was consistent with in-situ hybridization data at E15.5 
(Figure 5.14, C-E). Tgf-β1 is another key gene for eye development and overexpression of Tgf-β1 
causes anterior segment dysgenesis in mice (Flügel-Koch et al., 2002) and the ocular phenotype is 
similar to KTA48 mutants. Tgf-β1 has an increasing trend in expression at E12.5, and its expression 
is up-regulated at E15.5 and then down-regulated to normal level at P10 in KTA48 mutants (Figure 
5.12, D-F). These data showed that peroxidasin may affect eye development through regulation of 
Pax6 and Tgf-β 1expression. 
 
On the other hand, considering the point mutation in peroxidasin may cause a reduced activity of 
peroxidase and increase the level of inflammation, the inflammation-associated genes including 
TNF-α and IL-1β were selected to measure inflammation. The expression of TNF-α and IL-1β are 
up-regulated in E15.5 in mutants and continued to be up-regulated at P10, which is around 4 days 
before eye open in mice (Figure 5.13, A-D). These data suggest that congenital ocular 
inflammation occurs in the KTA48 mutants.  
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Figure 5.12 Up-regulation of Pax6 and Tgf-β 1 in the embryonic eyes at E15.5. (A-C) Real-time PCR showed 
that the expression of Pax6 is not altered at E12.5 in mutant eyes compared to wild types (p>0.05), but up-
regulated at E15.5 (p <0.01) and then reduced to the level comparable to the wild types (p>0.05). (D-F) The 
expression of Tgf-β1 has a trend to be up-regulated at E12.5 (p>0.05) and up-regulated at E15.5 in mutant eyes 
(p <0.05), and then decreased to the expression level comparable to wild-type eyes at P10 (p>0.05). Mt: a/a; 
E12.5 (N: Wt 5 Mt 5); E15.5 (N: Wt 4 Mt 6); P10 (N: Wt 4 Mt 4). 
 
 
 
 
Figure 5.13 Up-regulated mRNA expressions of inflammation marker genes at E15.5 mutant eyes. (A-D) 
Real-time PCR showed that the expression of inflammation marker genes (TNF-α and IL-1β) is up-regulated in 
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mutant eyes at E15.5 (p <0.01) and P10 (p <0.05), which suggests that ocular inflammation occurs in mutant 
eyes during eye development. Mt: a/a; E15.5 (N: Wt 4 Mt 6); P10 (N: Wt 4 Mt 4). 
 
 
 
Figure 5.14 The mRNA expression of Pax6 is still intensively expressed in the retina of KTA48 mutants by 
in-situ hybridization. (A-E) In-situ hybridization of the sections with Pax6 anti-sense RNA probes showed 
positive staining in the wild types and mutants. (A-B) At E13.5, Pax6 mRNA is mainly expressed in the retina 
and weakly expressed in the lens of the wild types (A). In mutants, Pax6 mRNA is not only expressed in the 
retina, but also expressed in the lens (B). (C-E) At E15.5, Pax6 mRNA is expressed in the lens epithelium and 
retina in wild types (C) and Pax6 mRNA is still intensively expressed in the retina of KTA48 mutants compared 
to wild types (D, E). (F-I) In-situ hybridization of the sections with Pax6 sense RNA probes showed no positive 
staining in the negative controls. Scale bar: 100 µm.  
  
82 
 
 
Figure 5.15 The localisation of Pax6 expression is changed in KTA48 mutant embryonic eyes by 
immunofluorescence. (A-D) At E13.5, Pax6 is highly expressed in the lens epithelium and retina in wild-type 
eyes (A-B), but it appears that Pax6 is not only expressed in the lens epithelium, but also in the lens fiber cells, 
and the expression of Pax6 seems to be decreased in the retinal ciliary margin in mutants (C-D). (E-J) At E17.5, 
Pax6 is expressed in the eye lids, corneal epithelium, lens, inner limiting membrane and retina in wild-type eyes 
(E-G). However, the expression of Pax6 is up-regulated in retina at E17.5 and it appears that there are more 
Pax6-positive cells in the outer layer of the retina (J) compared to wild types (G). Scale bar: A-D, 50 µm; E-J, 
20 µm. 
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5.1.6 Axon guidance from optic disc to optic tract is not affected in KTA48 mutant embryos 
at E15.5 
Axon guidance is also a very important event in visual system development, and PXN-2 (one of 
two types of peroxidasin in C. elegans) plays a role in axon guidance in C. elegans (Gotenstein et 
al., 2010). Therefore, I performed anterograde tracing to see whether there are morphological 
differences in the optic chiasm and optic nerve between wild types (N=5), heterozygous (N=3) and 
homozygous mutants (N=5) at E15.5, a stage when the optic chiasm has formed. No difference in 
the crossing and fasciculation of the optic chiasm and optic nerve was found between wild types 
and KTA48 mutants at E15.5 (Figure 5.16), suggesting that peroxidasin may not play a role in axon 
guidance during visual system development.   
 
Figure 5.16 No difference in the crossing and fasciculation of the optic chiasm and optic nerve was found 
between wild types and mutants at E15.5. Anterograde tracing showed that there is no difference in the 
crossing and fasciculation of the optic nerve (A, C, E), optic chiasm and optic tract (B, D, F) between wild types 
(A, B), heterozygous (C, D) and homozygous mutants (E, F). ON, optic nerve; OC, optic chiasm; OT, optic tract. 
Scale bar: 100 µm. 
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5.1.7 KTA48 is a new mouse model of anterior segment dysgenesis particularly Peters 
anomaly associated with microphthalmia and early-onset glaucoma 
To further investigate the eye phenotype of KTA48 mutants during postnatal periods, I observed 
the ocular structure by light microscopy and histology from early postnatal period to adult. 
Apparently, all the mutants presented microphthalmia, corneal opacity and shallow/missing 
anterior chamber. Most of the mutants showed broad corneal opacity, but in very few cases (less 
than 5%) the opacity is located at the central area of the cornea. At P21, when major eye 
morphogenesis is completed, more severe phenotypes are found in KTA48 mutants compared to 
the embryonic stages, including smaller eyes and lenses, the lens-cornea adhesion, thinner corneal 
epithelium and disorganized corneal stroma, missing or very shallow anterior chamber, lens matrix 
disorganization and disorganized lens epithelium, and iris and ciliary body hypoplasia (Figure 
5.17). All these phenotypes were found in all mutants at P17-P21 (Table 5.2). Although the lens 
stalk was found in 42.9% mutants at E15.5-E17.5 (Table 5.1), the corneal-lens adhesion was found 
in all mutants (Table 5.2). This data suggests that the corneal-lens adhesion  can be formed at later 
stages. Since corneal-lens adhesion and corneal opacity, two typical hallmarkers of Peter’s 
anomaly, are obvious in mutants, KTA48 homozygous mutant mice are also a new mouse model 
of Peters anomaly. Moreover, lens matrix was also found in the vitreous cavity as well as in the 
anterior chamber, whereas the lens matrix was only found in the anterior chamber and the area 
around the lens capsule. This data indicates that lens rupture is more severe and more lens fibers 
leak out of the lens into the vitreous cavity at the postnatal period. These phenotypes of the anterior 
segment dysgenesis are also a high risk for glaucoma and retinal damage.  
 
In addition, the retinal phenotypes occur more frequently at postnatal periods (Figure 5.17, F; Table 
5.2) compared to embryonic stages (Table 5.1). Not only retinal folds and rosette-like structure but 
also retinal retraction and retinal dysgenesis occur in 88.9% mutants (8/9, Table 5.2), whereas only 
retinal folds and rosette-like structure were found in 32.1% mutants (9/28, Table 5.1). This data 
indicates that retinal damage is progressively severe from embryonic stages to the postnatal periods. 
There are two possible reasons for retinal phenotypes in the mutants. One is that high ocular 
pressure caused by the anterior segment dysgenesis and ocular inflammation during embryonic 
stages, which could damage the retina. The second possibility is that vitreous scar is formed due 
to vitreous inflammation induced by the lens fibers in the vitreous cavity, which could cause 
85 
 
vitreous-retinal traction.  
 
 
Figure 5.17 Anterior segment dysgenesis in postnatal eye development in KTA48 mutants at three weeks. 
At P21, the stage that major eye morphogenesis is completed, the mutant eyes and lens displayed remarkable 
smaller eyes compared to wild types (A) and severely anterior segment dysgenesis including iris hypoplasia and 
underdevelopment of ciliary body (B and C), lens-corneal adhesion (D, E), thinner corneal epithelium and 
disorganized corneal stroma (D), disorganized lens matrix which leads to congenital cataract (E). The iris is 
attached to the cornea and lens (A, B and E), resulting in the block of aqueous humor flow into trabecular 
meshwork which is high risk for high ocular pressure and glaucoma. Ruptured lens capsule is also found in 
mutants (black arrowhead, E) and the lens matrix is found around the lens in the vitreous cavity (black arrow, 
E). The lens equator in mutants is also totally destroyed and there are very few secondary fiber cells near the 
lens equator (black broken circle, E). In wild types, the Schlemm’s canal develops well and ciliary body is 
located between cornea and sclera (arrow, C, WT), whereas in mutants the Schlemm’s canal is not obviously 
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found and cornea extends to retina regions (C). (F) Retinal rosette-like structure (arrowhead) and retinal traction 
(arrow) occur in mutants compared to wild types. C: cornea; I: iris; L: lens; R: retina; CE: corneal epithelium; 
CS: corneal stroma; En: endothelium; CB: ciliary body. Scale bar: A-B, 500 µm; C-D, 50 µm; E (WT), 200 µm; 
E (a/a, left), 100 µm; E (a/a, right), 50 µm.     
 
 
Table 5.2 Summary of eye phenotypes in KTA48 homozygous mutants at P17-P21 
 
Phenotype 
 
Disorganized 
corneal 
stromal cells 
 
Smaller 
eyes and 
lenses 
 
Disorganized 
lens matrix 
and lens 
rupture 
 
Lens 
tissue in 
AC and 
VC 
 
Lens-
corneal 
adhesion 
 
Iris-
corneal 
adhesion 
 
Iris and 
ciliary body 
hypoplasia 
 
Vitreous 
tissue 
 
Retinal   
folds 
and 
rosette 
 
Retinal 
tract 
 
Number   
(9 eyes) 
   
9/9 
 
9/9 
 
9/9 
 
9/9 
 
9/9 
 
9/9 
 
9/9 
 
2/9 
 
8/9 
 
8/9 
 
Percentage 
 
100% 
 
100% 
 
100% 
 
100% 
 
100% 
 
100% 
 
100% 
 
22.2% 
 
88.9% 
 
88.9% 
 This data is based on the histological observation of eyes. AC: anterior chamber; VC: vitreous cavity. 
 
To determine whether loss of function of peroxidasin induces glaucoma, I further analyzed the 
phenotypes of optic nerve head and retina in KTA48 mutants at P21 and 3 months. 3 wild-type eyes 
and 3 mutants were performed for immunofluorescence and the results were similar at each stage, 
respectively. At P21, retinal rosette-like structures were also found in the optic nerve head region 
in mutants (Figure 5.18, F) compared to wild types (Figure 5.18, A). GFAP is ectopically expressed 
in the inner plexiform layer in mutants (Figure 5.18, H, L-M, arrow), indicating that activated glial 
cells occur in this region. In some local regions, GFAP is expressed all through the retina and it 
appears that retinal Müller cells are activated in these regions (Figure 5.18, O). Neurofilament, a 
type of neuronal intermediate filament proteins, is a major component of the neuronal cytoskeleton 
and it is abundant in axons (Yuan et al., 2012). Therefore, the antibody against neurofilament can 
be used to stain the neuronal axons. Neurofilament staining showed that there are robust retinal 
ganglion cell axons stained in the optic nerve (Figure 5.18, E-F) and in the retinal nerve fiber layer 
and it is also expressed in the axons of the horizontal cells in wild types (Figure 5.19, F-G), whereas 
in mutants the optic nerve (axons of the retinal ganglion cells) is thinner (Figure 5.18, I-J) and 
disrupted axons of the retinal ganglion cells and horizontal cells (Figure 5.19, M-N) were found. 
Moreover, the cell number in the retinal ganglion cell layer is increased but interestingly the 
number of Brn3-positive retinal ganglion cells is almost absent in mutants. Although the retina 
appears thicker in mutants, the other retinal layers (except retinal ganglion cells) are well-
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developed compared to wild types (Figure 5.19, A-E and H-L). These data indicate that the retinal 
ganglion cells and the axons of the retinal ganglion cells (nerve fibers) are damaged in mutants at 
the early postnatal period (3 weeks). At 5 months, there is considerable loss of retinal ganglion 
cells and reduced thickness of the inner and outer nuclear layer in KTA48 mutants (Figure 5.20, I), 
suggesting that progressive damage of retinal ganglion cells occur in the mutants. Together, these 
data suggest that peroxidasin plays a role in the onset and development of early glaucoma.  
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Figure 5.18 Phenotypes of the retina and optic nerve in KTA48 mutants at P21. (A-J) Apparently the optic 
nerve is thinner in KTA48 mutants than in the wild types. There are local retinal folds and rosettes and retinal 
detachment (F) in the mutant retina. There is less staining for neurofilament in the neural fiber layer and optic 
nerve in mutants (J, arrow) compared to the wild-type controls (E), suggesting defects in the axons of retinal 
ganglion cells in the mutants. Some retinal glial cells are activated in the local inner plexiform layers of the 
mutants (arrow, H; L-M; L-M; O) and GFAP expression is increased in some regions of the mutant retina (O) 
compared to wild types (C, H, K and N). (P-S) Negative controls for the immunostaining in wild types and 
mutants. The fluorescence is absent or very weak non-specific fluorescence in the negative controls compared 
to wild-type positive staining. Scale bar: 100 µm. IPL: inner plexiform layer. 
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Figure 5.19 The number of retinal ganglion cells is increased but loss of Brn3 expression in KTA48 mutants 
at 5 months. (A-C, H-J) The number of retinal ganglion cells is increased in mutants (H, I, J) compared to wild 
types (A, B, C) but interestingly the expression of Brn3 is obviously decreased in mutants (K and L, arrow) 
compared to wild types (D and E, arrow). Correspondingly, the RGC axons in mutants are thinner (M; N, arrow) 
and both neural fiber layer and horizontal cells are disrupted in mutants compared to wild types (F and G). 
Negative controls showed no staining or very weak staining. NF: nerve fiber layer; GCL: retinal ganglion cell 
layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear layer; 
PL: out segments of photoreceptor; HC: horizontal cells. Scale bar: A-B, H-I, D, F, K, M, 50 µm; C, E, G, J, L, 
N, 20 µm.  
 
In adults, the mutants displayed more severe phenotypes and eye lids appeared to be nearly closed. 
The eye phenotypes in this stage are similar due to severe destroyment of the eyes during 
development. 5 independent samples were used for histology. Histology demonstrated more 
anterior segment phenotype compared to P21 including lens-cornea adhesion, cornea matrix 
disorganization and disarranged keratocytes, ruptures in lens epithelium and capsule, and lens 
matrix disorganization in mutants (performed in 5 independent mutant eyes). In addition, sclera 
uveolma, missing anterior chamber and the anterior segments attached together can also be found 
in mutants (Figure 5.20). The iris is attached to the corneal endothelium and the anterior chamber 
is very shallow or even missing, suggesting that high ocular pressure or glaucoma occurs in the 
mutants. These eye phenotypes of the anterior segment and microphthalmia are similar to clinical 
manifestation of patients with anterior segment dysgenesis, particularly with Peters anomaly. In 
addition, the extracellular matrix of the eyes is severely disrupted in adult mutant mice, which was 
revealed by Col4a2, E-cadherin and N-cadherin immunostaining (Figure 5.21). In wild types, 
Col4a2 is highly expressed in corneal epithelium, the outer layer of lens capsule and lens 
epithelium (Figure 5.21, A-C), whereas in mutants the expression of Col4a2 is significantly 
reduced in the corneal epithelium and lens capsule (Figure 5.21, D-E). E-cadherin is also expressed 
in the corneal epithelium and lens epithelium (Figure 5.21, F-G), and N-cadherin is expressed in 
the lens epithelium (Figure 5.21, H) in adult wild types. In mutants, the expression of E-cadherin 
is also obviously decreased in the corneal epithelial cells and lens epithelial cells (Figure 5.21, I-
J), and N-cadherin expression is reduced in the lens epithelial cells (Figure 5.21, K). Compared to 
the embryonic stage (Figure 5.11), the extracellular matrix and cell adhesion were progressively 
and severely damaged in adult mutant (Figure 5.21).  
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Figure 5.20 Microphthalmia, corneal opacity, cataract, iris and ciliary body hypoplasia, anterior chamber 
angle abnormalities, retinal dysplasia and ganglion cell loss in KTA48 adult mutants at 5 months. (A and 
C) Microphthalmia, smaller lens and local retinal dysplasia in KTA48 adult mutants. (B) Corneal opacity (black 
arrow), very shallow anterior chamber (white arrow) and scleral staphyloma (black arrowhead) in KTA48 
mutants. (D) Thinner corneal epithelium, disorganized stromal keratocytes and fibrosis-like changes in the region 
of corneal opacity of KTA48 mutants compared to wild types. (E) Iris hypoplasia, iris-corneal adhesion and iris-
lens adhesion were found in KTA48 mutants compared to wild types. (F) Ciliary body and Schlemm’s canal 
develop well in wild types, whereas the ciliary body is poorly developed and not formed as triangular structure 
in the cross-sections and the Schlemm’s canal is not seen and the anterior chamber angle is fully filled and the 
cornea extends to the scleral region in KTA48 mutants compared to wild types. (G-H) Severely disrupted lens 
epithelium, disorganized lens matrix and thinner lens capsule in KTA48 mutants compared to wild types. (I) Loss 
of ganglion cells, and the inner and outer nuclear layer become thinner in KTA48 mutants compared to wild types 
at 3 months. Scale bar: C, 500 µm; E, 200µm; H, 100 µm; F and I, 50 µm; D and G, 20 µm. 
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Figure 5.21 Decreased expression of extracellular matrix molecule (Col4a2) and cell adhesion molecules 
(E-cadherin and N-cadherin) in KTA48 mutants. (A-E) Col4a2 is expressed in the corneal epithelium (A-B), 
lens epithelium and the outer layer of the lens capsule (C) in wild types. The expression of Col4a2 is decreased 
in the corneal epithelium and lens capsule in mutants (D-E). (F-K) E-cadherin is expressed in the corneal 
epithelium (F) and lens epithelium (G), and N-cadherin is expressed in the lens epithelium (H) in wild types. 
The expression of E-cadherin and N-cadherin is greatly decreased and disrupted in the corneal epithelium and 
lens epithelium in mutants (I-K). Negative controls showed very weak non-specific staining in the corneal 
epithelium but absent staining in the lens epithelium cells. Double stained: G and H; J and K. Scale bar: A-E, 20 
µm; F-K, 50 µm. 
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5.2 PartⅡ: Bmpr1b is essential for optic nerve and ventral retinal development  
5.2.1 Mis-splicing of exon 10 in Ali030 homozygous mutants  
The genetic analysis showed that the point mutation (T->G transversion) was found at the second 
base pair of intron 10 of the Bmpr1b gene in Ali030 mutant mice (Figure 1.8, A), which suggests 
that it probably affects the splicing pattern of exon 10 or intron 10. To analyze the RNA splicing 
product of Bmpr1b gene in Ali030 mutants, RT-PCR was performed on retinal and whole eye 
preparations from the wild-type and mutant mice, respectively. The difference in Bmpr1b cDNA 
length between wild types and mutants was not obvious from the gel (Figure 5.22, A). Then full-
length Bmpr1b cDNA PCR product was purified from the gel and sent to GATC company for 
sequencing, but unfortunately most part of the cDNA can not be sequenced by the Sanger method, 
which may be due to the large size and low amount of cDNA, and the sensitivity of the sequencing 
method. Therefore I cloned Bmpr1b cDNA from mutant and wild-type eyes into the pcDNA3.1 
vector and sent it for sequencing. The sequencing results were shown as below (Figure 5.22, B). 
In wild types, exon 10 is located between exon 9 and exon 11, whereas in mutants, the exon 10 is 
missing between exon 9 and exon 11. This data suggests that exon 10 is mis-splicing by a mutation 
in the splicing donor site although it is located in the intron. There was no difference in splicing 
pattern between eyes and retina in mutants (the sequences are the same to Figure 5.22, B). The 
mis-splicing of exon 10 (1614-1744 bp, Bmpr1b mRNA NCBI reference sequence: NM_007560.4) 
in mutant Bmpr1b cDNA causes a translational frameshift from 1600 bp and a premature stop 
codon in 1822-1824bp (TAA), which is predicted to affect the cytoplasm domain including the 
conserved serine/threonine kinase (Figure 5.22, C). 
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Figure 5.22 Mis-splicing of exon 10 of Bmpr1b mRNA in Ali030 homozygous mutants. (A) Purified Bmpr1b 
cDNA product (wild types and mutant eye tissues) on the agarose gel and there is no obvious difference in the 
size of band between wild types and mutants. (B) The exon 10 is mis-spliced (skipped) in mutant Bmpr1b mRNA. 
Bmpr1b cDNA from P1 wild-type and mutant retina was cloned and sequenced, respectively. In homozygous 
mutants, there is a missing exon 10 between exon 9 and exon 11 compared to wild types. (C) Mis-splicing of 
exon is predicted to cause a translational frameshift after 1601 bp and affect the cytoplasm domain including the 
conserved serine/threonine kinase.  
 
 
5.2.2 Optic nerve head hypoplasia and ventral retinal gliosis without lens phenotypes in 
Ali030 mutants 
Previous studies showed that Bmpr1b affects optic nerve axon guidance (Liu et al., 2003) and BMP 
signaling is required for lens induction and development (Furuta and Hogan, 1998; Faber et al., 
2002). The eye phenotypes of Ali030 mutant mice were initially screened using funduscopy and 
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AC Master (a special equipment used to measure the depth of anterior chamber, lens thickness and 
eye size (Puk et al., 2006)), respectively. Funduscopy examination showed enlarged optic disc, and 
AC Master examination revealed that the axial length in mutant eyes is slightly longer than wild 
types which may be due to enlarged optic disc, but lens transparency are not affected in mutants 
by slit-lamp analysis (GMC report for Ali030, unpublished).  
 
Next, I analyzed the phenotype of optic nerve head (ONH), optic nerve, retina and lens by in-vivo 
retinal imaging (Spectral Domain Optic Coherence Tomography, SD-OCT) and histology. SD-
OCT revealed an enlarged and a very thin optic disc in the optic nerve head but a thicker inner 
plexiform layer in the ventral retina of the mutants (N=12 eyes, 6 mice) compared to wild types 
(N=10 eyes, 5 mice) (Figure 5.23, A-C). In addition, the remnant of the hyaloid vessel was found 
to be dislocated at the rim of the optic nerve head compared to the central location of the ONH in 
wild types (Figure 5.23, B). Moreover, a long retinal glial scar occurred in the ventral retina (Figure 
5.23, D), which was confirmed by further flat-mount immunostaining. Up-regulation of GFAP 
expression was found in the ventral retina of the mutants compared to wild types (Figure 5.24, A-
J). The activated glial cells were both found in the optic nerve head and ventral retina in mutants 
and they formed a glial scar in the ventral retina which is connected to the optic nerve head (Figure 
5.24, F-G). From the OCT section, there are distinct retinal layers in wild types (Figure 5.23, A 
and B, WT). However, in mutants, the distinct layers in most areas of the ventral retina disappear 
but form a dark zone from retinal ganglion cell layer to outer plexiform layer and some retinal 
defects showing small dark zone similar to rosette structure found in or between the photoreceptor 
layer and the RPE or choroid layer (Figure 5.23, B).  
 
Histology demonstrated that enlarged optic disc, especially in the central part, is found in the optic 
nerve head from early postnatal periods to adult, which suggests that it is optic nerve head 
hypoplasia (Figure 5.25, G-L). Moreover, a number of cells were aggregated in the inner plexiform 
layer and some cells seem to migrate from the inner nuclear layer to the inner plexiform layer 
(Figure 5.25, D and F). In addition, the inner limiting membrane and the retinal ganglion cell layer 
in the ventral retina are broken and the cells proliferate and migrate out of the retina (Figure 5.25, 
A-F). In consistency with OCT results, there are similar findings revealed by histology. Firstly, 
there is also a retinal delamination in the ventral gliosis retina and retinal rosette structure is clearly 
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found in this region. Secondly, the photoreceptor layer is thinner in mutants than wild types and 
rosette-like structure is formed. Thirdly, the remnant of the hyaloid vessels is located at the 
peripheral part of the ONH in mutants compared with wild-type controls where it is located in the 
central part (Figure 5.25, A-F). These data showed that Bmpr1b is essential for ventral retinal 
development in mice. However, no difference was found between mutant and wild-type lenses by 
histology, which suggests that Bmpr1b may be not critical for lens development. 
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Figure 5.23 Excavation of the optic nerve head, ventral retinal gliosis scar and epiretinal membrane in 
ventral retina in Ali030 mutants at 3 months. (A-C) OCT showed that the optic nerve is fully filled and there 
is a remnant of the hyaloid artery on the center of the optic nerve head in wild types (A-C, WT, yellow and black 
arrow), whereas in mutants the excavation of the optic nerve head was found, the central thickness is remarkably 
reduced and the remnant of the hyaloid artery was found in the rim of the optic nerve head in Ali030 mutants 
(A-C, yellow and black arrow and broken circle). There are several retinal defect regions showing small dark zone 
similar to rosette structure found in the photoreceptor layer or between the photoreceptor layer and the RPE (B, 
arrowheads). (D) A long retinal glial scar was found in the ventral retina in the mutants (white arrow) which was 
confirmed by later GFAP immunostaining (Figure 5.24) and the thickness of the ventral retina is increased (C, 
arrow, yellow area). (A-C) The ventral retinal gliosis is connected to the optic nerve head and it is involved in 
multiple layers in ventral retina (A-C, a/a, blue arrow), and there is a thick black layer on the surface of peripheral 
retinal region of the gliosis scar in mutants which is similar to epiretinal membrane (A, a/a, red arrowheads; B, 
a/a, blue arrow).  
 
 
 
 
Figure 5.24 Activated glial cells in optic nerve head and ventral retina at 1 month. (A-J) Flat-mount 
immunostaining showed that there are much more ONH cells (I, arrow) in the optic nerve of the mutants 
compared to wild-type controls (D). GFAP expression is up-regulated in the optic nerve head (H, J, arrow) and 
ventral retina (F, G, arrow) in mutants compared to wild-type controls (A-C, E), suggesting that glial cells are 
activated in these regions. These activated glial cells form a long aggregate (glial scar) in the ventral retina (G, 
arrow) and the glial scar is connected to the optic nerve head (G, arrowhead). Scale bar: A-B, 300 µm; C-E, H-
J, 200 µm. 
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Figure 5.25 Ventral retinal gliosis and optic nerve head hypoplasia in Ali030 mutants. (A-F) Retinal gliosis 
and retinal dysplasia are found in ventral retinal in mutants. (A-B) At P2, there are some more cells in the retinal 
ganglion cell layer in mutants (B, arrow), but it seems that there is no difference in the neural blast layer between 
wild types and mutants. (C-D) At P11, there are distinct retinal layers in the wild-type retina (C), but in mutants 
there are much more cells in the inner plexiform layer and it appears that the retinal ganglion cell layer is broken 
and the neural fibers from inner plexiform layer grow out of the retina through the broken GCL through cell 
migration (D, arrow). In addition, some cells appear to be from inner nuclear layer and retinal rosettes are found 
(D, broken circles). (E-F) At adult (5 months), the cell number in the inner plexiform layer is significantly 
increased compared to early postnatal periods (F, arrow), and there are thinner inner and outer nuclear layer and 
photoreceptor layer (F) compared to the wild-type controls (E). It is obvious that some cells in the inner 
plexiform are from inner nuclear layer (F, white arrow) and more severe retinal rosettes are found and the 
photoreceptor layer is disrupted (F, broken circles). (G-L) Enlarged optic nerve head holes were found in 
mutants at P2 (H, arrow), P11 (J, arrow) and adult (5 months) (L, arrow) compared to the wild-type controls (G, 
I, K). It appears that there are some more cells in the verge of the the optic nerve head at P11 (J, arrowhead) and 
adult (L, black arrowhead) in mutants. The remnant of the hyaloid artery was found in the rim of the optic nerve 
head (L, red arrowhead) in mutants which was consistent with the OCT finding. Scale bar: A-B, G-L, 100 µm; 
C-F, 50 µm. 
 
 
5.2.3 Activated glial cells in the optic nerve head and in the ventral retina, and 
hypodevelopment of the optic nerve in Ali030 mutants 
Immunofluorescence for sections also showed up-regulation and robust expression of GFAP in the 
optic nerve head and in the ventral retina compared to the wild-type controls, which demonstrated 
that the retinal gliosis occurs in the ventral retina of the mutants. Further analysis was performed 
to observe the distribution and morphology of activated glial cells in mutants. At different stages 
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in wild-type mice from P5 to adult, GFAP-positive cells are only found in the nerve fiber layer and 
retinal ganglion cell layer (Figure 5.26, A-D). However, in the mutants, the number of activated 
glial cells is significantly increased from P5 to adult (Figure 5.26, E-H). In the early postnatal 
period, the number of activated glial cells is mainly located at the inner plexiform layer and outer 
plexiform layer, and retinal rosettes were not found, whereas at later stages, such as P21 and adult, 
the range of retinal gliosis is more broad and the inner nuclear layer and outer plexiform layer are 
also involved as well as the inner plexiform layer. It appears that the activated glial cells with long 
processes invade different layers of the retina in mutants (Figure 5.26, G, H) compared to wild 
types (Figure 5.26, C, D). There is an increased area of the ventral gliosis retina at later stages. In 
addition, there are more activated glial cells above the retinal ganglion cell layer compared to the 
early period, indicating that these glial cells are proliferating and produce more glial cells.  
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Figure 5.26 Retinal gliosis in Ali030 mutants. (A-H) Ventral retinal gliosis was detected from early postnatal 
periods (P5) to adult (3 months) in Ali030 mutants. (A-D) In wild-type retina from P5 to 3 months, GFAP is only 
expressed in the retinal ganglion cell and nerve fiber layer. (E-H) Robust up-regulation of GFAP expression was 
found in nerve fiber layer, retinal ganglion cell layer, inner plexiform layer and outer plexiform layer, especially 
in the inner plexiform layer where there are a significantly increased number of activated glial cells. At P5, the 
100 
 
outer plexiform is not clearly formed in wild types (A) and is also not clear from DAPI picture in mutants (E). 
However, the expression of GFAP is significantly up-regulated in the outer plexiform in mutants (E) compared 
to wild types (A). The retinal gliosis occur more broadly with strong up-regulation of GFAP in the outer 
plexiform layer in the adult mutant retina compared to the early periods. The retinal fold is formed in the early 
period (P5, E) and at the later stage (P21, G; 3 months, H) retinal rosettes are formed. NFL: nerve fiber layer; 
GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: 
outer nuclear layer. Scale bar: 50 µm.  
 
In the optic nerve head, GFAP-positive cells are only found in the retinal ganglion cell layer and 
in the optic nerve in wild-type mice, while GFAP-positive cells with long branches are found in 
homozygous mutants (Figure 5.27, A-B and D-E), which suggests that the glial cells are activated 
in the optic nerve. In the optic nerve head, the astrocytes are also disorganized and GFAP-positive 
fibers are intercrossed in homozygous mutants compared to wild types (Figure 5.27, C and F).  
 
 
Figure 5.27 Activated and disorganized astrocytes in optic nerve head. (A-C) The wild-type retina showed 
GFAP-positive staining in the retinal ganglion cell layer and the optic nerve. (D-F) In mutants activated 
astrocytes with long processes were found in optic nerve head (arrow). In the optic nerve head, the astrocytes 
were disorganized in mutants (F) compared to the wild-type controls (C). Scale bar: A-B, A’-B’, D-E, D’-E’, 50 
µm; C and F, 20 µm. 
 
Further, we analyzed the optic nerve in the cross and longitudinal sections. The glial cells in the 
optic nerve is also activated compared to the wild-type controls (Figure 5.28, C, G), which is 
consistent with the findings in the optic nerve head (Figure 5.27). Moreover, the optic nerve is 
covered by three meningeal layers in the wild-type mice (Figure 5.28, A), whereas these meningeal 
layers are absent in the local area of the optic nerve but some cells of the optic nerve instead (Figure 
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5.28, E). The disrupted meningeal layers were located at the proximal and local area of the optic 
nerve in mutants. Interestingly, the number of Sox2-positive cells is obviously decreased in the 
optic nerve in mutants compared to the wild-type controls (Figure 5.28, B, F, I, K). Together with 
the histological findings, it suggests that the development of optic nerve is disrupted and this could 
be a hypodevelopmental process.   
 
 
 
 
Figure 5.28 Disrupted optic nerve of Ali030 mutants at P21. (A-H) Cross sections of the optic nerve. In wild 
types the optic nerve is covered by intact meningeal layers (A), but in the mutants the meningeal layers of the 
optic nerve are disrupted (E, arrow). (B-C) A number of Sox2-positive cells are in the optic nerve (B) and the 
glial cells are mainly located at the the peripheral region of the optic nerve (C) in wild types. In contrast, in 
mutants the number of Sox2-positive cells is decreased in the optic nerve (F) and the glial cells are more activated 
in the whole optic nerve (G). (I-L) Longitudinal sections of the optic nerve. Obviously, there are very few Sox2-
positive cells in some areas with the dense cells of the optic nerve in mutants (K and L, broken circles) compared 
to the broad Sox2-positive cells in the wild-type controls (K). (B-D, F-H, I-L) Red: Sox2; Green: GFAP; Blue: 
DAPI. Scale bar: A, E, 20 µm; B-D, F-H, I-L, 50 µm. 
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5.2.4 Loss of ventral retinal ganglion cells, axon misguidance in ventral retina and defective 
axons in the optic nerve in Ali030 mutants 
To investigate whether retinal ganglion cells and axons are affected by retinal gliosis, I did flat-
mount immunostaining to label retinal ganglion cells using Brn3, a marker for retinal ganglion 
cells (Soto et al., 2008; de Melo et al., 2011). Interestingly, I found only a few Brn3-positive cells 
in the ventral retina in mutants, whereas there are a number of Brn3-positive cells in any area of 
the retina in the wild-type controls (Figure 5.29, A-F). This result suggests that the number of 
retinal ganglion cells is greatly decreased in the ventral retina in mutants compared to wild types. 
This result indicates that increased number of activated glial cells in ventral retina could destroy 
retinal ganglion cells. The axons from retinal ganglion cells need to pass through the retina and 
enter the optic nerve head during eye development. I further observed the retinal ganglion cell 
axons by flat-mount immunostaining using the antibody against axons marker neurofilament. In 
consistency with the decreased number of retinal ganglion cells in the ventral retina, there are 
indeed a greatly decreased number of axons in the central ventral retina (Figure 5.29, I and L) 
compared to the wild-type controls (Figure 5.29, G and J). In wild-type mice, all the axons pass 
through the retina and enter the optic nerve head (Figure 5.29, I). Surprisingly, there are two 
bundles of axons in both sides near the central ventral retina, and almost all the axons in ventral 
retina do not enter the optic nerve head but go into both two bundles instead (Figure 5.29, I), which 
is not found in dorsal retina in mutants (Figure 5.29, H). In addition, there are several mislocalised 
axons found in the peripheral ventral retina and only a few found in the dorsal retina in mutants 
(Figure 5.29, K-L). These results suggest that axon guidance is severely affected in ventral retina 
in mutants. Furthermore, sectional immunostaining against neurofilament found that 
neurofilament is strongly expressed in the retinal nerve fiber layer, the optic nerve and horizontal 
cells in wild types at P11 and P21 (Figure 5.30, A-B and E-F). The strong axons bundles exist in 
the optic nerve of the wild-type mice at P11 and P21 (Figure 5.30, A and E). However, in mutants, 
the expression of neurofilament is both disrupted in the horizontal cells and is absent in some areas 
of the optic nerve at P11 and P21 (Figure 5.30, C-D and G-H). These results suggest that the axons 
of the optic nerve are defective and the horizontal cells are disrupted in the mutants at P11 and 
P21.  
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Figure 5.29 Loss of retinal ganglion cells and axon misguidance in gliosis retina in mutants. (A-F) Flat-
mount immunostaining against Brn3 showed that the number of retinal ganglion cells is greatly reduced and only 
a few retinal ganglion cells are found in the ventral retina in mutants (D-F) compared to wild types (A-C) at 3 
months. (G-L) In consistency with the loss of retinal ganglion cells, the number of retinal nerve fibers is also 
decreased in the center of the ventral retina, especially in the distal area in mutants (L, broken circle), but the 
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proximal retina exhibits two separate accumulation of axons to from the bundles (I, arrow) and nearly all the 
retinal axons project from peripheral to the two bundle, instead of the optic nerve head (I, broken circle). In 
addition, there are still a few mislocalised axons in the dorsal retina (K, arrow) in mutants although the global 
pattern is similar to wild types. Mislocalised axons are found in the distal ventral retina in mutants (L, arrow and 
arrowhead) (About L, to see the picture of ventral retina clearly in a global manner, L is composed of two pictures 
overlapped by manually). Scale bar: A, D, 300 µm; B-C, E-F, 50 µm; G-L: 300 µm. 
 
 
 
Figure 5.30 Axon defects of the optic nerve in Ali030 mutants. (A-B, E-F) Neurofilament is expressed in 
retinal axons in the nerve fiber layer and optic nerve and also expressed in the axons of the horizontal cells in 
the outer plexiform layer in wild types at P11 and P21. (C-D, G-H) The retinal ganglion cell axons are similar 
to wild types but seem thinner in mutants. However, disorganized axons are found in the optic nerve head at P11 
(C, arrow) and P21 (G, arrow). In addition, the axons of the retinal horizontal cells are also disorganized around 
the optic nerve head at P11 (C, arrowhead) and P21 (G, arrowhead). Scale bar: 50 µm. 
 
 
5.2.5 Retinal dysgenesis is associated with reactive gliosis in Ali030 mutants 
Another hallmark of ventral retinal gliosis in Ali030 mutants is retinal dysplasia. As we can see 
from the histology picture, retinal rosette and delamination are formed in Ali030 mutants (Figure 
5.25, D and F). The photoreceptor layer was thinner and a clump of inner nuclear layer abuts 
directly onto the retinal pigmental epithelium in mutants compared to wild types (Figure 5.23, B; 
Figure 5.25, D-E), which suggests that retina dysplasia occurs in the ventral gliosis retina in Ali030 
mutants. Then I further analyzed the dysplasia retina in greater details using different antibodies 
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to specific retinal cell markers. PDE6b is a marker for rod photoreceptor in retina (Pittler et al., 
2004; Mali et al., 2007). PDE6b immunostaining demonstrated a disruption and delamination in 
photoreceptor layers in the mutant ventral retina compared to wild types (Figure 5.31, A and E). 
Protein kinase C-alpha (PKC-α) is a specific marker for retinal bipolar cells (Greferath et al., 1990), 
through which visual information can be transmitted from photoreceptor to retinal ganglion cells. 
The lamination of retinal bipolar cells is disrupted in the ventral retinal gliosis region and some 
ectopic bipolar cells were found in the outer nuclear layer of the mutants (Figure 5.31, B and F). 
Otx2 can control the fate of photoreceptors and the specification of RPE cells, and it is expressed 
in the inner nuclear layer and RPEs in the retina (Beby and Lamonerie, 2013). Otx2 
immunostaining showed that the inner nuclear layer is disrupted and splits into two layers in retina 
(Figure 5.31, G) in mutants. The retinal pigmental epithelium is also disrupted and less RPE cells 
are in the ventral gliosis retina in Ali030 mutants compared to wild-type controls (Figure 5.31, C 
and G). Calretinin can be used to mark all amacrine cells and retinal ganglion cells (Haverkamp 
and Wässle, 2000). In wild types, calretinin is expressed in the retinal ganglion cells, amacrine 
cells and inner plexiform layer (Figure 5.31, D), whereas in mutants, missing retinal ganglion cells 
are found in the inner plexiform layer and the retinal ganglion cell layer is thinner or missing in 
the gliosis retina (Figure 5.31, H). The amacrine cells are located at the inner nuclear layer in the 
wild types (Figure 5.31, D), whereas in mutants the inner nuclear layer is totally disrupted in the 
ventral gliosis retina and interestingly there are some mislocalized amacrine cells in the inner 
plexiform layer (Figure 5.31, H). In contrast, the lamination and genesis of dorsal retina is not 
affected in mutants (data not shown). These results demonstrate that the retinal dysplasia occurs 
in the ventral gliosis retina of the mutants.  
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Figure 5.31 Retinal dysgenesis is found in the ventral gliosis region in Ali030 mutants at P21. (A-D) There 
is regular retinal lamination, and different types of retinal cells develop well in the wild-type retina. PDE6b is 
expressed in the photoreceptor layer (A); PKC-α is expressed in the bipolar cells (B); OTX2 is expressed in the 
inner nuclear layer and retinal pigmental epithelium (C); Calretinin is expressed in the ER lumen and is also a 
marker for immature neurons: it is expressed in the retinal ganglion cells, inner plexiform layer and inner nuclear 
layer (D). (E-F) The retina displayed delamination and rosettes of the photoreceptor in mutants. (E) The 
photoreceptor layer is discontinuous and some parts are thinner in mutants compared to wild types. (F) The 
bipolar cells are disrupted and their connections and axons are destroyed in mutants (arrow); a proliferative 
retinal gliosis region is above the axon terminals of the bipolar cells (circle), which is not found in wild types 
(B). (G) The inner nuclear layer is disrupted and it splits into two layers in retina (arrow) and there are remarkably 
decreased number of RPE cells compared to the wild-type controls (circles). (H) In the mutants, the number of 
retinal ganglion cells (arrowhead) is significantly reduced, the inner nuclear layer is disrupted and the connection 
of the inner nuclear layer is destroyed (arrow, below) in mutants. There is a retinal gliosis region with a number 
of ectopic calretinin-positive amacrine neurons (arrow, above). Scale bar: 50 µm. 
 
 
5.2.6 Regular ERG response in Ali030 aged mutants 
Electroretinogram (ERG) can be used to test the retinal function in mice as a screen method (Dalke 
et al., 2004). At 10 weeks, Ali030 homozygous mutants showed regular electrical response in retina 
compared to wild types by ERG (Figure 1.8, E, performed by Susanne Weber, HGMU). I further 
performed the ERG measurements in older mice (12 months) to investigate whether the ventral 
retina gliosis affects the retinal function in aged mutant mice. At 12 months, Ali030 mutants still 
showed regular electricity response to light flashes (500 and 12,500 cd/m2) (Figure 5.32). This data 
suggests that ventral retinal gliosis and local retinal dysplasia do not severely affect global retinal 
function. Further multi-focal ERG may be helpful to test and analyze local retinal functions. In 
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addition, due to the limitation of the small sample size (N=3 per group) used in this study, large 
samples could be needed to find the subtle changes.     
 
    
Figure 5.32 Regular global ERG responses in Ali030 mutants at 12 months. (A-B) At 12 months, Ali030 
mutants exhibit regular electrical response to the high light flashed (12,500 cd/m2) in retina revealed by ERG (B) 
compared to wild types (A). (C-D) At 12 months, Ali030 mutants exhibit regular electrical response to the low 
light flashed (500 cd/m2) revealed by ERG (D) compared to wild types (C). The number of mice was used in 
this study (WT: N = 3; Mt: N = 3). This figure here is one example of the three independent results. 
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5.2.7 Glial-like cells expressing Sox2, Pax2 and Nestin but not Pax6 are found in the ventral 
retinal gliosis and they are proliferating in Ali030 mutants 
Next, I analyzed the properties of these activated astrocytes in gliosis ventral retina. I chose four 
different stem cell/progenitor cell markers, Sox2, Pax2, Pax6 and Nestin. Sox2 (SRY (sex 
determining region Y)-box 2) is a transcription factor that is essential for stem cells pluripotency 
(Sarkar and Hochedlinger, 2013). Pax2 (Paired box gene 2) is a transcription factor which can 
control the fate choice of neuron and glia (Soukkarieh et al., 2007). Pax6 is a master control gene 
for eye development (Shaham et al., 2012) and it is essential for neuronal fate differentiation and 
determination in the retina (Philips et al., 2005) and also required for neurogenesis (Sansom et al., 
2009). I performed double immunofluorescence staining using two different antibodies on the 
retina and found that in wild-type retina some retinal ganglion cells express Sox2 (Figure 5.33, A 
and C), and GFAP-positive cells are only observed in the nerve fiber layer and retinal ganglion 
cell layer (Figure 5.33, A-B). However, in mutants there are a number of activated glial cells in all 
different retinal layers including inner plexiform layer and inner nuclear layer (Figure 5.33, E-F), 
and these activated glial cells express Sox2 (Figure 5.33, H, I-Q). Interestingly, in the vitreal side 
of the retinal glial region, as OCT demonstrated it is a thick epiretinal membrane (Fig. 5.23, A, red 
arrow; B, blue arrow), GFAP is also highly and densely expressed in the epiretinal membrane 
(Figure 5.33, F, I and L). In the epiretinal membrane, GFAP is overlapped with Sox2 which 
suggests that GFAP is not only expressed in the cytoplasm but also in the nuclei in this region. 
Interestingly, in the inner plexiform layer and inner nuclear layer, it appears that GFAP is mainly 
expressed in the cytoplasm and Sox2 is expressed in the nucleus of the same cells (Figure 5.33, H, 
I-K). Similar finding also occurs in the peripheral part of the ventral gliosis (Figure 5.33, L-N). 
These results suggest that the activated glial cells may undergo dynamic changes from inside to 
the outside of the retina. Nestin is not obviously expressed in the wild-type retina at P21 (Figure 
5.33, R-T), but Nestin can be detected in the ventral retinal gliosis region and it is co-expressed 
with GFAP in mutants (Figure 5.33, U-W), suggesting that activated glial cells also express Nestin. 
Pax2 is expressed in the retinal ganglion cell layer and some Pax2-positive cells also express Sox2 
in wild types (Figure 5.35, E-H), but Pax2 is highly expressed in the ventral retinal gliosis region 
of the mutants. It is localized in the nucleus and it co-expressed with Sox2 in the ventral retina 
gliosis region (E-H). Pax6 is expressed in the retinal ganglion cell layer and inner nuclear layer in 
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wild-type retina (Figure 5.35, I-J), whereas in mutants Pax6 is almost absent the ventral retina 
gliosis region (Figure 5.35, K-L). These data suggest that these ventral activated glial cells may 
have properties of retinal progenitor cells, especially which have the capacity to be driven to the 
glial cell fate. 
 
To further investigate whether these activated glial cells in the ventral retina are proliferating 
during the gliosis process, BrdU was injected intraperitoneally to label the proliferating cells at 
P21 and I found that the glial cells in the inner plexiform layer of the ventral gliosis retina are 
proliferating at P21 (Figure 5.33, A-F). The number of these BrdU-positive cells are obviously 
increased in mutants compared to wild types (Figure 5.34, A-F). Interestingly, these BrdU-positive 
cells also co-express with Sox2 but very few cells do not express Sox2 (Figure 5.34, J-O). 
Therefore, proliferative retinal gliosis occurs in the mutants. This proliferative ability could be due 
to the property of the progenitor cells.  
 
Interestingly, these GFAP/Sox2 positive cells in mutants display a remarkable heterogeneity in 
their morphology. Some GFAP/Sox2 positive cells have the star-like appearance (Figure 5.33, E-
N) and others have the morphology of bipolar cells (Figure 5.33, O-Q). Glutamate synthase (GS) 
is a marker for retinal Müller cells (the main type of glial cells in retina) which can be used to test 
whether activated glial cells are retinal Müller cells (Chen and Weber, 2002). Most of the activated 
glial cells do not express GS (5.36, H-S), suggesting that these cells are not retinal Müller cells, 
but astrocytes. Some cells in the inner plexiform layer are not retinal Müller cells because of their 
smaller size and different morphology although they co-express GS (Figure 5.36, H-K). The other 
activated glial cells in the outer plexiform layer which co-express GS, indicating that these cells 
are retinal Müller cells (Figure 5.36, P-S). Interestingly, up-regulation of GFAP expression can be 
found in some bipolar cells of the inner nuclear layer (Figure 5.33, O-Q). From the morphology 
and location and Sox2-positve expression, this type of the cells could be due to the changed fate 
of bipolar cells. In addition, Brn3 is normally expressed in the retinal ganglion cell layer and it 
does not co-express GFAP in wild types (Figure 5.37, A-C), whereas in mutants retinal ganglion 
cell layer was disrupted and ectopical Brn3-positve retinal ganglion cells were found in the inner 
plexiform layer (Figure 5.37, E). However, some Brn3-positive retinal ganglion cells in mutants 
showed up-regulation of GFAP (Figure 5.37, D-I), which indicates that these retinal neurons may 
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acquire the fate of glial cells. In addition, there are also some other astrocytes which are activated 
in the outer side of the photoreceptor layer which do not co-express with GS (Figure 5.36, P-S). 
These results showed that the activated glial cells are heterogeneous and at least three types of 
activated glial cells (retinal astrocytes, retinal Müller cells and the glial cells transdifferentiated 
from some retinal neurons) are involved in the ventral gliosis in mutants.  
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Figure 5.33 The activated glial cells in ventral retina express stem cell markers Sox2 and Nestin, and the 
heterogeneity of activated glial cells in Ali030 mutants at P21. (A-C) In wild types, Sox2 is expressed in the 
retinal ganglion cell layer and inner nuclear layer (A and C) and GFAP is only expressed in the nerve fiber layer 
and retinal ganglion cell layer (A and B). (E-H) However, in the gliosis ventral retina there are an increased 
number of activated glial cells in all different retinal layers (E and F) and Sox2 is abundantly expressed in the 
cell nuclei of the ventral gliosis retina (E and G). Moreover, Sox2 is expressed in the activated glial cells in the 
ventral gliosis retina. Interestingly, GFAP is overlapped with Sox2 in the vitreal side of the central part of the 
mutant retina (K, yellow), whereas in the inner nuclear layer and inner plexiform layer of the central retina (I-
K) and the peripheral gliosis region (L-N), GFAP is mainly expressed in the cytoplasm and Sox2 is expressed 
in the nucleus of the same cells (I-Q). In addition, GFAP can be found in the cytoplasm of the bipolar cells (with 
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bipolar structure) from the inner nuclear layer (O-Q, the right most cells). From the morphology, activated glial 
cells displayed different types of cell patterns, some with star structure and some with single process and some 
with bipolar appearance (K, N and Q). (R-W) In wild types, Nestin is not expressed in the retina (R-T), whereas 
in mutants Nestin is expressed and it can co-express with activated glial cells (U-W), which is a marker of stem 
cells. Scale bar: A-N, R-T, 100 µm; O-Q, U-W, 50 µm. 
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Figure 5.34 Proliferative ventral retinal gliosis in Ali030 mutant mice at P21. (A-F) In wild types, there are 
very few BrdU-positive cells in the retina (A-C, G). Compared to wild types, there are remarkably increased 
BrdU-positive cells in the ventral retinal gliosis region (D-F). (G-O) In wild types, very few BrdU-positive cells 
do not express Sox2. Interestingly, most of these BrdU-positive cells also express Sox2 in mutants (J-L, M-O). 
(P-U) For the negative controls, there is absent staining in the sections labeled with BrdU from wild types and 
mutants. The number of the samples was used in this study (WT: N=3; Mt: N=3). Scale bar: 100 µm.  
 
 
114 
 
 
 
 
Figure 5.35 Increased numbers of activated glia cells co-expressing Pax2 and Sox2, but not pax6 in the 
ventral gliosis retina in Ali030 mutants at 3 months. (A-D) In wild types, Pax2 is mainly expressed in the 
retinal ganglion cell layer and weakly expressed in inner nuclear layer, and there are a few Sox2-positive retinal 
ganglion cells highly-expressing Pax2 in the RGC layer. (I-J) Pax6 is normally expressed in the retinal ganglion 
cell layer and inner nuclear layer and some cells can be co-expressed with Sox2 in the outer region of inner 
nuclear layer in wild types. (E-H) However, in mutants, there are an increased number of cells expressing Pax2 
in the inner plexiform layer, ganglion cell layer and epiretinal membrane. In the epiretinal membrane there are a 
number of cells co-expressing Pax2 and Sox2, especially in the most inner layer of the epiretinal membrane, 
nearly all the cells co-express Pax2 and Sox2. (K-L) There are some disruption in the inner nuclear revealed by 
Pax6 immunostaining in mutants. Some Pax6-positive retinal ganglion cells are missing and form a 
discontinuous and disrupted RGC layer and all the cells in the epiretinal membrane don’t express Pax6 in mutants. 
Scale bar: 50 µm. 
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Figure 5.36 Mixed types of activated glial cells in the ventral gliosis retina in Ali030 mutants. (A-C) 
Glutamate synthase (GS), a marker for retinal Müller cells, is expressed in the nerve fiber and retinal ganglion 
cell layer. (D-G) In mutants, some activated glial cells do not co-express GS in the inner plexiform layer 
indicating that they are activated astrocytes although retinal Müller cells are activated and they can express Sox2 
in the nuclear layer. (H-K) But there are still some activated glial cells co-express GS in the inner plexiform 
layer, but they do not seem to be retinal Müller cells because of the smaller size and different morphology of 
these cells. (L-S) Double immunostaining of GS and GFAP was used to test whether activated glial cells are 
retinal Müller cells in ventral gliosis retina in mutants. In the inner plexiform layer and epiretinal membrane the 
main cells are activated astrocytes (Q-S, red arrowheads) and also some retinal Müller cells are activated in the 
outer plexiform layer due to up-regulated expression of GFAP (Q-S, arrow). There are still a few activated glial 
cells, which do not express GS (Q-S, white arrowheads). Scale bar: A-K, 20 µm; L-S, 50 µm. 
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Figure 5.37 Retinal ganglion cells could acquire the fate of glial cells in Ali030 mutants at P21. (A-C) In 
wild types, Brn3 is expressed in the retinal ganglion cell layer and GFAP is expressed in the nerve fiber layer 
and retinal ganglion cell layer; (D-E) In the central part of the ventral retinal gliosis in mutants, only a few Brn3-
positive cells are detected in the retinal ganglion cell layer (E, red arrow) but there are a number of activated 
astrocytes in the retinal ganglion cell layer (E, white arrow) and inner plexiform layer instead. There are some 
ectopical Brn3-positive retinal ganglion cells in the inner plexiform layer (E, white arrowhead). (G-I) In the 
peripheral region of the ventral retinal gliosis in mutants, there are still some Brn3-positive retinal ganglion cells 
and some of them showed up-regulation of GFAP (G-I, white arrowhead). In the negative controls, fluorescence 
was absent on the retina. Scale bar: 100 µm. 
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5.2.8 Mis-splicing of Bmpr1b may not play a role in the activation of retinal Müller cells in 
vitro 
MIO-MI cells, a retinal Müller cell line derived from postmortem adult human neural retina, 
retains the characteristics of primary retinal Müller cells in culture (Limb et al., 2002) and 
exhibited the characteristics of neural stem cells (Lawrence et al., 2007). In the mouse study, I 
found that only a few retinal Müller cells are activated in the ventral retina. Therefore, I further 
investigated whether Bmpr1b plays a direct role in the activation of retinal Müller cells using this 
cell line in vitro. Without any treatments, very few MIO-MI cells express GFAP (Figure 5.38, A), 
which is consistent with another study showing that occasional MIO-MI cells express GFAP (Limb 
et al., 2002). Interestingly, I found that the MIO-MI cells exhibited strongly enhanced expression 
of GFAP under the stimulation of GDF-5 (100 ng/ml and 500 ng/ml) (5.38, B-C) and BMP-2 (500 
ng/ml) (5.38, D) for 4 days. These indicate that GDF-5 and BMP2 may promote the activation of 
retinal Müller cells. After overexpression of Bmpr1b cDNA (wildtype and mutant, respectively), a 
few MIO-MI cells showed up-regulated expression of GFAP (5.38, E-F). However, these 
transfected MIO-MI cells were treated with BMP-2 for 4 days, there is still strongly up-regulated 
expression of GFAP in the cells, but there is no obvious difference between Bmpr1b wild-type 
cells and mutant cells (5.38, G-H). This data suggests that BMP-2 can activate retinal Müller cell 
line but may not signal through Bmpr1b. In contrast, a treatment of the transfected cells with GDF-
5 (500 ng/ml; 1500 ng/ml) for 4 days, fewer cells express GFAP compared to BMP-2 treatment 
group, and no obvious differences in GFAP expression were found between those cells 
overexpressing Bmpr1b wild-type cDNA and the cells overexpressing mutant cDNA (5.38, I-L). 
From my mouse study, only a few of activated retinal Müller cells were detected compared to a 
high number of activated astrocytes in ventral retina in Bmpr1b-mutant mice. Together, I found 
that two proteins, GDF-5 and BMP-2, induces the activation of MIO-MI cells, and BMP-2 
functions independently of Bmpr1b. Overexpression of Bmpr1b may play a role in the inhibition 
of MIO-MI cells activation, and it seems that the mis-splicing of Bmpr1b does not affect this 
process. 
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Figure 5.38 Mis-splicing of Bmpr1b may not play a role in the activation of retinal Müller cells in vitro. (A-
D) (A) Occasional MIO-MI cells express GFAP without any treatments. (B-D) Up-regulated expression of GFAP 
was found in MIO-MI cells when they are treated by GDF-5 (100 ng/ml and 500 ng/ml) and BMP-2 (500 ng/ml) 
for 96 hours, suggesting that GDF-5 and BMP-2 may promote MIO-MI cells to become activated glial cells. (E-
F) There are a few cells expressing GFAP when transfected with Bmpr1b wild-type and mutant cDNA, 
respectively. (G-L) The cells transfected with Bmpr1b wild-type (G, I, K) and mutant cDNA (H, J, L) were 
treated with BMP-2 (500 ng/ml, G, H) or GDF-5 (500 ng/ml, I, J; 1500 ng/ml, K, L). GFAP is still strongly up-
regulated in those transfected cells with BMP-2 (G-H), whereas a few cells treated with GDF-5 showed up-
regulated expression of GFAP (I-L). Scale bar: 50 µm.  
 
 
5.2.9 A delayed retinal development, ectopic expression of Pax2 and congenital ventral retina 
gliosis in Ali030 mutants during eye development 
As retinal gliosis was found in early postnatal retinal development, the question is that when and 
how the retinal gliosis happened in mutants. Therefore, I firstly performed ocular histology to see 
whether there are retinal phenotypes in mutants during embryonic stages. At E10.5, it appears that 
no obvious difference between mutants and the wild-type controls regarding the eye pattern was 
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found, but it seems that eye size is bigger in wild types compared to mutants (Figure 5.39). 
Interestingly, I found that optic fissure fails to close in some mutants (3/10 eyes), but not in all the 
cases at E17.5 (Figure 5.39). However, the optic fissures are closed at P5, P11, P21 and adult. 
These results indicate that this is the delayed closure of the optic fissure. Therefore, ventral retina 
development may be delayed in Ali030 mutants compared to the wild-type controls.  
 
 
Figure 5.39 Delayed closure of optic fissure at E17.5 in Ali030 
mutants. At E10.5, a clear eye-forming region was formed in the wild 
types, but in mutants it appears that this eye-forming region is not 
affected. At E17.5, the optic fissure in the ventral retina is completely 
closed in wild types, whereas there is a failure in closing the optic 
fissure in some mutants (3/10 eyes) (arrow).  
 
 
 
 
In consistency with this finding, the expression of Pax2, a transcription factor essential for optic 
nerve head development and the closure of optic fissure, is also changed in Ali030 mutants. Pax2 
is expressed in the optic stalk and ventral retina in early retinal development and then reduced to 
be limited to a junction between optic nerve and retina during late retinal development (Figure 
5.40, A-F). The expression pattern of Pax2 is dynamically changed in mutants in embryonic retinal 
development (Figure 5.40, G-L). At E10.5, Pax2 is expressed in the ventral retina and optic stalk 
in wild types, and the expression of Pax2 is not affected in mutants compared to wild types (Figure 
5.40, A-B, G-H). At E15.5, Pax2 is over-expressed in the ventral retina and the expression of the 
optic nerve head including dorsal junction is reduced in mutants, whereas it is only expressed in 
the retina-optic nerve junction in wild types (Figure 5.40, C-D, I-J). In addition, Brn3 
immunostaining showed that the neurogenesis of retinal ganglion cells is decreased (Figure 5.41, 
A-C) in mutants at E15.5. Anterograde tracing showed that there are no obvious differences in the 
crossing and fasciculation of the optic nerve and optic chiasm between wild types, heterozygous 
and homozygous mutants (5.41, D-F). However, the optic nerve tends to be thinner in mutants () 
compared to the wild-type controls () at E15.5 (p=0.0524) (Figure 5.41, D-F). At E17.5, the 
expression of Pax2 is still reduced in retinal-optic nerve junction but ectopically expressed in 
retinal pigment epithelium at the dorsal retina, whereas Pax2 begin to disappear compared to E15.5, 
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but still up-regulated expression in mutants compared to wild types in the ventral retina (Figure 
5.40, E-F, K-L). These results demonstrated that loss of function of Bmpr1b affects the closure of 
optic fissure and expression of Pax2 during embryonic retinal development.  
 
At E17.5, GFAP is strongly expressed in the optic nerve (Figure 5.42, A-B) and weakly expressed 
in the nerve fiber layer and inner plexiform layer (Figure 5.42, E-F) in wild types, whereas in 
mutants, the retinal folding are formed and GFAP is strongly expressed in different retinal layers 
in the retinal folding area (Figure 5.42, G-H). In the optic nerve, retinal folds are also found and 
interestingly GFAP is ectopically expressed in the RPE layer in mutants (Figure 5.33, C-D) 
compared to wild types (Figure 5.33, A-B), suggesting that the glial cells is ectopically activated 
in the optic nerve head during development. These results demonstrated that ventral retinal gliosis 
and ectopical glial cells in the optic nerve head are congenital in Ali030 mutants. 
 
 
Figure 5.40 Ectopic expression of Pax2 during eye development in Ali030 mutants. (A-F) At E10.5, Pax2 is 
mainly expressed in the ventral retina and in the optic stalk in wild-type embryos (A, B). At later stages, such as 
E15.5 and E17.5, Pax2 is limited to be expressed in optic nerve-retina junction and some cells in the optic nerve 
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head (C, D, E, F). (G-L) In mutants, at E10.5, Pax2 is mainly expressed at ventral retina, which seems similar 
expression to the wild-type controls (G, H). However, Pax2 is ectopically up-regulated expression in ventral 
retina and decreased expression in the dorsal junction between optic nerve and retina in mutants at E15.5 (I, J). 
At E17.5, Pax2 is also ectopically up-regulated expression in ventral retina but begin to disappear compared to 
E15.5 in mutants, and in the dorsal retina Pax2 is decreased to be expressed in RPE layer like a line structure 
mutants. Scale bar: 50 µm.   
 
 
 
 
 
Figure 5.41 Decreased neurogenesis of retinal ganglion cells and thinner optic nerve in Ali030 mutant at 
E15.5. (A-C) In wild-type retina, there is a number of retinal ganglion cells and very few cells express Pax2 (A), 
whereas in mutant retina there is still a number of cells expressing Pax2 in ventral retina and the retinal ganglion 
cells production is decreased in ventral retina during retinal neurogenesis at E15.5 (B, C). (D-F) Decreased 
number of retinal ganglion cells leads to decreased optic nerve thickness at E15.5. Anterograde tracing 
demonstrated normal crossing and fasciculation of the optic nerve and optic chiasm between wild types, 
heterozygous and homozygous mutants, but there is a trend that the optic nerve is thinner in homozygous mutants 
than that in the wild-type controls (p=0.0524), which is due to decreased number of retinal ganglion cells during 
retinal neurogenesis at E15.5 (D, F). OC: optic chiasm; ON: optic nerve; OT: optic tract. Scale bar: A-C, 20 µm; 
D-F, 100 µm. 
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Figure 5.42 Congenital ventral retinal gliosis and ectopic expression of GFAP in the optic nerve head of 
the Ali030 mutants at E17.5. (A-D) Strong GFAP is expressed in the optic nerve at E17.5 in wild types (A-B), 
whereas in mutants the GFAP is ectopically expressed in the RPE layer except the optic nerve (C-D). (E-H) 
GFAP is weakly expressed in the nerve fiber layer and inner plexiform layer of the wild-type retina at E17.5, 
whereas it strongly ectopically expressed in the retinal folding area in ventral retina (G-H). Scale bar: 50 µm. 
 
 
5.2.10 Glial-like cells expressing Sox2, Pax2 and Nestin are found in the epiretinal 
membranes and in the inner limiting membranes in patients with retinal gliosis 
In the mouse study, I found that the progenitor cell markers Sox2 and Nestin are co-expressed in 
the activated glial cells of the ventral gliosis retina in mutants. In another study, in the injury-
induced mouse brain gliosis, the astrocytes are activated and can be proliferative, which have the 
multiple-potent properties for self-renewal in vitro (Buffo et al., 2008). Then I put forward a 
hypothesis that these glial cells in retinal gliosis may have stem cell properties in order to maintain 
self-renewal and produce more glial cells. Therefore, I extend our mouse study to the analysis of 
clinical retinal gliosis samples to see whether similar cells expressing stem cell markers can be 
found. Firstly, I tested whether Sox2 and Nestin are also expressed in the glial cells in the epiretinal 
membrane (ERM) and inner limiting membrane (ILM) in the two different types of retinal gliosis 
samples, one is idiopathic retinal gliosis without other disease causes, and the other one is the 
retinal gliosis caused by specific reasons, such as diabetes, proliferative vitreous-retina diseases 
(PVR) and uveitis (an inflammation of uveal tract in the eye). Here, I referred to the latter with 
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specific reasons as secondary retinal gliosis. All the clinical samples were kindly provided by Dr. 
Petrovski and Dr. Lumi (Ljubljana, Slovenia). In general, the cell density in ERMs is much higher 
than those in ILMs, and correspondingly GFAP is highly expressed in ERMs (Figure 5.43; Figure 
5.44; Figure 5.45), suggesting that these cells are activated glial cells. GFAP is also highly 
expressed in some cells or even more from ILMs, but in a limited number (Figure 5.44; Figure 
5.47). Interestingly, the activated glial cells with long processes are both found in ILMs and ERMs 
and they seem to form a local network by their processes, and some cells form a multi-branch 
structure or form an aggregate in ERMs or ILMs (Figure 5.43-5.47). The glial cells expressing 
stem cell markers Sox2 and Nestin were found in all clinical samples (14 ERMs and 15 ILMs) 
(Figure 5.43-5.47). These cells in ERMs and ILMs also express Pax2 (Figure 5.48). These results 
suggest that activated glial cells are the dominant cells in ERMs and some cells or even more in 
ILMs seem to be GFAP-positive glial cells. Furthermore, some of these activated glial cells are 
not pure glial cells but glial-like cells due to the co-expression of progenitor cell markers Sox2, 
Pax2 and Nestin. These glial-like cells may have the properties of stem cells and they can keep 
them self-renewal and differentiate into more glial cells in the retina. Whether these glial-like cells 
initiate and produce a number of activated glial cells in ERMs remains to be investigated.  
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Figure 5.43 The glial-like cells in the epiretinal membranes from patients with idiopathic retinal gliosis. 
(A-C) There are a number of activated glial cells with long axons from cell bodies and they seem to form a local 
network in the epiretinal membranes from patients with idiopathic retinal gliosis. (C-F) These activated glial 
cells co-express stem cell markers Sox2 and Nestin (arrow and arrowhead). In these cells, there are some axons 
co-express Sox2, but not nestin and some processes only express nestin, but not sox2 and GFAP. Scale bar: 20 
µm. 
 
 
 
125 
 
 
Figure 5.44 The glial-like cells in the inner limiting membrane from patients with idiopathic retinal gliosis. 
In most cases, there are much less cells in the inner limiting membrane compared to the epiretinal membrane 
and correspondingly there are much fewer glial cells in the ILMs. These glial cells have long axons and exhibit 
muti-branch structure. It appears that these cells interact with each other by their processes. These glial cells also 
co-express stem cell markers Sox2 and Nestin. In very few cases, the ILM have the cells as many as ERMs, and 
these cells exhibit strong expression of GFAP, especially the area near macula. Scale bar: 50 µm. 
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Figure 5.45 The glial-like cells in the epiretinal membranes from patients with secondary retinal gliosis. 
(A-C) There are a number of cells in the epiretinal membranes and GFAP is highly expressed in these cells. 
These activated glial cells also have long processes. (D-G) These activated glial cells also co-express Sox2 and 
Nestin (E-G). Scale bar: A-C, 50 µm; D-G, 20 µm. 
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Figure 5.46 The glial-like cells in the epiretinal membrane from a patient with VMT. (A-E) There are a 
number of activated glial cells in the epiretinal membranes (B), in which a few cells co-express with stem cell 
markers Sox2 and Nestin (B-E, arrow) and most cells are the activated glial cells which do not express Sox2 and 
Nestin (B-E). Scale bar: 20 µm. 
 
 
Figure 5.47 The glial-like cells in the inner limiting membrane from a patient with VMT. (A-F) There are 
a few activated glial cells on the ILMs and the cells have long processes which co-express with stem cell markers 
Sox2 and Nestin. Scale bar: 20 µm. 
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Figure 5.48 The glial-like cells co-express Pax2 and Sox2 in ERMs and ILMs. (A-C) In ERMs, there are a 
number of Pax2-positive cells and some of them co-express with Sox2. (D-F) There are fewer cells in ILMs than 
in ERMs, and they also express Pax2 and Sox2. Scale bar: 50 µm. 
 
 
Figure 5.49 Negative control of the epiretinal and inner limiting membrane. (A-H) Staining for these ERMs 
and ILMs using secondary antibodies (anti-rabbit, anti-goat, anti-mouse) without primary antibody. The cells in 
ERMs and ILMs are not stained with secondary antibodies. Scale bar: 50 µm. 
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6 Discussion 
6.1 Peroxidasin is essential for eye development 
The purpose of this study was to characterize the first rodent model suffering from a mutation 
within the peroxidasin gene. The main findings in this study is that the mutation within peroxidasin 
results in abnormal proliferation and differentiation of the lens, leading to anterior segment 
dysgenesis and microphthalmia, and this process could be mediated by up-regulation of Pax6 and 
Tgf-β1, two conserved and key genes for eye development. In addition, peroxidasin is involved in 
the consolidation of basement membrane (lens capsule) in the eyes and the deficiency in 
peroxidasin causes a rupture in the lens capsule together with lens epithelium, resulting in 
abnormal lens fibers extruding into the anterior and posterior chamber from the lens, which is 
another factor affecting anterior segment development and inflammation. Moreover, the mutant 
eyes at E15.5 and in the early postnatal period showed a condition of inflammation. Based on the 
data obtained from this study, we propose a series of events initiated by deficiency of peroxidasin. 
 
In KTA48 mutants (ENU-induced peroxidasin mutant mice), a nonsense mutation in the peroxidase 
domain within peroxidasin was identified, and it is predicted to form a premature stop codon within 
the peroxidase domain causing a loss of function including peroxidase enzyme activity. The 
microarray data showed that the expression of peroxidasin is reduced in mutant eyes (2.21 times) 
compared to the wild-type eyes at E12.5 (From Dr. Marion Horsch, Institute of Experimental 
Genetics, Helmholtz Center Munich). Moreover, western blot showed that peroxidasin is not 
expressed in E15.5 mutant eyes compared to wild types. These results suggest that loss of function 
of peroxidasin occurs in KTA48 mutants. Our mutant mice display an autosomal recessive pattern 
of inheritance with complete penetrance, which is also in accordance to the condition in human 
patients with ASD (Reis and Semina, 2011). Compared to the manifestation in the patients with 
peroxidasin mutations presenting congenital cataract, corneal opacity and developmental 
glaucoma (Khan et al., 2011), our peroxidasin-deficient mice exhibit very similar but more severe 
eye defects, including severe anterior segment dysgenesis and microphthalmia (particularly Peters’ 
anomaly mainly due to corneal-lens adhesion and corneal opacity) and some mutant mice present 
retinal dysplasia including retinal rosette-like structures.  
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During embryonic eye development, the mutant mice exhibit obvious eye phenotypes, suggesting 
that peroxidasin plays an important role in eye development. Especially at E15.5, histology showed 
smaller eyes, corneal epithelial dysplasia, disorganized keratocytes and corneal stroma, smaller 
lenses with ruptures in the lens epithelium and in the capsule, disorganized lens fibers and abundant 
retrolental cells in the vitreous and anterior chamber angle in mutants; in some cases (nearly 50%) 
of the mutant embryos, persistent corneal-lens adhesion was found. These observations on 
pathological morphology provide a general pathogenesis process by which mutations in 
perxodasin leads to delayed and abnormal eye development.  
 
Interestingly, the ocular abnormalities of the mutant mice are little variable both within and 
between eyes, and most mutants exhibit broad corneal opacity with corneal-lens adhesion while a 
few mutants present central corneal opacity with or without congenital corneal-lens adhesion and 
even the severity of the lens ruptures. This is in accordance to the studies showing that specific 
gene mutations in human patients cause a range of anterior segment dysgenesis phenotypes 
including Peters anomaly, Axenfeld-Rieger anomaly and iriogoniodysgenesis (Gould and John, 
2002). Also, in Khan’s study the patients with the mutation in PXDN showed a different pattern of 
corneal opacity, including broad and central opacity (Khan et al., 2011). I detected the eye 
morphology of the mutant mice based on C3H and C57BL/6 background by histology and found 
that there is no obvious difference in these mice with different genetic background. These indicated 
that the variability of eye phenotypes may be dependent on the complexity in the function of 
peroxidasin during eye development as well as the complex molecular process of the anterior 
segment development but not on the genetic background. Moreover, the corneal phenotypes in 
KTA48 mutants are similar to the histological findings from the cornea with Peters anomaly, 
including disrupted endothelial, immature cells with a fibroblastic configuration, higher cell 
density and abnormal extracellular matrix in the central cornea (Ohkawa et al., 2003).  
 
Peroxidasin does not strongly affect early eye development, because peroxidasin-mutants do not 
exhibit gross morphological changes at E9.5-E12.5. At E13.5, the lens vesicle is filled by the lens 
fibers and the expression of γ-crystallin is not changed, suggesting that the primary lens 
differentiation is not affected at this stage. However, more retrolental cells in the vitreous were 
found in the mutant eyes, suggesting it may be involved in the aberrant development of the ocular 
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hyaloid vascular system during the early eye development. Later at E15.5, the anterior segment 
dysgenesis and smaller eye size are obvious and similar to the adult in mutants. The ocular 
mesenchymal cells in the anterior chamber angle form abnormal aggregate population. Anterior 
segment development depends on the interaction between mesenchymal cells and other eye tissues; 
abnormal development of mesenchymal cells could cause a failure of proper interaction resulting 
in anterior segment dysgenesis (Cvekl et al., 2004).  
 
Considering smaller eye and lens size and abnormal anterior segment development in peroxidasin-
mutant eyes during embryonic stages, I propose that the mutant eyes underwent abnormal 
proliferation and differentiation. In-vivo BrdU labeling demonstrated a decreased number of 
proliferating cells in the lens epithelium compared to the wild types at E14.5, E15.5 and E17.5. 
Correspondingly, Foxe3, a molecule which is necessary for lens cell proliferation (Medina-
Martinez and Jamrich, 2007; Tholozan et al., 2007), is expressed at a lower level in the lens 
epithelium in the mutant eyes during eye development at E15.5, E17.5 and P11; it is also 
ectopically expressed in the posterior chamber and vitreous at P11. In addition, caspase-3 positive 
cells was not detected in the mutant embryonic eyes. Therefore, I conclude that smaller eye size is 
not mediated by apoptosis, but by a decreased cell proliferation during development. On the other 
hand, I further propose that the anterior epithelial cells failed to differentiate into secondary fiber 
cells so that the lens cannot grow to the normal size. The primary fiber cells, which are 
differentiated from posterior lens epithelial cells and elongate to fill the lens vesicle, do not seem 
to be affected during early eye development before E14.5. But subsequently, the secondary fiber 
cells which are differentiated from the lens epithelial cells in the lens equator are greatly affected 
after E14.5. In the mutants, less secondary fiber cells with their dramatic changes in cell shape are 
present. The lens epithelial cells in the equator are thinner in the mutants compared to the wild-
type controls. Prox1, a molecule necessary for lens differentiation (Wigle et al., 1999; Cui et al., 
2004), is ectopically expressed in the vitreous, posterior lens and central lens; its expression is 
decreased in the lens epithelium at P11. Together, these results demonstrate that peroxidasin is 
required for regulation of cell proliferation and differentiation in the lens during development.  
 
Mutations in most genes coding for transcription factors can lead to anterior segment dysgenesis, 
such as PAX6, FOXC1, PITX2, PITX3, Foxe3, Ap2α (Reis and Semina, 2011). My study 
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demonstrated that a type of secreted molecule combing extracellular matrix motifs and 
extracellular peroxidase which is different from transcription factors, is also necessary for anterior 
segment development. Considering several different domains in peroxidasin, I proposed that 
peroxidasin may play different roles during eye development. In one aspect, I detected the 
expression of different conserved genes including transcription factors for eye development and 
found that Pax6 and Tgf-β1 undergo dynamic expression changes during eye development in 
peroxidasin-mutant eyes, which is slightly up-regulated at E12.5 but strongly up-regulated at 
E15.5 (p<0.05), the stage when most obvious phenotypes occur. However, the expression of Pax6 
and Tgf-β1 in mutant eyes recovers to the normal level at P10. These results indicates that 
peroxidasin may regulate eye development through the regulation of Pax6 and Tgf-β1expression. 
Overexpression of Pax6 in the mouse eye can also affect the normal development of anterior 
segment, resulting in corneal opacity (Schedl et al., 1996; Dorà et al., 2008; Davis and Piatigorsky, 
2011), iris hypoplasia (Schedl et al., 1996), abnormal lens fiber cell differentiation (Dorà et al., 
2008), microphthalmia (Schedl et al., 1996; Manuel et al., 2008) and retinal dysplasia (Manuel et 
al., 2008). Also, transgenic Pax6 mice also exhibit a variable phenotype ranging from almost 
normal eyes to severely microphthalmia (Schedl et al., 1996). These eye malformations are similar 
to the eye phenotypes in our mutants. The expression of Tgf-β1 is up-regulated in mutant 
embryonic eyes, suggesting that Bmp signaling is affected by the deficiency in peroxidasin. A 
study also showed that overexpression of Tgf-β1 causes anterior subcapsular cataract and corneal 
opacity (Srinivasan et al., 1998), and microphthalmia and anterior segment dysgenesis (Flügel-
Koch et al., 2002), which are also similar to the eye phenotypes of the KTA48 mutants. The detailed 
mechanisms by which peroxidasin regulates the expression of Pax6 and Tgf-β1 are still unclear. I 
propose that peroxidasin may affect Pax6 and Tgf-β1 expression through membrane receptors. 
Thus it could alter downstream signaling and dysregulates the expression of Pax6 and Tgf-β1.  
  
Consistent with an important role of peroxidasin in the formation and consolidation of the 
extracellular matrix in Drosophila and C. elegans (Nelson et al., 1994; Gotenstein et al., 2010), I 
observed that there are dramatic changes in basement membrane in peroxidasin-mutant embryonic 
eyes. Firstly, ruptures of the lens capsule and lens epithelium adhesion occur, and thinner lens 
capsule was found in embryonic and postnatal eyes of the mutants at E15.5. Secondly, the inner 
limiting membrane is also disrupted in mutants at E17.5. These also suggest the basement 
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membrane is aberrant and the amount of ECM is reduced by the deficiency of peroxidasin. In our 
study, peroxidasin is also detected in vitreous nucleated cells and can be secreted into the vitreous 
during embryonic eye development. On the basis of our basement membrane findings and the 
changes in the anterior segment, I propose that peroxidasin-expressing nucleated cells migrates 
into the vitreous and anterior chamber angle, and then peroxidasin is secreted to be involved in the 
lens capsule and anterior chamber angle to consolidate the extracellular matrix in the eyes, 
respectively. Moreover, lens epithelial cells also express peroxidasin, which can also contribute to 
the lens epithelium adhesion and could be involved in the consolidation of the lens capsule. 
Collagen IV, the main component of basement membrane, is mainly expressed in the lens capsule 
(Kelley et al., 2002) and highly expressed in the inner limiting membrane (Sarthy, 1993; Bradshaw 
et al., 1995; Halfter et al., 2005) during eye development. A recent study demonstrated that 
peroxidasin crosslinks with Collagen IV in the basement membrane (Bhave et al., 2012). Thus, 
peroxidasin may consolidate the basement membrane of the lens and retina by crossing with 
Collagen IV during eye development, and a loss of function of peroxidasin may probably fail to 
crosslink collagen IV and thereby destabilize the ocular basement membrane and lens epithelial 
cell adhesion, resulting in ruptures of the lens capsule and inner limiting membrane and disruptions 
in the adhesion between the lens epithelial cells. Taken together, these observations confirmed that 
peroxidasin is involved in ECM consolidation in a higher organism and also showed that 
peroxidasin is essential for basement membrane and cell adhesion during embryonic eye 
development.  
 
In addition, primary lens fiber cells need to grow and elongate; in the mutants, they migrate out of 
the lens into the anterior chamber and vitreous cavity through the rupture of lens capsule and the 
lens epithelium. The lens fibers in the anterior chamber can worsen the development of the anterior 
segment, and lens matrix in the anterior chamber including corneal-iris angle could severely affect 
the contribution of the mesenchymal cells to differentiate into the different cells types during 
anterior segment development. Moreover, the lens crystallin in the anterior chamber can induce 
ocular inflammation and glaucoma (Chang et al., 1989; Xiao et al., 1992; Sowka et al., 2004). 
During the embryonic stage (E15.5) and the early postnatal period before eye opening (P11), some 
key cytokines for promoting inflammation such as IL-1β and TNF-α are also up-regulated 
suggesting that congenital ocular inflammation occurs. There are two possible factors contributing 
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to the ocular inflammation, one is a reduced peroxidase activity which can produce more active 
oxygen species. The other one is lens crystallin in the anterior chamber.  
 
Many risk factors for glaucoma were found in KTA48 mutants including smaller eyes, and iris-
corneal adhesion, lens-corneal adhesion and lens crystallin in the anterior chamber. Therefore, 
KTA48 mutants could have glaucoma although it is very difficult to measure ocular pressure in 
these mice due to nearly closed eye lids. The hallmark of glaucoma is the damage of optic nerve 
head and retina including loss of retinal ganglion cells and their axons (Quigley, 2011). I examined 
the retina and optic nerve head during early postnatal periods and adult by immunostaining. I found 
that the expression of Brn3 in the retinal ganglion cell layer at 3-week is significantly decreased 
in the retina, suggesting that RGCs are damaged. Moreover, the nerve fibers, consisting of retinal 
ganglion cell axons, are much thinner in the retina and optic nerve head in mutants than in normal 
controls, suggesting that the retinal ganglion cells are degenerative and the axons are damaged in 
mutants. Together, these indicate that glaucoma occurs in the KTA48 mice in early periods after 
births and it could be congenital glaucoma due to congenital anterior segment dysgenesis. 
Compared to retinal changes at 3 weeks, in adult mutant mice loss of retinal ganglion cells, thinner 
inner and outer nuclear layers were found, suggesting that progressive retinal degeneration occurs. 
Taken together, these indicate that congenital glaucoma occurs in the early postnatal period and 
develops progressively. Therefore, peroxidasin could play a role in the onset of congenital 
glaucoma. Our study also provides possible reasons and mechanisms for the developmental 
glaucoma found in the patients with PXDN (Khan et al., 2011). 
 
A missense mutation in the peroxidase domain of PXN causes abnormal axon guidance in 
C.elegans, specifically left-right guidance of commissural guidance (Gotenstein et al., 2010). Axon 
guidance also plays an important role during visual system development (Petros, et al., 2008; 
Haupt C et al., 2008). However, there are no obvious differences in the morphology of the optic 
nerve, optic tract and optic chiasm when the optic chiasm is mature at E15.5. This indicates that 
peroxidasin may not play a general role in axon guidance but a specific function in C.elegans.   
 
In summary, our ENU-induced peroxidasin mutant mice mimic most features of patients with 
corneal opacity, congenital cataract and developmental glaucoma due to PXDN mutations. Our 
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study suggests that peroxidasin is essential for eye development including proliferation and 
differentiation, which is most probably mediated by regulation of Pax6 and Tgf-β1. In addition, 
peroxidasin is also essential for basement membrane integrity and cell adhesion during lens and 
retinal development. Our studies provide insights for the eye defects found in the patients with 
PXDN mutations and we propose a series of events initiated by the deficiency of peroxidasin, 
which may not only help to understand the role of peroxidasin in eye development, but also aid in 
the development of novel strategies to treat congenital anterior segment dysgenesis including 
corneal opacity, cataract and glaucoma. 
 
 
 
 
Perspective 
1. Due to up-regulated expression of Pax6 and Tgf-β1 was found in mutant eyes at E15.5, 
peroxidasin may regulate the expression of Pax6 and Tgf-β1. To confirm this point, one can 
use pax6 or Tgf-β1, peroxidasin double mutant mice to investigate whether the eye 
phenotypes can be partially rescued compared to the eye phenotypes in peroxidasin mutants. 
Another question is that how peroxidasin regulates the expression of Pax6 and Tgf-β1. In 
vitro study by treatment with peroxidasin or transfection with peroxidasin cDNA in cell lines 
could help to solve this question.  
 
2. Peroxidasin can be secreted by vitreous nucleated cells in the embryonic stages. It appears that 
there are different cell types in the vitreous during eye development based on different 
morphologies. The immunostaining for some cell markers are helpful to indentify the 
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properties of these cells. It appears that extraocular mesenchymal cells can enter into the eye 
through the space of the optic nerve head. This work will help to understand brain-eye 
interactions during embryonic development.  
 
3. There are multiple domains in the peroxidasin including leucine-rich repeats, peroxidase 
domain and von Willebrand factor domain. These different domains should have different roles 
during eye development. What’s the special role of its different domains during the eye 
development? Are there any alternative protein products? Is it also a transmembrane receptor? 
What is the possible existing ligands/receptors and the signaling pathways of peroxidasin? 
Does peroxidasin have protective effect on anterior segment dysgenesis?  
 
4. Peroxidasin is a secreted molecule and recent study showed that it can be fastly secreted and 
circulates in the plasma. Whether peroxidasin can enter into the eye through circulating blood 
during eye development is unclear. Another question is that whether peroxidasin also functions 
within the cell cytoplasm or cell nuclear is also unclear.  
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6.2  Bmpr1b is essential for ventral retinal development 
In the present study, I characterized a mouse cells and disorganized axons in the optic nerve head 
and optic nerve in mutants, model of optic nerve hypoplasia and retinal gliosis caused by a splice 
donor site mutation in Bmpr1b. This splice donor site mutation in intron 10 of Bmpr1b results in 
skipping of exon 10, thereby introducing a translational frameshift and a premature stop codon, 
which is predicted to affect the cytoplasm domain including conserved serine/threonine kinase. 
Then I demonstrated that this event has dysregulated the expression of ocular Pax2 in embryonic 
development leading to optic nerve hypoplasia and ventral retinal gliosis associated with retinal 
dysplasia in mice. Subsequently, the ventral retina gliosis is associated with decreased 
neurogenesis of retinal ganglion cells. Moreover, the astrocytes are also more activated and they 
are associated with a decreased number of Sox2-positive precursor and disorganized axons in the 
optic nerve head and optic nerve in mutants, suggesting a hypodevelopmental event. The activated 
astrocytes in ventral gliosis retina are proliferating and likely to be gliogenic precursors. In addition, 
these precursor-like glial cells may play a general role in the pathogenesis of retinal gliosis in mice 
and humans.  
 
The most important finding of the study is that Bmpr1b mutant mice exhibit ventral retinal gliosis 
caused by a genetic defect, which is different from most other studies on reactive gliosis by 
chemical toxicity or injury. Although Bmp signalling pathway is shown to be necessary for the 
oligodendrocyte development (Feigenson et al., 2011), there remains the debate between the 
relationship between Bmpr1b and gliosis. Bmpr1b-null mice develop hyperactive reactive 
astrocytes and have attenuated glial scar following injury in the spinal cord (Sahni et al., 2010), 
whereas another study showed that the number of activated astrocytes in Bmpr1b-null mice is less 
than in wild types which was due to the defect of glia cell maturation (See et al., 2007). In 
consistency with Sahni et al (2010), our mutant mice showed ventral retinal gliosis that increased 
numbers of strong activated astroglia cells are found in the ventral retina, optic nerve head and 
optic nerve from early postnatal period to adult. These activated glial cells form a long aggregate 
with branches in the ventral retina which are involved in different retinal layers and this long glial 
cell aggregate is also connected to the optic nerve head. These demonstrate that Bmpr1b is essential 
for ventral retinal glial cells development. In-vivo BrdU labelling revealed that the activated glial 
cells are proliferating in the postnatal eye development and these glial cells can express Pax2, Sox2 
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and Nestin, but not Pax6. Pax2 can inhibit the fate of neuron but promotes the differentiation of 
glial cells (Soukkarieh et al., 2007) and Pax6 is required for neuronal differentiation (Hsieh and 
Yang, 2009). Together, these suggest that the activated glial cells in the ventral retina probably 
have properties of precursors with the gliogenic population (Pax2) but not neurogenic populations 
(Pax6). Here the deficiency in Bmpr1b causes more gliogenic precursor population in the retina, 
which is also consistent with the work by Lee et al (2008) demonstrating that inhibition of 
BMPR1B expression in primary glioblastomas can expand the clonogenic stem population. In 
addition, astrocytes can acquire the properties of stem cells and become multi-potent cells in the 
reactive gliosis induced by brain injury (Buffo et al., 2008). Furthermore, a few activated cells in 
the outer plexiform layer of the ventral gliosis retina express GS, the markers for retinal Müller 
cells (Das et al., 2006; Del Debbio et al., 2010), suggesting that the glial cells are from retinal 
Müller cells. This finding is consistent with the study showing that activated retinal Müller cells 
express progenitor markers such as Nestin in the retinal gliosis induced by toxic substances (Chang 
et al., 2007). A small population of the other activated glia cells do not express GS but they show 
a star-like morphology which indicates that they are probably from retinal astrocytes. These 
suggest that different types of glial cells including retinal Müller cells and astrocytes are involved 
in the ventral retinal gliosis. Interestingly, I found that a few BrdU-positive cells co-express PKCα, 
a marker for bipolar cells, in the gliosis retina in mutants after injection of BrdU in adult mice. It 
suggests that these GFAP and Pax2-positive/Pax6-negative precursor cells may still have the 
ability to differentiate into interneurons. This finding is consistent with another study that reduced 
expression of Pax6 in retinal progenitors decreases the neurogenesis of retinal ganglion cells but 
enhances the amacrine interneuron production (Hsieh and Yang, 2009).  
 
Together with other studies showing that the reactive cells (Müller cells) in the retinal gliosis may 
also have properties of stem cells (Das et al., 2006), I put forward the hypothesis that activated 
glial cells having a characteristic of precursors may play a general role in the pathogenesis of 
retinal gliosis, which keeps them to differentiate into more glia cells under the specific conditions. 
Clinically, there are only a few studies showing that those cells expressing Nestin were found in 
the epiretinal membranes (Mayer et al., 2003) and that the proliferating cells expressing neural 
stem cell markers (Nestin, Sox2 and Pax6) were around the ora seratta region in human PVR 
(Proliferative vitreoretinopathy) eyes (Johnsen et al., 2012). Then we further analyzed clinical 
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retinal gliosis samples including idiopathic retinal gliosis and secondary retinal gliosis using 
similar progenitor markers in the mouse study. Similar to our mouse data, we found that there are 
a number of activated glia cells (strong GFAP expression) in the epiretinal membrane and inner 
limiting membrane, which also express Pax2, Sox2 and Nestin. These data supports our hypothesis 
that GFAP-positive precursors play a general role in the pathogenesis of retinal gliosis. 
Interestingly, the morphology of these glia cells is variable, some exhibit long branches and the 
others display star-like morphology and they form networks with their long branches in the 
epiretinal membrane and inner limiting membrane, which is similar to the activated glial cells 
aggregate in our mouse models. Together, these demonstrated that these astrocytes expressing 
markers of progenitors in the retinal gliosis are similar between mouse and human, indicating 
similar intrinsic mechanism in the formation and development of retinal gliosis.  
 
Another striking finding is the finding of optic nerve head coloboma in the mutants. The optic 
nerve head coloboma was found in the very early postnatal period such as P5, suggesting that this 
is the change of optic nerve head hypoplasia arising from hypodevelopment of the optic nerve 
head. Similar to the gliosis in the ventral retina, the glial cells in the optic nerve head and optic 
nerve are also activated. The axons and the glia cells in the optic nerve also showed disorganized 
arrangements and decreased numbers of Sox2-expressing cells, indicating a 
hypodevelopmental/degenerating change in the optic nerve. We further found that Pax2 is 
ectopically expressed in the optic disk and ventral retina during embryonic retinal development, 
suggesting that these events may be initiated by the mutation in Bmpr1b. Meanwhile, aberrant 
expression of Pax2 in the retina causes decreased neurogenesis of retinal ganglion cells resulting 
in a reduced number of axons from RGC which is also another factor for the optic nerve hypoplasia. 
Therefore, we showed that Bmpr1b is necessary for optic nerve development and it can lead to 
optic nerve head coloboma through regulation of Pax2. 
 
Furthermore, we examined ventral embryonic retina and optic nerve in mutants compared to the 
wild-type controls during embryonic eye development. Consistent with our data from postnatal 
periods, there are also dramatic changes in ventral retina and optic nerve head during the 
embryonic retinal development. We found that Pax2 is ectopically over-expressed in the ventral 
retina and asymmetrically expressed in the optic nerve head, whereas it is only symmetrically 
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expressed in the optic nerve head region in wild types at E15.5 and E17.5. Several studies showed 
that mutations in PAX2/Pax2 gene are associated with or even causes optic nerve coloboma in 
humans (Tagami et al., 2010; Alur et al., 2010) and mice (Alur et al., 2010). The number of axons 
is also reduced in mice with Pax2 mutations (Alur et al., 2008). Previous studies showed that the 
retinal astrocytes are immigrants from the optic nerve through retinal vessel (Watanabe and Raff, 
1988), whereas others showed that they derive from retinal Müller cells (Reichenbach and Wohlrab, 
1986). In my study, I did not find abnormal migration of activated astrocytes from optic nerve head 
to retina, but found ectopically activated glial cells across the different layers of the ventral retina 
in the mutants, suggesting that these activated glial cells may occur after migration or they 
originate from retinal progenitors. Together, Bmpr1b may control the expression of Pax2 in ventral 
retina during retinal development and play an important role in the differentiation and maturation 
of retinal glial cells. The ectopical expression of Pax2 and abnormal activation of glial cells may 
be the initial events for optic nerve hypoplasia and later ventral retinal gliosis. The relationship 
between Bmp signalling and Pax2 remains unclear. Another study showed that BMP7 interacts 
with SHH to regulate Pax2 expression in astrocytes (Sehgal et al., 2009), which also supports that 
Bmp signalling regulated the expression of Pax2. Meanwhile, the number of retinal ganglion cells 
is reduced in the ventral retina where ectopical Pax2 is expressed, suggesting that decreased 
neurogenesis of RGC by overexpression of Pax2. In addition, the optic nerve in mutants tends to 
be thinner than wild types at E15.5 revealed by anterograde tracing, which may be due to reduced 
number of retinal ganglion cells I found. In addition, Bmpr1b is also necessary for the fate 
determination of commissural neurons and axon guidance in the spinal cord (Yamauchi et al., 
2008). In Bmpr1b-knockout mice, abnormal axon guidance was found in the ventral retina in 
during embryonic eye development (Liu et al., 2003). We further analyzed the morphology of the 
optic nerve and optic chiasm at E15.5, when the optic chiasm is already mature. However, axon 
guidance in the optic nerve and optic chiasm are not affected in mutants. Interestingly, there are a 
number of retinal ganglion cell axons entering into the axon bundles instead of optic nerve head 
in the ventral retina, and there are also a few axons mislocalised in the dorsal retina in mutants, 
indicating that retinal axon misguidance occurs Bmpr1b-mutant mice. Together, these results 
indicate that Bmpr1b may play a role of axon guidance in the retina, but not in the higher visual 
pathway. Meanwhile, on the basis of our results, axon guidance may be a secondary event or 
affected by abnormal ventral retinal gliosis in Bmpr1b-mutant mice. 
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In addition, retinal dysgenesis is associated with the ventral retinal gliosis in the mutants. The 
ventral gliosis retina exhibits dysplasia conditions in mutants, including retinal delamination and 
retinal rosettes. More interestingly, the cells from the inner nuclear layer migrate into the inner 
plexiform layer in mutants. The synapses of the bipolar cells are disrupted and ectopical retinal 
ganglion cells are found in the inner plexiform layer. These retina changes may be partly due to 
abnormal retinal development and partly due to the gliosis. Interestingly, ERG showed regular 
retinal electricity transmission in the mutant retina although retinal gliosis and retinal dysplasia 
occurs in the ventral retina. Considering that global ERG was performed in our study, local retina 
dysfunction may not be detected because of less sensitivity. To find some more details of ERG in 
Ali030 mutants, ERG and visually evoked potential (VEP, it is a tool to be used to test electricity 
transmission from optic nerve head to visual cortex) were performed and analyzed in Prof. Jan 
Kremers’ lab (Department of Ophthalmology, University of Erlangen-Nürnberg). The amplitudes 
of the a- and b-wave are reduced in the Ali030 mutants by scotopic and photopic flash ERG, which 
suggest that the function of outer retina is impaired. This result is consistent with the histology and 
immunostaining results showed that disrupted photoreceptor layer and outer nuclear layer. 
Currently, the data of visually evoked potential (VEP) is being analysed. The decreased visual 
acuity revealed by optokinetic drum in Ali030 mutants may due to the abnormal electrical 
transmission in retina and the optic nerve. 
 
Although a few studies demonstrated that lens development is mediated by Bmpr1 (Rajagopal et 
al., 2008; 2009) and the downstream signalling molecule Smad4 (Liu et al., 2010). These results 
suggest that Bmp signalling pathway is important for lens development. However, lens is not 
affected in Ali030 mutant mice, indicating that Bmpr1b is not important for lens development, and 
the deficiency effect of Bmpr1b can be compensated by Bmpr1a during lens development.  
 
In summary, we characterized a mouse model of optic nerve head hypoplasia and retinal gliosis 
induced by a splicing donor site mutation in Bmpr1b. Our work demonstrated that this mutation 
causes optic nerve head coloboma and ventral retinal gliosis by overexpression of Pax2 in the 
ventral retina and ectopic expression of Pax2 in the optic nerve head region during embryonic 
retinal development. This also helps to significantly advance the understanding of intrinsic 
mechanisms of the retinal gliosis and optic nerve hypoplasia. 
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Perspective                                                                                  
Our study demonstrated that Bmpr1b is key for optic nerve head and ventral retina development 
through regulation of Pax2 expression. How Bmp signalling regulates Pax2 and what the 
downstream signalling is remains unclear. Further in vitro study using cell culture combined with 
knockdown of Bmpr1b, transfection with mutant Bmpr1b cDNA and other biochemical methods 
may elucidate the mechanism. In the other aspect, our work showed that the activated astrocytes 
are proliferating and express precursor markers such as Pax2, Sox2 and Nestin. We are still lacking 
of direct evidence showing that they are stem cells. Lineage tracing (for example, electroporation 
transfection of GFP-Sox2 plasmid in the retina in vivo) combined with BrdU labelling can solve 
this question. Also, similar methods can be used in the cultured human retinal gliosis samples, such 
as epiretinal membrane and internal limiting membrane, which will not only help us to understand 
the mechanism of retinal gliosis, but also may develop a novel strategy for treatment. Some Sox2-
positive cells in the inner nuclear layer (showing neuron-like morphology) and some retinal 
ganglion cells (expressing Brn3) can express GFAP, a glial cell marker. Whether Bmpr1b can used 
for cell reprogramming (for example, glial cell to neuron) is to be investigated. In addition, retinal 
gliosis can be induced by gene defects. Whether the idiopathic retinal gliosis is caused by the gene 
mutations in humans is to be investigated. In my study, I realized that there is a number of Sox2 
positive and/or Pax6 positive cells in the inner nuclear layer in the adult retina. These cells have a 
very small population co-expressing Sox2 and Pax6. The question is that what the role of these 
cells in adult retina is and whether these cells keep the properties of stem cells and also differentiate 
into postmitotic cells in adult retina. Understanding of these questions may help to find novel 
treatments for retinal degenerative diseases. 
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8. Abbreviations 
 
ALDH1A3        Aldehyde dehydrogenase family 1, subfamily A3 
AP2α                 Transcription factor AP-2-alpha 
ASD                   Anterior segment dysgenesis 
bHLH                basic helix-loop-helix 
Barhl2               BarH-like homeobox 2 
Beta igh3           Transforming growth factor-beta-induced gene 
BMP                  Bone morphogenetic protein 
BR                     Bmp receptors  
Brn3                  POU-domain transcription factors 
Bmpr1a             Bone morphogenetic protein receptor, type Ia 
Bmpr1b             Bone morphogenetic protein receptor, type Ib 
BrdU                  5-Bromo-2’-Deoxyuridine 
C12orf57           Chromosome 12 open reading frame 57 
cDNA                 Complementary  DNA 
Chx10                Ceh-10 homeodomain containing homolog 
CO2                      Carbon dioxide 
COL                   Collagen  
CRALBP            Cellular retinaldehyde binding protein  
Crybb1               β B1-Crystallin 
DAPI                  4', 6-diamidino-2-phenylindole 
DEPC                 Diethylpyrocarbonate 
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DIG                    Digoxigenin 
DiI                      1, 1'-dioctadecyl-3, 3, 3', 3'-tetramethylindocarbocyanine perchlorate 
DiO                       3, 3'-Dioctadecyloxacarbocyanine perchlorate     
DNA                   Deoxyribonucleic acid 
Dyl                      Dysgenetic lens 
dNTPs                Deoxyribonucleotide triphosphates 
ECM                   Extracellular matrix 
EDTA                  Ethylenediaminetetraacetic acid 
EM                      Electron microscopy 
ENU                    N-ethyl-N-nitrosourea 
ERG                    Electroretinography  
ERM                   Epiretinal membrane   
FBS                     Fetal bovine serum 
FCS                     Fetal calf serum 
FGF19                 Fibroblast growth factor-19 
Foxc1                   Forkhead box C1 
Foxe3                   Forkhead box protein E3 
Foxn4                   Forkhead box N4 
GCL                     Retinal ganglion cell layer  
GDF-5                  Growth and differentiation factor 5 
GFAP                   Glial fibrillary acidic protein   
GMC                    German mouse clinic 
GPCRs                 G protein-coupled receptors 
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Gpr48                   G protein–coupled receptor 48 
Grg4                  Groucho/TLE family protein 4           
GS                      Glutamine synthetase.  
HCl                    Hydochloric acid 
Hes                     Hairy and enhancer of split  
HMGU                 Helmholtz Center Munich or German Research Center for Environmental Health 
IL                        Interleukin 
ILM                    Inner limiting membrane 
INL                     Inner nuclear layer  
INbL                   Inner neuroblast layer 
IPL                      Inner plexiform layer 
IPTG                   Isopropylthio-β-galactoside  
JNK                     C-Jun NH2-terminal kinase  
KCl                      Potassium chloride 
LB                        Lysogeny broth 
LDL                     Low-density lipoprotein 
Lhx2                    LIM homeodomain transcription factor 
MAP2                  Microtubule-associated protein 
Mash1                  Mammalian achaete-scute homolog 1 
Math5                  Helix-loop-helix protein mATH-5 
MG50                   MELANOMA-ASSOCIATED GENE 50  
MIO-MI               Moorfields/Institute of Ophthal- mology-Müller 1 
MITF                    Microphthalmia-associated transcription factor  
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MMP                    Matrix metalloproteinases 
Msx-2                   Msh homeobox 2   
NaCl                     Sodium chloride  
NaOH                   Sodium hydroxide  
NGF                      Nerve growth factor 
ODZ3                    Odd Oz/ten-m homolog 3, a transmembrane protein 
ONH                      Optic nerve head 
ONL                      Outer nuclear layer 
ONbL                    Outer neuroblast layer 
OPL                       Outer plexiform layer 
OS                          Outer Segment 
Otx2                       Orthodenticle homeobox 2 
Ox-LDL                 Oxidized low-density lipoprotein 
P21                          Protein 21 or tumor protein 21 
P27                          Protein 27 or tumor protein 27 
P53                          Protein 53 or tumor protein 53 
Pax2                        Paired box gene 2   
Pax6                        Paired box 6     
PBS                         Phosphate buffered saline 
PCR                        Polymerase chain reaction 
Pde6b                      Beta- subunit of phosphodiesterase-6 
PFA                         Paraformaldehyde  
Pitx2                        Paired-like homeodomain 2 
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Pitx3                        Paired-like homeodomain 3 
PKC-α                     Protein kinase C-alpha  
Prox1                       Prospero homeobox 1 
PVR                         Proliferative vitreous-retina diseases  
PXDN                      Peroxidasin 
PXN                         Peroxidasin (Drosophila) 
qRT-PCR                 quantitative reverse transcription PCR 
RGC                         Retinal ganglion cell 
RNA                         Ribonucleic acid 
RPE                          Retina pigmental epithelium  
SD-OCT                   Spectral domain optical coherence tomography  
Shh                            Sonic hedgehog 
Sox2                          SRY (sex determining region Y)-box 2 
TGFβ1                      Transforming growth factor beta 1 
TMEM126A             Transmembrane protein 126A 
TNF-α                       Tumor necrosis factor alpha 
TUBA8                      Alpha-tubulin 8 
VEP                           Visually evoked potential 
VPO1                        Vascular peroxidase 1  
VMT                         Vitreomacular traction 
vWF                          Von Willebrand factor 
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